<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420301227</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112155</dc:identifier><eid>1-s2.0-S0223523420301227</eid><prism:doi>10.1016/j.ejmech.2020.112155</prism:doi><pii>S0223-5234(20)30122-7</pii><dc:title>Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>192</prism:volume><prism:startingPage>112155</prism:startingpage><prism:pageRange>112155</prism:pagerange><articleNumber>112155</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-04-15</prism:coverdate><prism:coverDisplayDate>15 April 2020</prism:coverdisplaydate><prism:copyright>Â© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Xu, Pengfei</dc:creator><dc:creator>Shen, Pei</dc:creator><dc:creator>Yu, Bin</dc:creator><dc:creator>Xu, Xi</dc:creator><dc:creator>Ge, Raoling</dc:creator><dc:creator>Cheng, Xinying</dc:creator><dc:creator>Chen, Qiuyu</dc:creator><dc:creator>Bian, Jinlei</dc:creator><dc:creator>Li, Zhiyu</dc:creator><dc:creator>Wang, JuBo</dc:creator><dc:description>
                  The Janus kinases or JAKs are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of autoimmune diseases and myeloproliferative disorders. JAKs are activated upon ligand induced receptor homo- or heterodimerization, which results in the immediate phosphorylation of tyrosine residues and the phosphotyrosines then serve as docking sites for cytoplasmic signal transducer and activator of transcription (STAT) proteins which become phosphorylated by the JAKs upon recruitment to the receptor complex. The phosphorylated STAT proteins dimerize and travel to the cellular nucleus, where they act as transcription factors. Interfering in the JAK-STAT pathway has yielded the only approved small molecule kinase inhibitors for immunological indications. Numerous medicinal chemistry studies are currently aimed at the design of novel and potent inhibitors for JAKs. Additionally, whether the second-generation inhibitors which possessed selectivity for JAKs are more efficient are under research. This Perspective summarizes the progress in the discovery and development of JAKs inhibitors, including the potential binding site and approaches for identifying small-molecule inhibitors, as well as future therapeutic perspectives in autoimmune diseases and myeloproliferative disorders are also put forward in order to provide reference and rational for the drug discovery of novel and potent JAKs inhibitors.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Autoimmune diseases</dcterms:subject><dcterms:subject>JAKs inhibitors</dcterms:subject><dcterms:subject>Rheumatoid arthritis (RA)</dcterms:subject><dcterms:subject>SAR</dcterms:subject><dcterms:subject>Medicinal chemistry</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420301227" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420301227" rel="scidir"/></link></coredata><objects><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="617" height="170" size="22042">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="758" height="430" size="64193">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="960" size="230386">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="758" height="286" size="46949">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="517" size="100930">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr19.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="544" height="171" size="27024">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="662" height="325" size="59216">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr14.jpg?httpAccept=%2A%2F%2A</object><object ref="gr20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="707" height="199" size="33804">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr20.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="473" height="200" size="43837">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="617" height="103" size="19525">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="664" height="571" size="76499">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr16.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="758" height="449" size="120641">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="616" height="488" size="63738">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="547" height="267" size="40280">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="381" height="188" size="25348">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr18.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="372" size="54384">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="266" size="45068">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="706" height="315" size="45969">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="807" height="224" size="44801">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr17.jpg?httpAccept=%2A%2F%2A</object><object ref="gr22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="758" height="223" size="61583">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr22.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="750" height="173" size="36053">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="496" size="74302">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr21.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="547" height="266" size="36708">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2051">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="124" size="7652">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="106" height="163" size="9652">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="83" size="6064">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr13.sml?httpAccept=%2A%2F%2A</object><object ref="gr19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="159" size="10661">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr19.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="69" size="4898">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="6088">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr14.sml?httpAccept=%2A%2F%2A</object><object ref="gr20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="62" size="2607">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr20.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="9452">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="37" size="1877">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="191" height="164" size="4729">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr16.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="130" size="13810">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="164" size="5170">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="107" size="5468">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="4031">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr18.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="131" size="4964">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="5876">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr15.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="98" size="4343">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="61" size="3747">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr17.sml?httpAccept=%2A%2F%2A</object><object ref="gr22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="64" size="6808">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr22.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="50" size="4230">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="gr21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="152" size="7270">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr21.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="107" size="5181">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2733" height="751" size="178768">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3354" height="1901" size="602831">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="4254" size="2225688">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3354" height="1266" size="368694">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="2288" size="874150">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2411" height="759" size="259252">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2933" height="1440" size="544900">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3129" height="880" size="271405">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2093" height="886" size="357202">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2733" height="458" size="144073">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2939" height="2526" size="624695">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3354" height="1988" size="991097">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2729" height="2164" size="507366">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2421" height="1183" size="291993">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1688" height="834" size="169461">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1647" size="423676">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="1178" size="350056">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3128" height="1397" size="329280">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3571" height="990" size="340810">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3354" height="986" size="514523">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3320" height="765" size="277975">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="2197" size="620729">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2421" height="1178" size="279097">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="3014192">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420301227-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85080064639</scopus-id><scopus-eid>2-s2.0-85080064639</scopus-eid><pubmed-id>32120325</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85080064639" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200218">2020-02-18</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200218">2020-02-18</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200229">2020-02-29</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200229">2020-02-29</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-03-25T16:43:59</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420301227</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30122-7</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420301227</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112155</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00055</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20201215">2020-12-15T23:33:42.769742Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200415</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1582073438">2020-02-19T00:50:38.338869Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>192</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>192</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 192</xocs:vol-iss-suppl-text>
      <xocs:sort-order>3</xocs:sort-order>
      <xocs:first-fp>112155</xocs:first-fp>
      <xocs:article-number>112155</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112155</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200415</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 April 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-04-15</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review Papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Â© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>JANUSKINASESJAKSEFFICIENTTHERAPEUTICTARGETSFORAUTOIMMUNEDISEASESMYELOPROLIFERATIVEDISORDERS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>XU</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>P</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>JAKs and their immunological functions</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>JAKs structural aspects</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>JAKs immunological functions</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Assays to monitor JAK modulation</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Enzymatic assays</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Mobility shift assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>HTRF assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cellular and human whole blood (HWB) assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>
                  <ce:italic>InÂ vivo</ce:italic> assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>JAKs inhibitors in autoimmune diseases and myeloproliferative disorders</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Pan-inhibitors as the first-generation inhibitors for the treatment of autoimmune diseases and myeloproliferative disorders</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Tofacitinib</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Ruxolitinib</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Baricitinib</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Peficitinib</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Other pan-inhibitors of JAKs enzyme family under clinical or preclinical study</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Advances in the second-generation JAKs inhibitors with selectivity to JAKs enzyme family for the treatment of autoimmune diseases and myeloproliferative disorders</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>JAK1 selectivity inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>JAK2 selectivity inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>JAK3 selectivity inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>TYK2 selectivity inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Funding</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>List of Abbreviations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>AMATYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1101</xocs:ref-first-fp>
            <xocs:ref-last-lp>1116</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>SOLOUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>65</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>BRYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>9030</xocs:ref-first-fp>
            <xocs:ref-last-lp>9058</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>BALBOA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1328</xocs:ref-first-fp>
            <xocs:ref-last-lp>1337</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>CERNY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1549</xocs:ref-first-fp>
            <xocs:ref-last-lp>1565</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>SCHON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1323</xocs:ref-first-fp>
            <xocs:ref-last-lp>1337</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>ALUNNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>898</xocs:ref-first-fp>
            <xocs:ref-last-lp>911</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>GREMESEA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>25</xocs:ref-first-fp>
            <xocs:ref-last-lp>31</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>CIECHANOWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>648</xocs:ref-first-fp>
            <xocs:ref-last-lp>658</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>SERRALOPEZMATENCIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>353</xocs:ref-first-fp>
            <xocs:ref-last-lp>360</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>NASH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>280</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>SANZSANZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1835</xocs:ref-first-fp>
            <xocs:ref-last-lp>1841</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>SAHARINEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>3387</xocs:ref-first-fp>
            <xocs:ref-last-lp>3395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>SAHARINEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1448</xocs:ref-first-fp>
            <xocs:ref-last-lp>1459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>SAHARINEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>47954</xocs:ref-first-fp>
            <xocs:ref-last-lp>47963</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>KRALOVICS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1779</xocs:ref-first-fp>
            <xocs:ref-last-lp>1790</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>LEVINE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>3377</xocs:ref-first-fp>
            <xocs:ref-last-lp>3379</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>STAERK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>41893</xocs:ref-first-fp>
            <xocs:ref-last-lp>41899</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>YEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>8991</xocs:ref-first-fp>
            <xocs:ref-last-lp>8996</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2335</xocs:ref-first-fp>
            <xocs:ref-last-lp>2344</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>BANDARANAYAKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>754</xocs:ref-first-fp>
            <xocs:ref-last-lp>759</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>GOLDSMITH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>7006</xocs:ref-first-fp>
            <xocs:ref-last-lp>7011</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>LUPARDUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>8025</xocs:ref-first-fp>
            <xocs:ref-last-lp>8030</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>BOGGON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>996</xocs:ref-first-fp>
            <xocs:ref-last-lp>1002</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>LUCET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>176</xocs:ref-first-fp>
            <xocs:ref-last-lp>183</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>WILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>219</xocs:ref-first-fp>
            <xocs:ref-last-lp>232</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>CHRENCIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>413</xocs:ref-first-fp>
            <xocs:ref-last-lp>433</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>BECHMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>104392</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>DAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>186</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>CAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>767</xocs:ref-first-fp>
            <xocs:ref-last-lp>777</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>VANDENBOSCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>96</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>4948</xocs:ref-first-fp>
            <xocs:ref-last-lp>4953</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>HAMMAREN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>63</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>CLARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5023</xocs:ref-first-fp>
            <xocs:ref-last-lp>5038</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>CHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>3324</xocs:ref-first-fp>
            <xocs:ref-last-lp>3338</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>ELSAYED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>10440</xocs:ref-first-fp>
            <xocs:ref-last-lp>10462</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>KARANTANOSA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>426</xocs:ref-first-fp>
            <xocs:ref-last-lp>432</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>BAXTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1054</xocs:ref-first-fp>
            <xocs:ref-last-lp>1061</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>LIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>7334</xocs:ref-first-fp>
            <xocs:ref-last-lp>7349</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>SCHENKEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>8440</xocs:ref-first-fp>
            <xocs:ref-last-lp>8450</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>HANAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>10090</xocs:ref-first-fp>
            <xocs:ref-last-lp>10107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>ROSKOSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>784</xocs:ref-first-fp>
            <xocs:ref-last-lp>803</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>SCHINDLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>20059</xocs:ref-first-fp>
            <xocs:ref-last-lp>20063</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>137</xocs:ref-first-fp>
            <xocs:ref-last-lp>149</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>LIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>175</xocs:ref-first-fp>
            <xocs:ref-last-lp>187</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>388</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>SHUAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>900</xocs:ref-first-fp>
            <xocs:ref-last-lp>911</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>607</xocs:ref-first-fp>
            <xocs:ref-last-lp>621</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>JIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>69</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>PERRIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>996</xocs:ref-first-fp>
            <xocs:ref-last-lp>1004</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>BENICCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>933</xocs:ref-first-fp>
            <xocs:ref-last-lp>945</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>BRUBAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>PRESENTEDAPPLIEDPHARMACEUTICALCHEMISTRYCONFERENCEBOSTONMA</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>DISCOVERYORALLYBIOAVAILABLEJAK1INHIBITORFORVALIDATIONJAK1SELECTIVEHYPOTHESIS</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>WAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>850</xocs:ref-first-fp>
            <xocs:ref-last-lp>855</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>MENET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>9323</xocs:ref-first-fp>
            <xocs:ref-last-lp>9342</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>PURANDARE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>280</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>HEGEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1505</xocs:ref-first-fp>
            <xocs:ref-last-lp>1515</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>CARVALHO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>615</xocs:ref-first-fp>
            <xocs:ref-last-lp>624</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>MESA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>103</xocs:ref-first-fp>
            <xocs:ref-last-lp>104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>SANCHEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3041</xocs:ref-first-fp>
            <xocs:ref-last-lp>3052</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>HAMAGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4971</xocs:ref-first-fp>
            <xocs:ref-last-lp>4983</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>FLANAGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>8468</xocs:ref-first-fp>
            <xocs:ref-last-lp>8484</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>MARICAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>5096</xocs:ref-first-fp>
            <xocs:ref-last-lp>5098</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>PATEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>411</xocs:ref-first-fp>
            <xocs:ref-last-lp>418</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>QUINTASCARDAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3109</xocs:ref-first-fp>
            <xocs:ref-last-lp>3117</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>PADRON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>3746</xocs:ref-first-fp>
            <xocs:ref-last-lp>3754</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>FOGELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5382</xocs:ref-first-fp>
            <xocs:ref-last-lp>5393</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>46</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>JAGASIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>52</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>FRIDMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5298</xocs:ref-first-fp>
            <xocs:ref-last-lp>5307</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>MULLARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>JABBARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>351</xocs:ref-first-fp>
            <xocs:ref-last-lp>355</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>KHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1607</xocs:ref-first-fp>
            <xocs:ref-last-lp>1618</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>PAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>109122</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>WALLACE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>402</xocs:ref-first-fp>
            <xocs:ref-last-lp>403</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>GUTTMANYASSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>913</xocs:ref-first-fp>
            <xocs:ref-last-lp>921</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>ITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>25</xocs:ref-first-fp>
            <xocs:ref-last-lp>33</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>BAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>175</xocs:ref-first-fp>
            <xocs:ref-last-lp>187</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>TAKEUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1057</xocs:ref-first-fp>
            <xocs:ref-last-lp>1064</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>GENOVESE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>932</xocs:ref-first-fp>
            <xocs:ref-last-lp>942</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>KIVITZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>709</xocs:ref-first-fp>
            <xocs:ref-last-lp>719</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>TAKEUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1305</xocs:ref-first-fp>
            <xocs:ref-last-lp>1309</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>SANDS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1158</xocs:ref-first-fp>
            <xocs:ref-last-lp>1169</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>PAPP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>767</xocs:ref-first-fp>
            <xocs:ref-last-lp>776</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>GONZALES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>317</xocs:ref-first-fp>
            <xocs:ref-last-lp>324</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>MESA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3844</xocs:ref-first-fp>
            <xocs:ref-last-lp>3850</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>FENSOME</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>8597</xocs:ref-first-fp>
            <xocs:ref-last-lp>8612</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>HOWARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>379</xocs:ref-first-fp>
            <xocs:ref-last-lp>388</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>COFFEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1174</xocs:ref-first-fp>
            <xocs:ref-last-lp>1184</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>THOMPSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1219</xocs:ref-first-fp>
            <xocs:ref-last-lp>1223</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>TANIMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>SU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>144</xocs:ref-first-fp>
            <xocs:ref-last-lp>158</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>FUKUYAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>394</xocs:ref-first-fp>
            <xocs:ref-last-lp>405</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>COSGROVE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>TYNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5232</xocs:ref-first-fp>
            <xocs:ref-last-lp>5240</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>TEFFERI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>29</xocs:ref-first-fp>
            <xocs:ref-last-lp>34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>QI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2997</xocs:ref-first-fp>
            <xocs:ref-last-lp>3005</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>SANTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3259</xocs:ref-first-fp>
            <xocs:ref-last-lp>3271</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>BLUNT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2313</xocs:ref-first-fp>
            <xocs:ref-last-lp>2324</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>NAKAGAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>4611</xocs:ref-first-fp>
            <xocs:ref-last-lp>4620</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>DERENZINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>e46</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>HEDVAT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>487</xocs:ref-first-fp>
            <xocs:ref-last-lp>497</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>NI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>22</xocs:ref-first-fp>
            <xocs:ref-last-lp>30</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>GRIMSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5235</xocs:ref-first-fp>
            <xocs:ref-last-lp>5244</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>GURO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2477</xocs:ref-first-fp>
            <xocs:ref-last-lp>2478</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>YIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1562</xocs:ref-first-fp>
            <xocs:ref-last-lp>1576</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>MOSLIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>8953</xocs:ref-first-fp>
            <xocs:ref-last-lp>8972</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>FLEISCHMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1788</xocs:ref-first-fp>
            <xocs:ref-last-lp>1800</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>ZAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4764</xocs:ref-first-fp>
            <xocs:ref-last-lp>4785</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>PARMENTIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>23</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>MOHAMED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1319</xocs:ref-first-fp>
            <xocs:ref-last-lp>1327</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>VANROMPAEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3568</xocs:ref-first-fp>
            <xocs:ref-last-lp>3577</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>VAZQUEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1130</xocs:ref-first-fp>
            <xocs:ref-last-lp>1152</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>MASCARENHAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>327</xocs:ref-first-fp>
            <xocs:ref-last-lp>335</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>LUDBROOK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>985</xocs:ref-first-fp>
            <xocs:ref-last-lp>995</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>MASAROVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>310</xocs:ref-first-fp>
            <xocs:ref-last-lp>327</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>MCNALLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>587</xocs:ref-first-fp>
            <xocs:ref-last-lp>593</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>WILLIAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>4638</xocs:ref-first-fp>
            <xocs:ref-last-lp>4658</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>HEXNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5663</xocs:ref-first-fp>
            <xocs:ref-last-lp>5671</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>LEVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>885</xocs:ref-first-fp>
            <xocs:ref-last-lp>887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>LEVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>3885</xocs:ref-first-fp>
            <xocs:ref-last-lp>3891</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>SMITH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>3669</xocs:ref-first-fp>
            <xocs:ref-last-lp>3676</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref125">
            <xocs:ref-normalized-surname>BECK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>16686</xocs:ref-first-fp>
            <xocs:ref-last-lp>16698</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref126">
            <xocs:ref-normalized-surname>MASCARENHAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1343</xocs:ref-first-fp>
            <xocs:ref-last-lp>1345</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref127">
            <xocs:ref-normalized-surname>GIACOMINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>76</xocs:ref-first-fp>
            <xocs:ref-last-lp>85</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref128">
            <xocs:ref-normalized-surname>WERNIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>311</xocs:ref-first-fp>
            <xocs:ref-last-lp>320</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref129">
            <xocs:ref-normalized-surname>PARDANANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>643</xocs:ref-first-fp>
            <xocs:ref-last-lp>651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref130">
            <xocs:ref-normalized-surname>JAMIESON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>294</xocs:ref-first-fp>
            <xocs:ref-last-lp>302</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref131">
            <xocs:ref-normalized-surname>WILLIAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>169</xocs:ref-first-fp>
            <xocs:ref-last-lp>196</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref132">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>e109</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref133">
            <xocs:ref-normalized-surname>HART</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>845</xocs:ref-first-fp>
            <xocs:ref-last-lp>849</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref134">
            <xocs:ref-normalized-surname>DUGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>5243</xocs:ref-first-fp>
            <xocs:ref-last-lp>5254</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref135">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1379</xocs:ref-first-fp>
            <xocs:ref-last-lp>1386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref136">
            <xocs:ref-normalized-surname>KURODA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>619</xocs:ref-first-fp>
            <xocs:ref-last-lp>624</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref137">
            <xocs:ref-normalized-surname>NAKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>e29</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref138">
            <xocs:ref-normalized-surname>BAFFERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1945</xocs:ref-first-fp>
            <xocs:ref-last-lp>1955</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref139">
            <xocs:ref-normalized-surname>THORARENSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1971</xocs:ref-first-fp>
            <xocs:ref-last-lp>1993</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref140">
            <xocs:ref-normalized-surname>TELLIEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>3442</xocs:ref-first-fp>
            <xocs:ref-last-lp>3451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref141">
            <xocs:ref-normalized-surname>MAHAJAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>405</xocs:ref-first-fp>
            <xocs:ref-last-lp>414</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref142">
            <xocs:ref-normalized-surname>FORSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1335</xocs:ref-first-fp>
            <xocs:ref-last-lp>1340</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref143">
            <xocs:ref-normalized-surname>CASIMIROGARCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>10665</xocs:ref-first-fp>
            <xocs:ref-last-lp>10699</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref144">
            <xocs:ref-normalized-surname>WROBLESKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>8973</xocs:ref-first-fp>
            <xocs:ref-last-lp>8995</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref145">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>388</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref146">
            <xocs:ref-normalized-surname>MASCARENHAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3008</xocs:ref-first-fp>
            <xocs:ref-last-lp>3014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref147">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>261</xocs:ref-first-fp>
            <xocs:ref-last-lp>270</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref148">
            <xocs:ref-normalized-surname>QUINTASCARDAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1124</xocs:ref-first-fp>
            <xocs:ref-last-lp>1127</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref149">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>8233</xocs:ref-first-fp>
            <xocs:ref-last-lp>8262</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref150">
            <xocs:ref-normalized-surname>GE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1847</xocs:ref-first-fp>
            <xocs:ref-last-lp>1857</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>XUX2020X112155</xocs:refkey3>
         <xocs:refkey4ai>XUX2020X112155XP</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-02-28T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-02-28T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">Â© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-02-18T09:55:25.994Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30122-7</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420301227</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420301227</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112155</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-12-15T23:33:42.769742Z</xocs:timestamp>
         <xocs:cover-date-start>2020-04-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/MAIN/application/pdf/cd825c7af2808759a1c5376e38346738/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>6314206</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>28</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420301227-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/PREVIEW/image/png/c0d50ff2e0250f3a5d73a5d1e81719db/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>44399</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr6/DOWNSAMPLED/image/jpeg/24b1109674a77c32c3819102ba17a883/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22042</xocs:filesize>
               <xocs:pixel-height>170</xocs:pixel-height>
               <xocs:pixel-width>617</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr9/DOWNSAMPLED/image/jpeg/51b7efb29ac66c98ace8a2ded8dd1f5d/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64193</xocs:filesize>
               <xocs:pixel-height>430</xocs:pixel-height>
               <xocs:pixel-width>758</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr2/DOWNSAMPLED/image/jpeg/cd82bbd58722a0dd09c31369cf1c2274/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>230386</xocs:filesize>
               <xocs:pixel-height>960</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr13/DOWNSAMPLED/image/jpeg/d30576d07c6ebce64857901db7e8b2af/gr13.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>46949</xocs:filesize>
               <xocs:pixel-height>286</xocs:pixel-height>
               <xocs:pixel-width>758</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr19/DOWNSAMPLED/image/jpeg/556b776fde27e89ec6f57b4fb6df8202/gr19.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>100930</xocs:filesize>
               <xocs:pixel-height>517</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr1/DOWNSAMPLED/image/jpeg/58740ab24c799325ab71e51fe5cc0884/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27024</xocs:filesize>
               <xocs:pixel-height>171</xocs:pixel-height>
               <xocs:pixel-width>544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr14/DOWNSAMPLED/image/jpeg/8439045fab48f55a3393e8c39034c9a2/gr14.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59216</xocs:filesize>
               <xocs:pixel-height>325</xocs:pixel-height>
               <xocs:pixel-width>662</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr20/DOWNSAMPLED/image/jpeg/bbc56df52f5e40c3fa581f6e419edbfe/gr20.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33804</xocs:filesize>
               <xocs:pixel-height>199</xocs:pixel-height>
               <xocs:pixel-width>707</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/fx1/DOWNSAMPLED/image/jpeg/a1ac16240f21ec1bd2da60960f48aa0a/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43837</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>473</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr7/DOWNSAMPLED/image/jpeg/f1da548d5182b8af90162b92d319e679/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19525</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>617</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr16/DOWNSAMPLED/image/jpeg/db3dda5aa59d488fd9ca6c97d6fc1e8f/gr16.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>76499</xocs:filesize>
               <xocs:pixel-height>571</xocs:pixel-height>
               <xocs:pixel-width>664</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr3/DOWNSAMPLED/image/jpeg/fe95029938d60c3ead710d2606725fac/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>120641</xocs:filesize>
               <xocs:pixel-height>449</xocs:pixel-height>
               <xocs:pixel-width>758</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr12/DOWNSAMPLED/image/jpeg/924bee05e9cb4d40d44f13cd48d0654e/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63738</xocs:filesize>
               <xocs:pixel-height>488</xocs:pixel-height>
               <xocs:pixel-width>616</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr4/DOWNSAMPLED/image/jpeg/9a1852808a10078d8d7d9afeaa49e4ca/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40280</xocs:filesize>
               <xocs:pixel-height>267</xocs:pixel-height>
               <xocs:pixel-width>547</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr18/DOWNSAMPLED/image/jpeg/e715789a07c85dfd5888264fafea6c6d/gr18.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25348</xocs:filesize>
               <xocs:pixel-height>188</xocs:pixel-height>
               <xocs:pixel-width>381</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr10/DOWNSAMPLED/image/jpeg/e449a51c66db5343d5daece2baff0f7c/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54384</xocs:filesize>
               <xocs:pixel-height>372</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr15/DOWNSAMPLED/image/jpeg/039961e7ad5c7680bf12cee89eb00b8f/gr15.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45068</xocs:filesize>
               <xocs:pixel-height>266</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr8/DOWNSAMPLED/image/jpeg/eecad7e7062e1e39532e3740f5b4deb9/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45969</xocs:filesize>
               <xocs:pixel-height>315</xocs:pixel-height>
               <xocs:pixel-width>706</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr17/DOWNSAMPLED/image/jpeg/0867fccf92c6188e9346b4b30c2f837c/gr17.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44801</xocs:filesize>
               <xocs:pixel-height>224</xocs:pixel-height>
               <xocs:pixel-width>807</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr22/DOWNSAMPLED/image/jpeg/97371c13ca821d794761e4b6e8d5f1d2/gr22.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61583</xocs:filesize>
               <xocs:pixel-height>223</xocs:pixel-height>
               <xocs:pixel-width>758</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr11/DOWNSAMPLED/image/jpeg/7f5c43571ccf46561aadbbb89e3e2a93/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36053</xocs:filesize>
               <xocs:pixel-height>173</xocs:pixel-height>
               <xocs:pixel-width>750</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr21/DOWNSAMPLED/image/jpeg/bba72fcd4b6cb630b7c7b311eba21e7b/gr21.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>74302</xocs:filesize>
               <xocs:pixel-height>496</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr5/DOWNSAMPLED/image/jpeg/bab6d0bb0fbaada786477572d3989f8c/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36708</xocs:filesize>
               <xocs:pixel-height>266</xocs:pixel-height>
               <xocs:pixel-width>547</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr6/THUMBNAIL/image/gif/dce7196ae368a7a37a87ddca64a769b6/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2051</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr9/THUMBNAIL/image/gif/d6a16bbd904143af393fc6200a1910d2/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7652</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr2/THUMBNAIL/image/gif/9822a5db78d1b9091fd377d5ec28a995/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9652</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>106</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr13/THUMBNAIL/image/gif/eb7919598dcece3c1bbacceb5ec7a977/gr13.sml</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6064</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr19/THUMBNAIL/image/gif/8760637405f207fbbb71751ecb77f04e/gr19.sml</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10661</xocs:filesize>
               <xocs:pixel-height>159</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr1/THUMBNAIL/image/gif/e604129fd0aeb83494bd1b7c1dcfd1c1/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4898</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr14/THUMBNAIL/image/gif/5c6e4b1e61b761f603f0445a442d4f4b/gr14.sml</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6088</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr20/THUMBNAIL/image/gif/a305d69d37e7b3c05a672b791b8efe62/gr20.sml</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2607</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/fx1/THUMBNAIL/image/gif/ab08ad1a0d857e1c590a93f878be3b0b/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9452</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr7/THUMBNAIL/image/gif/6e8e49920b5fa7e0541431b4ffa0ced4/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1877</xocs:filesize>
               <xocs:pixel-height>37</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr16/THUMBNAIL/image/gif/d47ea0d42eaf7456a2d77667125a762d/gr16.sml</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4729</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>191</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr3/THUMBNAIL/image/gif/c4550b0071d0619abeebf425da3eddaf/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13810</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr12/THUMBNAIL/image/gif/b43f51270e27a00246b86e97fb3c6d0e/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5170</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr4/THUMBNAIL/image/gif/684165bb3e86d0583733a10d246f9704/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5468</xocs:filesize>
               <xocs:pixel-height>107</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr18/THUMBNAIL/image/gif/94c89508de5ccc86f7572072851309d3/gr18.sml</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4031</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr10/THUMBNAIL/image/gif/57a8bd3641b85f11668324e0b8572398/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4964</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr15/THUMBNAIL/image/gif/b7327888d86d427b496e7b77231098dc/gr15.sml</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5876</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr8/THUMBNAIL/image/gif/3bf3ce598e77c68efcbfaf5a077e71d6/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4343</xocs:filesize>
               <xocs:pixel-height>98</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr17/THUMBNAIL/image/gif/f9a7888d5d110c10f8f336054e45add0/gr17.sml</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3747</xocs:filesize>
               <xocs:pixel-height>61</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr22/THUMBNAIL/image/gif/243d75fc1bc4defd7bf39f80fd91cbb7/gr22.sml</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6808</xocs:filesize>
               <xocs:pixel-height>64</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr11/THUMBNAIL/image/gif/ca2fc5542d5095f1cf943744ba239582/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4230</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr21/THUMBNAIL/image/gif/0157cc4586c34a16cbf58c977a610759/gr21.sml</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7270</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr5/THUMBNAIL/image/gif/49ab7310102b37374d88ca7782ada95c/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5181</xocs:filesize>
               <xocs:pixel-height>107</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr6/HIGHRES/image/jpeg/aa78df96209e57e225ae8124d5636c61/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>178768</xocs:filesize>
               <xocs:pixel-height>751</xocs:pixel-height>
               <xocs:pixel-width>2733</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr9/HIGHRES/image/jpeg/1bda7a6ee3a480f3f07de6da94e7de40/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>602831</xocs:filesize>
               <xocs:pixel-height>1901</xocs:pixel-height>
               <xocs:pixel-width>3354</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr2/HIGHRES/image/jpeg/583f74111aab29f53b9cd56287a8d457/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2225688</xocs:filesize>
               <xocs:pixel-height>4254</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr13/HIGHRES/image/jpeg/41a2ed1fbf2ed0348383dd706a997f64/gr13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>368694</xocs:filesize>
               <xocs:pixel-height>1266</xocs:pixel-height>
               <xocs:pixel-width>3354</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr19/HIGHRES/image/jpeg/f9af181d2379d0973b5d400be147961f/gr19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>874150</xocs:filesize>
               <xocs:pixel-height>2288</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr1/HIGHRES/image/jpeg/d7f8dc529e306d92a678809f87fee277/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>259252</xocs:filesize>
               <xocs:pixel-height>759</xocs:pixel-height>
               <xocs:pixel-width>2411</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr14/HIGHRES/image/jpeg/5df22aa483e715cc68f0c725226b7708/gr14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>544900</xocs:filesize>
               <xocs:pixel-height>1440</xocs:pixel-height>
               <xocs:pixel-width>2933</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr20/HIGHRES/image/jpeg/22ff378ee9a7ef011b21e199ef7aa7b0/gr20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>271405</xocs:filesize>
               <xocs:pixel-height>880</xocs:pixel-height>
               <xocs:pixel-width>3129</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/fx1/HIGHRES/image/jpeg/95a3f344322dd3dd5fbd1417772a64cd/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>357202</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>2093</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr7/HIGHRES/image/jpeg/e7f4455c57eca7c48cc074665e98e448/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>144073</xocs:filesize>
               <xocs:pixel-height>458</xocs:pixel-height>
               <xocs:pixel-width>2733</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr16/HIGHRES/image/jpeg/899a7c9c966292d518da70cdb65af824/gr16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>624695</xocs:filesize>
               <xocs:pixel-height>2526</xocs:pixel-height>
               <xocs:pixel-width>2939</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr3/HIGHRES/image/jpeg/615962aad0cdb2cb81a3d5498be3e166/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>991097</xocs:filesize>
               <xocs:pixel-height>1988</xocs:pixel-height>
               <xocs:pixel-width>3354</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr12/HIGHRES/image/jpeg/9b9f82c8a3e5210470f02b114d7d1f06/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>507366</xocs:filesize>
               <xocs:pixel-height>2164</xocs:pixel-height>
               <xocs:pixel-width>2729</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr4/HIGHRES/image/jpeg/4b55a47389c2a7d942c7727d5e732cfa/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>291993</xocs:filesize>
               <xocs:pixel-height>1183</xocs:pixel-height>
               <xocs:pixel-width>2421</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr18/HIGHRES/image/jpeg/1d7e1be82c7cee2e8a16f0d830906a6e/gr18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>169461</xocs:filesize>
               <xocs:pixel-height>834</xocs:pixel-height>
               <xocs:pixel-width>1688</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr10/HIGHRES/image/jpeg/23a69b8e10a796063f2b7d64b87aaf81/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>423676</xocs:filesize>
               <xocs:pixel-height>1647</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr15/HIGHRES/image/jpeg/64db1367f740a992d82fdc715220bb0b/gr15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>350056</xocs:filesize>
               <xocs:pixel-height>1178</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr8/HIGHRES/image/jpeg/f43a6f909b0bafe91561a63c2c24768e/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>329280</xocs:filesize>
               <xocs:pixel-height>1397</xocs:pixel-height>
               <xocs:pixel-width>3128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr17/HIGHRES/image/jpeg/c925df33f7f028539b72a0010c827072/gr17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>340810</xocs:filesize>
               <xocs:pixel-height>990</xocs:pixel-height>
               <xocs:pixel-width>3571</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr22/HIGHRES/image/jpeg/2b288351af8fafdef952c04aaf89d8b0/gr22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>514523</xocs:filesize>
               <xocs:pixel-height>986</xocs:pixel-height>
               <xocs:pixel-width>3354</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr11/HIGHRES/image/jpeg/99bcadfd6825870bb3ab5162f3768f0e/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>277975</xocs:filesize>
               <xocs:pixel-height>765</xocs:pixel-height>
               <xocs:pixel-width>3320</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr21/HIGHRES/image/jpeg/66e5b4c7b528d199408582aa35349ec8/gr21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>620729</xocs:filesize>
               <xocs:pixel-height>2197</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420301227/gr5/HIGHRES/image/jpeg/6f68320464557c53196b883eb4406083/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>279097</xocs:filesize>
               <xocs:pixel-height>1178</xocs:pixel-height>
               <xocs:pixel-width>2421</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420301227-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>3014192</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10LTJNX0GGB/MAIN/application/pdf/4379caf20330b103eff788f6b5ace277/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112155</aid>
            <ce:article-number>112155</ce:article-number>
            <ce:pii>S0223-5234(20)30122-7</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112155</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig.Â 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">JAK/STAT pathway. 1: Cytokine binding, complex formation, activation, and phosphorylation of JAKs. 2: Recruitment and phosphorylation of STAT. 3: Phosphorylated STAT (p-STAT) dimerization. 4: Nuclear translocation and DNA binding of p-STAT dimer. 5: Gene transcription.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig.Â 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420301227/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig.Â 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">(A) Schematic view and structure of JAKs. (B) Structure and binding sites of JAK1 (PDB: <ce:inter-ref id="intref0010" xlink:href="pdb:4E5W" xlink:type="simple">4E5W</ce:inter-ref>). (C) Structure and binding sites of JAK2 (PDB: <ce:inter-ref id="intref0015" xlink:href="pdb:6DRW" xlink:type="simple">6DRW</ce:inter-ref>). (D) Structure and binding sites of JAK3 (PDB: <ce:inter-ref id="intref0020" xlink:href="pdb:6NY4" xlink:type="simple">6NY4</ce:inter-ref>). (E) Structure and binding sites of TYK2 (PDB: <ce:inter-ref id="intref0025" xlink:href="pdb:6DBK" xlink:type="simple">6DBK</ce:inter-ref>). (F) X-ray cocrystal structures with sequence alignment for JAK1 (yellow, 4E5W), JAK2 (blue, 6DRW), JAK3 (magenta, 6NY4), and TYK2 (green, 6DBK). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig.Â 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420301227/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig.Â 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">The biological responses mediated through the JAKs enzyme pathway.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig.Â 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420301227/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig.Â 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">The FAM-labeled polypeptide substrate is capable of being phosphorylated by protein kinase, and the corresponding device then draws traces of liquid into the microfluidic chip. The polypeptide substrate or product then enters the capillary electrophoresis with an electric field and moves in a positively charged direction. Since the polypeptide product carries phosphate ions, its relative migration speed is faster, according to which the phosphorylated and non-phosphorylated polypeptides can be separated and detected by a fluorescence detection system. Finally, the actual product conversion can be known by comparing the peak height of the product and the substrate.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig.Â 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420301227/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig.Â 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">The HTRF method labels a biotin on a peptide substrate that specifically binds to the XL665-labeled streptavidin. In the first step, the kinase adds a phosphate group to the polypeptide substrate then the Eu-labeled specific phosphorylated antibody can be recognized and bound thereto. Thus, in the second step of detection, a complex of XL665-labeled streptavidin, a phosphorylated polypeptide substrate and an Eu-labeled phosphorylated antibody can be formed. FRET can be formed due to the short distance between XL665 and Eu. On the other hand, Eu has a relatively long fluorescence half-life and can be applied to the detection of time-resolved fluorescence.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig.Â 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420301227/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig.Â 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Approved JAKs pan-inhibitors for the treatment of immunological diseases. Scaffold participating in binding to the hinge region of the active site are shown in red with overstriking lines. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig.Â 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420301227/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig.Â 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Evolution of compound structures from HTS lead compound (<ce:bold>5</ce:bold>) to <ce:bold>1</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig.Â 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523420301227/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig.Â 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Retrosynthetic analysis of <ce:bold>1</ce:bold> and starting materials described in the literature to assemble the piperidine fragment.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig.Â 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523420301227/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig.Â 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">(A) Evolution of compound structures from a potent and moderately selective JAK3 inhibitor (<ce:bold>9</ce:bold>) to <ce:bold>4</ce:bold>. (B) Predicted binding mode of compound <ce:bold>10</ce:bold> (green) and <ce:bold>9</ce:bold> (orange) to JAK3 (PDB: <ce:inter-ref id="intref0030" xlink:href="pdb:6AAK" xlink:type="simple">6AAK</ce:inter-ref>). (C) Crystal structure of JAK3 in a complex with <ce:bold>4</ce:bold> (PDB: <ce:inter-ref id="intref0035" xlink:href="pdb:6AAK" xlink:type="simple">6AAK</ce:inter-ref>). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig.Â 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523420301227/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig.Â 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Pan-inhibitors of JAKs enzyme family for the treatment of immunological diseases in clinical trials. Scaffold participating in binding to the hinge region of the active site are shown in red with overstriking lines. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig.Â 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S0223523420301227/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig.Â 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Evolution of compound structures for the discovery of a potent dual JAK1/TYK2 inhibitor.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig.Â 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S0223523420301227/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig.Â 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">JAK1 selectivity inhibitors approved or in clinical trials for the treatment of immunological diseases. Scaffold participating in binding to the hinge region of the active site are shown in red with overstriking lines. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig.Â 12</ce:alt-text>
               <ce:link locator="gr12" xlink:href="pii:S0223523420301227/gr12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig13">
               <ce:label>Fig.Â 13</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">(A) Detailed binding mode of <ce:bold>25</ce:bold> and JAK1 (PDB ID: <ce:inter-ref id="intref0040" xlink:href="pdb:4IVB" xlink:type="simple">4IVB</ce:inter-ref>); (B) Detailed binding mode of <ce:bold>25</ce:bold> and JAK2 (PDB ID: <ce:inter-ref id="intref0045" xlink:href="pdb:2XA4" xlink:type="simple">2XA4</ce:inter-ref>); Carbon atoms of <ce:bold>25</ce:bold> are shown in yellow stick. Hydrogen bonds are represented by gray dashed lines and H â¦ Ï binding is represented by yellow dashed lines. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Fig.Â 13</ce:alt-text>
               <ce:link locator="gr13" xlink:href="pii:S0223523420301227/gr13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig14">
               <ce:label>Fig.Â 14</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="fspara0075" view="all">Progression of Galapagos lead to <ce:bold>26</ce:bold>. Four sites of the original lead molecule <ce:bold>30</ce:bold> were optimized leading to <ce:bold>26</ce:bold>. The conserved triazolopyridine cyclopropanecarboxamide moiety is reported to be a key hinge-binding pharmacophoric feature for the series.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Fig.Â 14</ce:alt-text>
               <ce:link locator="gr14" xlink:href="pii:S0223523420301227/gr14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig15">
               <ce:label>Fig.Â 15</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="fspara0080" view="all">(A) X-ray crystal structure of <ce:bold>27</ce:bold> in complex with JAK1 (PDB ID: <ce:inter-ref id="intref0050" xlink:href="pdb:6BBU" xlink:type="simple">6BBU</ce:inter-ref>). The ligand <ce:bold>27</ce:bold> is shown in green. (B) X-ray crystal structure of <ce:bold>27</ce:bold> in complex with JAK2 (PDB ID: <ce:inter-ref id="intref0055" xlink:href="pdb:6BBV" xlink:type="simple">6BBV</ce:inter-ref>). The ligand <ce:bold>27</ce:bold> is shown in green. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Fig.Â 15</ce:alt-text>
               <ce:link locator="gr15" xlink:href="pii:S0223523420301227/gr15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig16">
               <ce:label>Fig.Â 16</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="fspara0085" view="all">JAK2 selectivity inhibitors approved or in clinical trials for the treatment of immunological diseases. Scaffold participating in binding to the hinge region of the active site are shown in red. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0090" role="short">Fig.Â 16</ce:alt-text>
               <ce:link locator="gr16" xlink:href="pii:S0223523420301227/gr16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig17">
               <ce:label>Fig.Â 17</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="fspara0090" view="all">The optimization of an in-house library screening hit to afford a development candidate <ce:bold>30</ce:bold> (<ce:bold>SB1518</ce:bold>) (PDB ID: <ce:inter-ref id="intref0060" xlink:href="pdb:6DRW" xlink:type="simple">6DRW</ce:inter-ref>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0095" role="short">Fig.Â 17</ce:alt-text>
               <ce:link locator="gr17" xlink:href="pii:S0223523420301227/gr17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig18">
               <ce:label>Fig.Â 18</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="fspara0095" view="all">Identification of a promising candidate, Compound <ce:bold>34</ce:bold> (<ce:bold>Gandotinib</ce:bold> or <ce:bold>LY2784544</ce:bold>), from lead compound <ce:bold>40</ce:bold> that was screened from the Lilly compound library.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0100" role="short">Fig.Â 18</ce:alt-text>
               <ce:link locator="gr18" xlink:href="pii:S0223523420301227/gr18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig19">
               <ce:label>Fig.Â 19</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="fspara0100" view="all">(A) The discovery of a clinical candidate <ce:bold>35</ce:bold> from dialkylthiazole <ce:bold>41</ce:bold>. (B) Model of <ce:bold>44</ce:bold> bound to the kinase catalytic domain of JAK1 (PDB ID: <ce:inter-ref id="intref0065" xlink:href="pdb:4E5W" xlink:type="simple">4E5W</ce:inter-ref>). (C) Crystal structure of <ce:bold>35</ce:bold> bound to the kinase catalytic domain of JAK2 (PDB ID: <ce:inter-ref id="intref0070" xlink:href="pdb:3Q32" xlink:type="simple">3Q32</ce:inter-ref>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0105" role="short">Fig.Â 19</ce:alt-text>
               <ce:link locator="gr19" xlink:href="pii:S0223523420301227/gr19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig20">
               <ce:label>Fig.Â 20</ce:label>
               <ce:caption id="cap0105">
                  <ce:simple-para id="fspara0105" view="all">JAK3 selectivity inhibitors for the treatment of immunological diseases in clinical trials. Scaffold participating in binding to the hinge region of the active site are shown in red with overstriking lines. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0110" role="short">Fig.Â 20</ce:alt-text>
               <ce:link locator="gr20" xlink:href="pii:S0223523420301227/gr20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig21">
               <ce:label>Fig.Â 21</ce:label>
               <ce:caption id="cap0110">
                  <ce:simple-para id="fspara0110" view="all">Identification of the first orally active JAK3 specific inhibitor (<ce:bold>47</ce:bold>), which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909 (PDB ID: <ce:inter-ref id="intref0075" xlink:href="pdb:5TOZ" xlink:type="simple">5TOZ</ce:inter-ref>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0115" role="short">Fig.Â 21</ce:alt-text>
               <ce:link locator="gr21" xlink:href="pii:S0223523420301227/gr21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig22">
               <ce:label>Fig.Â 22</ce:label>
               <ce:caption id="cap0115">
                  <ce:simple-para id="fspara0115" view="all">TYK2 selectivity inhibitors binding to a pseudokinase domain (JH2) for the treatment of autoimmune diseases in clinical trials (PDB ID: <ce:inter-ref id="intref0080" xlink:href="pdb:3ZON" xlink:type="simple">3ZON</ce:inter-ref>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0120" role="short">Fig.Â 22</ce:alt-text>
               <ce:link locator="gr22" xlink:href="pii:S0223523420301227/gr22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>TableÂ 1</ce:label>
               <ce:caption id="cap0120">
                  <ce:simple-para id="tspara0010" view="all">Summary of the representative available crystal structures of JAKs and JAKs-ligand complex.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0125" role="short">TableÂ 1</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAKs isoform</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Binding dimain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ligand</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">PDB code</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Publication year</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TYK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BMS-986165</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6NZR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2019.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TYK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyk2-IN-5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6NSL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2019.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TYK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-06700841</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6DBK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Peficitinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6AAH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Peficitinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6AAJ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Peficitinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6AAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TYK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Peficitinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6AAM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AZD7762</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5WIL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5WIM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-04965842</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6BBU</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-04965842</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6BBV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2018.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Filgotinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5UT5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2017.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-06651600</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5TTS</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2017.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-06263276</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5TQ3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2017.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TG101209</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5HEZ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2016.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FM381</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5LWM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2016.10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Decernotinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4YTC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2015.8</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JH1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Filgotinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4P7E</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2014.11</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>TableÂ 2</ce:label>
               <ce:caption id="cap0125">
                  <ce:simple-para id="tspara0015" view="all">Reported enzymatic potency for JAK family members approved by FDA and PMDA.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0130" role="short">TableÂ 2</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col5" namest="col2" role="colgroup">enzyme assay IC<inf loc="post">50</inf> (nM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TYK2</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">77</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">489</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">487</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">787</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left"><1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>TableÂ 3</ce:label>
               <ce:caption id="cap0130">
                  <ce:simple-para id="tspara0020" view="all">Pharmacokinetic parameters of <ce:bold>Peficitinib</ce:bold> (<ce:bold>4</ce:bold>) in rats after oral (po) and intravenous administration (iv).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0135" role="short">TableÂ 3</ce:alt-text>
               <tgroup cols="9">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Dose (mg/kg)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">C<inf loc="post">max</inf> (ng/mL)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">t<inf loc="post">max</inf> (h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AUC<inf loc="post">0-â</inf> (ng<sup loc="post">.</sup>h/mL)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">t<inf loc="post">1/2</inf> (h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CLtot (L/h/kg)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Vdss (L/kg)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">F (%)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">po</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">125.67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">263.67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">iv</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">574.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>TableÂ 4</ce:label>
               <ce:caption id="cap0135">
                  <ce:simple-para id="tspara0025" view="all">Cytokine inhibition profile of <ce:bold>PF-04965842</ce:bold> in HWB: IC<ce:inf loc="post">50</ce:inf> values and number of repeats (n).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0140" role="short">TableÂ 4</ce:alt-text>
               <tgroup cols="11">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <colspec colname="col11" colnum="11"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IFNÎ±<cross-ref id="crosref1115" refid="tbl4fna">
                              <sup loc="post">a</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT3 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IFNÎ³<cross-ref id="crosref1120" refid="tbl4fnb">
                              <sup loc="post">b</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT1 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CD14<sup loc="post">+</sup> IL-6<cross-ref id="crosref1125" refid="tbl4fnc">
                              <sup loc="post">c</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT1 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-10<cross-ref id="crosref1130" refid="tbl4fna">
                              <sup loc="post">a</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT3 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CD8<inf loc="post">+</inf>IL-15<cross-ref id="crosref1135" refid="tbl4fnd">
                              <sup loc="post">d</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT5 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-21<cross-ref id="crosref1140" refid="tbl4fnd">
                              <sup loc="post">d</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT3 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-27<cross-ref id="crosref1145" refid="tbl4fnb">
                              <sup loc="post">b</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT3 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-12<cross-ref id="crosref1150" refid="tbl4fne">
                              <sup loc="post">e</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT4 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-23<cross-ref id="crosref1155" refid="tbl4fne">
                              <sup loc="post">e</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT3 IC<inf loc="post">50</inf> (Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CD34<sup loc="post">+</sup> EPO<cross-ref id="crosref1160" refid="tbl4fnf">
                              <sup loc="post">f</sup>
                           </cross-ref> 
                           <inf loc="post">p</inf>STAT5 IC<inf loc="post">50</inf> (Î¼M)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 4)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 2)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 4)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 2)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 5)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 2)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 2)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 2)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 1)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(nÂ =Â 5)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">PF-04965842</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.189</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.163</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.163</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.511</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.298</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.511</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.271</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.673</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.452</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.178</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Signals through JAK1/TYK2.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Signals through JAK1/JAK2.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Signals through JAK1/JAK2 or TYK2.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0025" view="all">Signals through JAK1/JAK3.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fne">
                  <ce:label>e</ce:label>
                  <ce:note-para id="ntpara0030" view="all">Signals through JAK2/TYK2.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnf">
                  <ce:label>f</ce:label>
                  <ce:note-para id="ntpara0035" view="all">Signals through JAK2/JAK2.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420301227-1334468d133ea9f048a3b7c8de81ea10">
                  <ce:given-name>Pengfei</ce:given-name>
                  <ce:surname>Xu</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420301227-73bbf5c5e0df57fe9606bfbcd4e0523c">
                  <ce:given-name>Pei</ce:given-name>
                  <ce:surname>Shen</ce:surname>
                  <ce:cross-ref id="crosref0015" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420301227-c0d45040a502e4d23d021870f4eb2e30">
                  <ce:given-name>Bin</ce:given-name>
                  <ce:surname>Yu</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420301227-c91804b28baf8aa2b52dd93fb552c5bc">
                  <ce:given-name>Xi</ce:given-name>
                  <ce:surname>Xu</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420301227-66949ec4a2ef5f3418dd9cc1ad1489fb">
                  <ce:given-name>Raoling</ce:given-name>
                  <ce:surname>Ge</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523420301227-32c8a7378d0af17f8fdf433de9c6d4f8">
                  <ce:given-name>Xinying</ce:given-name>
                  <ce:surname>Cheng</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420301227-382cfd7ec840057bbf0ee96d5d79c614">
                  <ce:given-name>Qiuyu</ce:given-name>
                  <ce:surname>Chen</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523420301227-98c85e40316dc74abd31c358b6257d98">
                  <ce:given-name>Jinlei</ce:given-name>
                  <ce:surname>Bian</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0050" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523420301227-4ab2a82e356c267d1143c7cc4b0d3d75">
                  <ce:given-name>Zhiyu</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au10" author-id="S0223523420301227-07c1d891bc34ee21f0fd2e73da68fe47">
                  <ce:given-name>JuBo</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0080" refid="cor2">
                     <ce:sup loc="post">ââ</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420301227-c3fd7adf63bd0d71e2b8235a554fa4bf">
                  <ce:label>a</ce:label>
                  <ce:textfn>Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tongjiaxiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, P.R.China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420301227-b88dc79baea99642b6ddb6e44422d5a9">
                  <ce:label>b</ce:label>
                  <ce:textfn>Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 21009, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Jiangsu Key Laboratory of Drug Design and Optimization</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>21009</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 21009, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523420301227-973bf6c6afc738b15beb585f78435417">
                  <ce:label>c</ce:label>
                  <ce:textfn>Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, 650000, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institute of Medical Biology</sa:organization>
                     <sa:organization>Chinese Academy of Medical Sciences</sa:organization>
                     <sa:city>Kunming</sa:city>
                     <sa:postal-code>650000</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, 650000, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>â</ce:label>
                  <ce:text>Corresponding author. Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tongjiaxiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>ââ</ce:label>
                  <ce:text>Corresponding author. Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tongjiaxiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="29" month="12" year="2019"/></ce:date-received>
            <ce:date-revised day="16" month="2" year="2020"/></ce:date-revised>
            <ce:date-accepted day="16" month="2" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">The Janus kinases or JAKs are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of autoimmune diseases and myeloproliferative disorders. JAKs are activated upon ligand induced receptor homo- or heterodimerization, which results in the immediate phosphorylation of tyrosine residues and the phosphotyrosines then serve as docking sites for cytoplasmic signal transducer and activator of transcription (STAT) proteins which become phosphorylated by the JAKs upon recruitment to the receptor complex. The phosphorylated STAT proteins dimerize and travel to the cellular nucleus, where they act as transcription factors. Interfering in the JAK-STAT pathway has yielded the only approved small molecule kinase inhibitors for immunological indications. Numerous medicinal chemistry studies are currently aimed at the design of novel and potent inhibitors for JAKs. Additionally, whether the second-generation inhibitors which possessed selectivity for JAKs are more efficient are under research. This Perspective summarizes the progress in the discovery and development of JAKs inhibitors, including the potential binding site and approaches for identifying small-molecule inhibitors, as well as future therapeutic perspectives in autoimmune diseases and myeloproliferative disorders are also put forward in order to provide reference and rational for the drug discovery of novel and potent JAKs inhibitors.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420301227/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Autoimmune diseases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>JAKs inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Rheumatoid arthritis (RA)</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>SAR</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Medicinal chemistry</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Protein tyrosine kinases (PTKs) are kinases that catalyze the transfer of É£-phosphate from ATP to protein tyrosine residues [<ce:cross-ref id="crosref0085" refid="bib1">1</ce:cross-ref>]. They can also catalyze the phosphorylation of various substrate protein tyrosine residues, which play an essential role in cell growth, differentiation and proliferation. PTKs are divided into non-receptor tyrosine kinases (NRTKs) and receptor tyrosine kinases (RPTKs) according to whether PTKs exist in membrane receptor or not [<ce:cross-ref id="crosref0090" refid="bib2">2</ce:cross-ref>]. At present, numbers of PTKs have been described and studied, among which Janus kinases (JAKs) are the most extensively researched (NRTKs) from an immunological viewpoint [<ce:cross-ref id="crosref0095" refid="bib3">3</ce:cross-ref>]. The activation of JAKs through the binding of various ligands, such as IFN, LPS, or growth factors will cause the phosphorylation of receptor-associated JAKs. The activated JAKs will lead to the phosphorylation of STAT at tyrosine residues. Finally, phosphorylated STAT (p-STAT) proteins form homo- and heteropolymers which translocate into the nucleus where they induce transcription of target immunity genes, including inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), and pro-inflammatory cytokines [<ce:cross-ref id="crosref0100" refid="bib4">4</ce:cross-ref>]. The simplified vision of the signal cascade is shown in <ce:cross-ref id="crosref0105" refid="fig1">Fig.Â 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>.</ce:para>
                  <ce:para id="p0035" view="all">The innate and adaptive immunity are the components of immune system, of which inappropriate or insufficient responses could result in visceral or systemic dysfunctions [<ce:cross-ref id="crosref0110" refid="bib5">5</ce:cross-ref>]. The first-line defense against pathogens is provided by the innate immune system, which consists of kinds of cell types including macrophages, mononuclear phagocyte, neutrophil granulocyte, dendritic cells, etc. Adaptive immunity, which is targeted at only one pathogen, is the ability of human body to resist infection through acquired infection such as asymptomatic infection or artificial inoculation including vaccine, toxoid, immunoglobulin, etc [<ce:cross-ref id="crosref0115" refid="bib6">6</ce:cross-ref>,<ce:cross-ref id="crosref0120" refid="bib7">7</ce:cross-ref>]. Numbers of cytokines could be released to promote the inflammatory response when JAK-STAT pathways were activated. Therefore, the over-activation of the JAK-STAT pathways have been found in many autoimmune diseases which manifest a large quantity of conditions characterized by errant, chronic auto-inflammation against self-tissues like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc [<ce:cross-ref id="crosref0125" refid="bib8">8</ce:cross-ref>]. Different kinds of proinflammatory cytokines like IL-6 and the type I interferons coupled with JAKs to activate this pathway and exacerbate symptoms of autoimmune diseases, which indicated JAKs play a pivotal role in immunity and autoimmunity [<ce:cross-ref id="crosref0130" refid="bib9">9</ce:cross-ref>]. The approval of the JAKs inhibitor <ce:bold>Tofacitinib</ce:bold> (Xeljanz) in 2012 by the U.S. Food and Drug Administration (FDA) for the treatment of inflammatory indications had demonstrated the efficiency of these therapeutic targets in autoimmune diseases [<ce:cross-ref id="crosref0135" refid="bib10">10</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">In our review, we will summarize the immunological functions of JAKs, as well as a detailed look at the JAKs inhibitors currently in the clinic or approved for the therapeutic efficiency in autoimmune diseases.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">JAKs and their immunological functions</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">JAKs structural aspects</ce:section-title>
                     <ce:para id="p0045" view="all">The JAKs family were first discovered in the early 1990s [<ce:cross-ref id="crosref0140" refid="bib11">11</ce:cross-ref>]. Four members including Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3) and tyrosine kinase 2 (TYK2) are composed in the JAKs family. All subtypes are highly homologous and relatively large protein (120â130Â kDa) of the tyrosine kinase families [<ce:cross-ref id="crosref0145" refid="bib12">12</ce:cross-ref>]. These four enzymes possess seven distinct homologous regions which could be divided into four structural domains including FERM-domain, Src homology domain (SH2), pseudo-kinase domain and kinase domain shown in <ce:cross-ref id="crosref0150" refid="fig2">Fig.Â 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>. There are two structurally related domains in the JAKs which are kinase domain (JH1) and pseudo-kinase domain (JH2) and the tandem kinase domains are the characteristic feature of the JAKs. JH1 is an active protein tyrosine kinase catalytic domain while JH2 is classified as a pseudo-kinase domain which is not functional catalytically [<ce:cross-ref id="crosref0155" refid="bib13">13</ce:cross-ref>]. However, recent research on the JH2 of the JAK2 and TYK2 had indicated that JH2 has an important regulatory role and mutations in JH2 of JAKs have been shown to cause, or be linked to, hematological and immunological diseases [<ce:cross-ref id="crosref0160" refid="bib14">14</ce:cross-ref>]. In general, biochemical data supported by clinical evidence suggest that JH2 possesses both negative as well as positive regulatory function [<ce:cross-ref id="crosref0165" refid="bib15">15</ce:cross-ref>,<ce:cross-ref id="crosref0170" refid="bib16">16</ce:cross-ref>]. Deletion of JH2 causes increased basal activity in JAK2 and JAK3 while abrogating cytokine-induced signaling [<ce:cross-ref id="crosref0175" refid="bib17">17</ce:cross-ref>]. The most frequent somatic mutation, V617F, results in constitutively active JAK2, and is responsible for >95% of polycythemia vera cases and â¼50% of essential thrombocythemia and primary myelofibrosis cases [<ce:cross-ref id="crosref0180" refid="bib18">18</ce:cross-ref>,<ce:cross-ref id="crosref0185" refid="bib19">19</ce:cross-ref>]. The homologous mutations V678F in TYK2 and V658F in JAK1 JH2 also result in a gain-of-function phenotype, suggesting that JH2 plays a similar regulatory function in these JAK kinases [<ce:cross-ref id="crosref0190" refid="bib20">20</ce:cross-ref>]. Random mutagenesis approaches identified mutations in TYK2 JH2 that abrogate the intrinsic catalytic activity and formation of the high-affinity IFN type I receptor [<ce:cross-ref id="crosref0195" refid="bib21">21</ce:cross-ref>]. A similar phenotype is also observed in the autoimmune disease-linked I684S variant of TYK2 [<ce:cross-ref id="crosref0200" refid="bib22">22</ce:cross-ref>]. Recent biochemical and structural data suggests that the pseudokinase domain of JAK2 has low levels of catalytic activity and negatively regulates the activity of the kinase domain [<ce:cross-ref id="crosref0205" refid="bib23">23</ce:cross-ref>,<ce:cross-ref id="crosref0210" refid="bib24">24</ce:cross-ref>]. Crystal structures of inhibitor-bound TYK2 JH2 have been solved but its biochemical and nucleotide-binding characteristics are still elusive. Several members of the pseudokinase family, including TYK2 are linked to human diseases, which has raised interest towards their therapeutic targeting. The JH3 and JH4 supposed to be the SH2 which are believed to play a structural role in stabilizing the confirmation of the JAKs primarily. while the FERM domain (JH5, JH6 and JH7) have the function to interact directly with the intracellular domain of the cytokine receptor and appear to be essential for the overall regulation of the JAKs [<ce:cross-ref id="crosref0215" refid="bib25">25</ce:cross-ref>]. Structures of JAKs had been determined by X-ray crystallography since 2005 and the crystal structure of the JAK3 domain in complex with staurosporine analog <ce:bold>AFN941</ce:bold> illustrated the JAKs protein structure firstly [<ce:cross-ref id="crosref0220" refid="bib26">26</ce:cross-ref>]. In 2006, the crystal structure of the JAK2 domain combined with a pan-JAK inhibitor, 2-<ce:italic>t</ce:italic>-butyl-9-fluoro-3,6-dihydro-7<ce:italic>H</ce:italic>-benz[h]-imidaz[4,5-<ce:italic>f</ce:italic>]isoquinoline-7-one (<ce:bold>CMP6</ce:bold>) developed by Merck Research Laboratories was reported [<ce:cross-ref id="crosref0225" refid="bib27">27</ce:cross-ref>]. JAK1 domain structures in complex with two JAK-specific inhibitors, <ce:bold>CMP6</ce:bold> and <ce:bold>CP-690,550</ce:bold> (<ce:bold>Tofacitinib</ce:bold>) which was developed by Pfizer respectively were provided in 2009 [<ce:cross-ref id="crosref0230" refid="bib28">28</ce:cross-ref>]. Chrencik, Jill E., etÂ al. reported the crystal structures of TYK2, a first in class structure, in complex with <ce:bold>CMP6</ce:bold> which bind in the ATP-binding cavity of JAK isozymes in orientation similar to that observed in crystal structures of JAK1 and JAK2 in 2010 [<ce:cross-ref id="crosref0235" refid="bib29">29</ce:cross-ref>]. At this point, all crystal structures of JAKs family had been disclosed and the development of the inhibitor targeted JAKs enzyme for the treatment of kinds of autoimmune diseases progressed rapidly. As a result, more and more crystal structures of JAKs complex with great numbers of small molecule compounds had been reported recently and four representable protein structures which exhibited in <ce:cross-ref id="crosref0240" refid="fig2">Fig.Â 2</ce:cross-ref> showed the binding pattern of small molecules to proteins. The representative structures of JAKs determined by X-ray crystallography with different ligands are listed (<ce:cross-ref id="crosref0245" refid="tbl1">TableÂ 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>). In published crystal structures of the JAKs, all compounds interact similarly across the JAKs, binding deep in the ATP binding site and making key hydrogen bond interactions with the hinge region [<ce:cross-ref id="crosref0250" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0255" refid="bib30">30</ce:cross-ref>]. In addition, compounds could interact directly with the glycine rich loop (P-loop) in most cases. The homology within the ATP binding site of the JAKs leads to the lack of selectivity of the JAKs inhibitors for JAKs enzyme even under the direction of JAKs crystal structures. Therefore, the first-generation JAKs inhibitors were all pan-inhibitors and the second-generation JAKs inhibitors which possess JAKs enzyme selectivity emerged due to more and more side effects resulted from the inhibition of all JAKs enzyme [<ce:cross-ref id="crosref0260" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0265" refid="bib31">31</ce:cross-ref>]. This part will be discussed in more detail in the next section.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">JAKs immunological functions</ce:section-title>
                     <ce:para id="p0050" view="all">The etiology of many inflammatory and autoimmune diseases is not fully understood while combination of genetic predispositions, environmental and lifestyle triggers are always involved in these conditions [<ce:cross-ref id="crosref0270" refid="bib32">32</ce:cross-ref>]. The undesirable autoimmune responses are often leaded by a break in T and B-cell tolerance against self-antigens which are involved in most pathogenic inflammatory state. As a result, monoclonal antibodies that derive their activity by binding to and blocking the cytokine receptor or the cytokine itself were developed such as Adalimumab which targeted on the biologic tumor necrosis factor (TNF) [<ce:cross-ref id="crosref0275" refid="bib33">33</ce:cross-ref>]. However, there are kinds of disadvantages about these monoclonal antibody drugs including the high cost and inconvenient administration. As a consequence, Protein kinases participated in the signal transduction pathways to modulate the inflammatory response were explored to develop efficient small molecule compounds in the treatment of these autoimmune diseases [<ce:cross-ref id="crosref0280" refid="bib8">8</ce:cross-ref>,<ce:cross-ref id="crosref0285" refid="bib34">34</ce:cross-ref>]. The JAKs play a critical role in both innate and adaptive immunity making them attractive targets for several therapeutic indications of autoimmune diseases for the reason of many cytokines and growth factors important for a variety of immune, inflammatory, and hematopoietic functions signal through JAK/STAT [<ce:cross-ref id="crosref0290" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0295" refid="bib35">35</ce:cross-ref>]. Different kinds of cytokine binding triggers receptor dimerization, which leads to JAK enzyme activation in which the two JAKs phosphorylate each other. Subsequently, JAK-mediated STAT phosphorylation induces dimerization of the STAT signal transduction proteins and their translocation to the nucleus, which initiates gene transcription.</ce:para>
                     <ce:para id="p0055" view="all">Four members including JAK1, JAK2, JAK3 and TYK2 are the content of JAKs enzyme family which expressed in human cells and tissues extensively [<ce:cross-ref id="crosref0300" refid="bib36">36</ce:cross-ref>]. JAK1, which was initially identified in a screen for novel kinases, existed wildly in human tissue cells. Biochemical and genetic studies have indicated a functional and physical association between JAK1 and the cell cytokines such as IFN-Î±/Î², IFN-É£, IL-2, IL-4, IL-6 and IL-10 receptors. Interestingly, the activation of JAK/STAT pathway is through the recruitment and phosphorylation of a pair of JAKs [<ce:cross-ref id="crosref0305" refid="bib36">36</ce:cross-ref>,<ce:cross-ref id="crosref0310" refid="bib37">37</ce:cross-ref>]. JAK1 pairs with the other three JAKs enzyme except itself to transport series of ILs and IFNs in regulating lots of functions such as differentiation of T-cells and NK-cells, antiviral and inflammation as shown in <ce:cross-ref id="crosref0315" refid="fig3">Fig.Â 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>. Characterization of JAK1 knock-out tissues confirmed a critical role for this kinase in the response to IFN, IL cytokine families. Consequently, JAK1 mediation is associated with several autoimmune diseases including RA, Psoriasis and Crohnâs disease which indicates JAK1 might be an efficient therapeutic target for these autoimmune diseases and the development of the JAKs inhibitors in recent years proves it [<ce:cross-ref id="crosref0320" refid="bib38">38</ce:cross-ref>]. Initial biochemical studies implicated JAK2 in the response to receptors from the single-chain such as EPO, TPO and IL-3, IL-5, and GM-CSF cytokine families, as well as the IFNÎ³ receptor [<ce:cross-ref id="crosref0325" refid="bib39">39</ce:cross-ref>]. JAK2 is the only one JAKs enzyme which could pair with itself to transport cytokines in regulating functions including Erythropoiesis, Myelopoiesis and inflammation. JAK2 knock-out mice died of anemia which was consistent with a critical role in definitive erythropoiesis and analysis of JAK2 tissues confirmed an important role in directing the responses to IL-3, IL-5 and IFNÉ£ receptor families [<ce:cross-ref id="crosref0330" refid="bib40">40</ce:cross-ref>]. As a consequence, side effects such as anemia and granulocytopenia could appear when the JAK2 enzyme was inhibited by JAKs pan-inhibitor like <ce:bold>Baricitinib</ce:bold>. Therefore, much efforts have been concentrated on the research of selective JAKs inhibitor also called second generation JAKs enzyme inhibitors in order to avoid these conditions in recent years. On the other hand, humans with JAK2 mutations exhibit myeloproliferative disorders which reminds us targeting on the JAK2 enzyme may be an efficient approach for the treatment of myeloproliferative neoplasms (MPNs) [<ce:cross-refs id="crosrefs0010" refid="bib41 bib42 bib43">41â43</ce:cross-refs>]. JAK3 enzyme is mainly expressed in various hematopoietic tissue cells such as bone marrow cells, thymocytes, NK cells, and activated B lymphocytes and T lymphocytes. Leukocyte-specific JAK3 exclusively associates with the IL-2 receptor É£-chain [<ce:cross-ref id="crosref0335" refid="bib44">44</ce:cross-ref>]. This chain also serves as a component for the receptors of several lymphotrophic cytokines such as IL-4, IL-7, IL-9, IL-15, and IL-21 shown in <ce:cross-ref id="crosref0340" refid="fig3">Fig.Â 3</ce:cross-ref>. It can pair with JAK1 to transport different cytokines so as to play a critical role in lymphoid activity which is associated with severe combined immunodeficiency disease. Consistently, JAK3 knock-out mice develop a similar, but less severe, immunodeficiency syndrome [<ce:cross-ref id="crosref0345" refid="bib45">45</ce:cross-ref>]. Based on the functional characteristics of various subtypes of the JAKs kinase family and specific tissue distribution, JAK3 has become a popular target for the treatment of autoimmune diseases and several small molecule drugs targeted on JAK3 had been approved by FDA in the treatment of autoimmune diseases like <ce:bold>Tofacitinib</ce:bold>. TYK2 regulates the phosphorylation of STAT proteins downstream of the receptors for the cytokines IL-12 and IL-23 as well as Type I interferons such as IFNÎ± and IFNÎ², resulting in the activation of STAT-dependent transcription and functional responses specific for these receptors [<ce:cross-ref id="crosref0350" refid="bib45">45</ce:cross-ref>,<ce:cross-ref id="crosref0355" refid="bib46">46</ce:cross-ref>]. These receptor signaling pathways play key roles in the pathogenesis of autoimmune and inflammatory diseases. Meanwhile, TYK2 deficient mice were reported to be resistant to collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE). As a result, TYK2 has been rationalized as a promising target for developing orally active therapeutic agents for autoimmune and inflammatory disorders [<ce:cross-ref id="crosref0360" refid="bib47">47</ce:cross-ref>]. Interestingly, small molecule compounds targeted on TYK2 enzyme are mostly focused on the TYK2 pseudokinase domain (JH2) for the reason of an important regulatory role of JH2 in TYK2 function and high degree of homology among the JH1 of all JAK family members which is difficult to inhibit TYK2 selectively [<ce:cross-ref id="crosref0365" refid="bib48">48</ce:cross-ref>]. In general, JAKs enzyme play a very important role in the occurrence and development of autoimmune diseases such as RA and all JAKs subtypes participated in the transport of cytokines to affect the cells functions which have been confirmed being an efficient drug target for the treatment of immunity diseases [<ce:cross-ref id="crosref0370" refid="bib49">49</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0050">Assays to monitor JAK modulation</ce:section-title>
                  <ce:para id="p0060" view="all">It is significant to study the assay technology platforms for discovering JAKs inhibitors due to the potential mechanism of compound action and compound-mediated assay interference. Such knowledge would be helpful for the discovery of efficacious JAKs inhibitors. Therefore, we will describe currently available assays for the identification and evaluation of JAKs inhibitors. Basic principles of the different assay types will be included.</ce:para>
                  <ce:section id="sec3.1" view="all">
                     <ce:label>3.1</ce:label>
                     <ce:section-title id="sectitle0055">Enzymatic assays</ce:section-title>
                     <ce:para id="p0065" view="all">Various reagent companies are competing to develop related kinase assays and kits for screening and optimizing new compounds as new drug candidates due to the successful development of a series of drugs targeting protein kinases such as JAKs, AKT and EGFR [<ce:cross-ref id="crosref0375" refid="bib50">50</ce:cross-ref>,<ce:cross-ref id="crosref0380" refid="bib51">51</ce:cross-ref>]. Among them, the biochemical detection method of protein kinase is the most numerous. There are two different classifications of biochemical detection methods for protein kinases: classification according to the detection target or the methodology of the test. According to the detection target, it can be divided into detecting ATP consumption, detecting ADP production amount, detecting peptide substrate and detecting kinase itself. According to the methodological classification of detection, there are isotope labeling analysis, mass spectrometry, nuclear magnetic resonance, reversed phase high performance liquid chromatography and capillary electrophoresis, etc. However, the most frequently used methods are radiolabeled ATP, fluorescent labeling (including fluorescence polarization, fluorescence conjugate energy transfer, time-resolved fluorescence, and chemiluminescence). These methods all use microplate as a carrier that has the advantages of low reagent consumption, fast detection speed and high flux. According to the literatures, there are two most commonly kinases detection assays applied for the enzyme activity test for inhibitors of the JAKs enzyme family including mobility shift assay and HTRF assay and these two assays would be discussed in details in the followed part.</ce:para>
                     <ce:section id="sec3.1.1" view="all">
                        <ce:label>3.1.1</ce:label>
                        <ce:section-title id="sectitle0060">Mobility shift assay</ce:section-title>
                        <ce:para id="p0070" view="all">There is a difference of two charges between the substrate and the product after the kinase reaction that a portion of the substrate is made as a product by the addition of a phosphate group to the kinase. The mobility shift assay uses this difference to separate the substrate and product by using capillary electrophoresis [<ce:cross-ref id="crosref0385" refid="bib52">52</ce:cross-ref>]. PerkinElmerâs Caliper can transfer trace amounts of kinase reaction to microfluidic chips for detection and the process is shown in <ce:cross-ref id="crosref0390" refid="fig4">Fig.Â 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>. FAM or other fluorescent labeling should be attached to the N-terminus of the peptide substrate firstly and the enzymatic reaction should be carried out in the microplate when mobility shift assay is used. at the same time, the aspirating needle should suck a trace amount of the enzyme reaction liquid into the inside of the detection chip. The fluorescently labeled polypeptide substrate and the reaction product are separated due to the difference in charge when a voltage is applied to the separation line in the chip and then the signal is excited and detected in the detection window. The signal of the substrate and product can be seen simultaneously at each sample. The actual conversion rate can be calculated by comparing the peak heights of the polypeptide product and the polypeptide substrate. The advantage of this method is that the enzymatic experiments can be monitored in real time without the addition of a suspending reagent. Additionally, it becomes simple and convenient for the study of enzymatic properties such as slow binding of compounds or irreversible binding tests. In inÂ vitro enzymatic activity tests: the phosphorylation of JAK tide (for JAK2 and JAK3) or IRS1 (for JAK1 and TYK2) peptide substrates were quantified by using a peptide mobility shift assay. Endpoint reactions were carried out at the apparent <ce:italic>Km</ce:italic> (MgATP) for each enzyme (4Â Î¼M for JAK2 and JAK3, 40Â Î¼M for JAK1 and 7Â Î¼M for TYK2) in the presence of compounds and 1Â Î¼M substrate. Samples were analyzed by LabChip 3000 and data was analyzed by using HTS Well Analyzer Software to determine the amount of product formed which was expressed as percent of control activity based on uninhibited and no enzyme controls. Dose-response data were fit using 4 parameter logistic fit software to determine IC<ce:inf loc="post">50</ce:inf>.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.2" view="all">
                        <ce:label>3.1.2</ce:label>
                        <ce:section-title id="sectitle0065">HTRF assay</ce:section-title>
                        <ce:para id="p0075" view="all">It is the abbreviation of homogeneous time-resolved fluorescence technology (the principle is shown in <ce:cross-ref id="crosref0395" refid="fig5">Fig.Â 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>), which improves the TR-FRET technology along with sensitivity and stability. HTRF technology uses a cryptate to provide a more stable bond with europium to avoid the risk of europium atoms falling off. In addition to screening for protein kinase inhibitors, it can also be used to study protein-protein interaction (PPI) inhibitors, the amount of soluble protein and studies of signaling pathway-related proteins [<ce:cross-ref id="crosref0400" refid="bib53">53</ce:cross-ref>]. This detection methods have the following advantages: (1) The antibody is selective, specific, and has a high signal-to-noise ratio; (2) It avoids the interference of the autofluorescence of the compound itself on the experiment; (3) The fluorescence signal has a longer stabilization time and does not need to be detected immediately. (4) Homogeneous reaction, it is easy to quantify. In inÂ vitro enzymatic activity tests: The reactions employed a common peptide substrate, LCB-EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First, 250Â nL of diluted compounds in DMSO were dispensed into the wells of a dry 384-well Black plate. Next, 18Â Î¼L of 1.11Â ÃÂ enzyme and 1.11Â ÃÂ substrate in 1Â ÃÂ assay buffer were added to the wells and shaken and then preincubated for 30Â min at ambient temperature to allow compound binding to equilibrate. After equilibration, 2Â Î¼L of 10Â ÃÂ ATP in 1Â ÃÂ assay buffer was added to initiate the kinase reaction and the plates were shaken and then incubated at ambient temperature for 120Â min. At the end of the incubation, 20Â Î¼L of 2Â ÃÂ stop buffer (streptavidin-Dylight 650, Eu-tagged pY20 antibody, EDTA, HEPES, and Triton) was added to quench the reaction. Plates were shaken and centrifuged and then incubated 60Â min at ambient temperature and then read on a PerkinElmer Envision (Î»exÂ =Â 337Â nm, Î»emÂ =Â 665 and 615Â nm, TRF delay timeÂ =Â 20 Î¼s). HTRF signalÂ =Â 10,000 â 665Â nm reading/615Â nm reading. After normalization to untreated controls, the percent inhibition of the HTRF signal at each compound concentration was calculated. The plot of percent inhibition versus the log of compound concentration was fit with a 4-parameter dose response equation to calculate IC<ce:inf loc="post">50</ce:inf> values.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec3.2" view="all">
                     <ce:label>3.2</ce:label>
                     <ce:section-title id="sectitle0070">Cellular and human whole blood (HWB) assays</ce:section-title>
                     <ce:para id="p0080" view="all">The JAK family is an example of nonreceptor tyrosine kinases (or receptor-associated signaling kinases) that were contrast to transmembrane receptors whose intracellular component contains kinase activity, the cytoplasmic domain of type I and type II cytokine receptors activate JAK family members upon cytokine binding to the receptor leading to JAK phosphorylation and subsequent downstream signaling. As a result, activity based on cellular were usually applied for the determination of the selectivity for different JAK enzymes of the inhibitors due to the differences in <ce:italic>K</ce:italic>
                        <ce:inf loc="post">
                           <ce:italic>M</ce:italic>
                        </ce:inf> values for ATP in the various JAK isoforms [<ce:cross-ref id="crosref0405" refid="bib54">54</ce:cross-ref>]. These cellular assays measure the inhibition of phosphorylation of downstream STAT proteins, either in human blood-derived cell lines such as TF-1Â cells, in human peripheral blood mononuclear cells (PBMCs) or in human whole blood (HWB), upon treatment with varying stimuli. The different cellular stimuli used induce phosphorylation of STATs by either dual JAK3/1, JAK2, dual JAK1/TYK2 or dual JAK2/1 containing pathways. For instance, TF-1Â cells were used to measure JAK1 dependent STAT3 phosphorylation downstream of IL-6 stimulation and JAK2 dependent STAT5 phosphorylation downstream of EPO stimulation. NK92 cells were used to measure TYK2 dependent STAT4 phosphorylation downstream of IL-12 stimulation. PBMCs were used to measure JAK3 dependent STAT5 phosphorylation downstream of IL-15 stimulation. The reason that cell-based assays could be used to judge the selectivity of compounds for different JAK enzymes as different cytokines could cause divergence of different JAK kinases to cause phosphorylation of downstream proteins. Signaling by IL-15 is mediated through the JAK1/JAK3 heterodimer, while signaling by IL-10 is mediated through the JAK1/TYK2 heterodimer. Signaling by IFN is mediated through the JAK1/JAK2 heterodimer, while signaling by IL-12 is mediated through the JAK2/TYK2 heterodimer. Signaling by GM CSF is mediated through the JAK2 heterodimer, while signaling by IL-6 is mediated through the JAK1/TYK2 and JAK2 heterodimer [<ce:cross-ref id="crosref0410" refid="bib55">55</ce:cross-ref>].</ce:para>
                     <ce:para id="p0085" view="all">Since JAKs directly phosphorylate STAT proteins in response to specific cytokine stimulation, measuring the extent of STAT phosphorylation in cells is an indirect measurement of JAK inhibition. The potency and selectivity of inhibitors JAKs enzymes were therefore assessed inÂ vitro in whole blood using intracellular flow cytometry to measure STAT phosphorylation. HWB assays could reflect the activity and selectivity of compounds for JAKs enzyme realistically and efficiently and they are also the most important inÂ vitro experiments for the discovery of potential JAKs inhibitors [<ce:cross-ref id="crosref0415" refid="bib56">56</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.3" view="all">
                     <ce:label>3.3</ce:label>
                     <ce:section-title id="sectitle0075">
                        <ce:italic>InÂ vivo</ce:italic> assays</ce:section-title>
                     <ce:para id="p0090" view="all">The most <ce:italic>inÂ vivo</ce:italic> experiments of JAKs inhibitors are focused on animal models of RA especially for the inhibitors of JAK1, JAK3 and TYK2. However, the evaluation of p-STAT5 levels in female athymic mice which were inoculated SET2 cells and propagated as subcutaneous xenografts is usually used for the <ce:italic>inÂ vivo</ce:italic> experiments of JAK2 inhibitors [<ce:cross-ref id="crosref0420" refid="bib57">57</ce:cross-ref>].</ce:para>
                     <ce:para id="p0095" view="all">Adjuvant-induced arthritis (AIA) in rats and CIA in rats and mice are three most commonly used models for testing potential new therapies for RA. AIA in rats was the first animal model of RA to be described and it is still widely used in the preclinical testing of new agents for arthritis. Classic AIA is induced in Lewis rats by a single intradermal injection of complete Freund adjuvant (CFA). This AIA model is characterized by reliable, rapid onset and progression of a robust and easily measurable polyarticular inflammation, marked bone resorption and periosteal bone proliferation. The effect of JAK1 inhibition by PF-04965842, a drug candidate in clinical phase III, <ce:italic>inÂ vivo</ce:italic> was evaluated using a therapeutic dosing paradigm in a rat AIA disease model. Female Lewis rats immunized with complete Freundâs adjuvant were dosed orally with PF-04965842 or vehicle for seven consecutive days after disease onset as measured by hind paw volume using plethysmography. In the initial study, immunized rats were dosed QD with either 5, 15, or 50Â mg/kg of 25 or vehicle (PO). Because a significant reduction in paw swelling was observed for all doses, a second study was conducted focused on lower doses (0.5, 1, 5, or 15Â mg/kg 25 or vehicle control). A significant reduction of hind paw swelling was observed down to 1Â mg/kg.</ce:para>
                     <ce:para id="p0100" view="all">CIA was first described in rats and is a commonly used model for assessing the efficacy of potential new therapeutic agents for RA. Rat CIA has many similarities to human RA such as females are more susceptible, the onset of arthritis is rapid, typically developing 10â13 days after immunization and peaking at about day 20 then gradually declining. Rat CIA differs from human RA in that it is self-limiting and not characterized by exacerbations and remissions. The rat CIA model differs from the AIA model in several ways: arthritic disease is less common and less severe, there is greater involvement of B cells and the CIA model is complement dependent. A highly JAK1 selective inhibitor 3-((4-Chloro-3-methoxyphenyl) amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide was studied in a rat CIA using a therapeutic dosing paradigm. Rats were immunized and boosted with collagen intradermally at the base of the tail on days one and seven. Animals were stratified into treatment groups with comparable levels of paw inflammation on day 16 and treatment with 3-((4-Chloro-3-methoxyphenyl) amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide (po BID) and dexamethasone (po QD) was initiated on day 17. Both compounds exhibited dose dependent inhibition of inflammation.</ce:para>
                     <ce:para id="p0105" view="all">CIA can be induced by immunization of genetically susceptible strains of mice with heterologous type II collagen in CFA. Following immunization, the animals develop an autoimmune polyarthritis that is characterized by severe cartilage and bone erosions. The lesions in affected joints are similar to those seen in rat CIA. Mouse CIA shares several clinical, histopathological and immunological features with human RA including erythaema and oedema, synovitis, pannus formation and cartilage and bone erosion. The mouse CIA model has a slower onset and a more prolonged duration than the rat CIA model. The mouse has the advantage that there are extensive immunological and genetic tools available to manipulate the disease in this species. A phosphate prodrug was tested in such mouse collagen induced arthritis study. The lower dose of (2R,3R)-2-((3-Carbamoyl-6-phenylpyrrolo[l,2-b] pyridazin-4-yl)amino)-3-hydroxybutyl dihydrogen phosphate, disodium demonstrated comparable efficacy to <ce:bold>Tofacitinib</ce:bold> and it was gratified to observe increased efficacy at the high dose of (2R,3R)-2-((3-Carbamoyl-6-phenylpyrrolo[l,2-b] pyridazin-4-yl)amino)-3-hydroxybutyl dihydrogen phosphate, disodium. Additionally, it displayed robust dose dependent efficacy in mouse CIA model, which demonstrated preclinically that a JAK1/3 inhibitor profile may have utility in the treatment of autoimmune disease [<ce:cross-ref id="crosref0425" refid="bib58">58</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0080">JAKs inhibitors in autoimmune diseases and myeloproliferative disorders</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0085">Pan-inhibitors as the first-generation inhibitors for the treatment of autoimmune diseases and myeloproliferative disorders</ce:section-title>
                     <ce:para id="p0110" view="all">There are currently a series of JAKs inhibitors in development for inflammatory indications and four pan-inhibitors had been approved by FDA or PMDA for the treatment of RA and MPNs which are listed below in <ce:cross-ref id="crosref0430" refid="fig6">Fig.Â 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>. <ce:bold>Tofacitinib</ce:bold> (<ce:bold>1</ce:bold>), developed by Pfizer, received its first regulatory approval for the treatment of moderate to severe RA by FDA on November 6, 2012, under the trade name Xeljanz [<ce:cross-ref id="crosref0435" refid="bib59">59</ce:cross-ref>]. <ce:bold>Ruxolitinib</ce:bold> (<ce:bold>2</ce:bold>), co-developed by Incyte and Novartis, had been approved for the treatment of myelofibrosis under the trade name Jakafi by FDA on November, 2011 [<ce:cross-ref id="crosref0440" refid="bib60">60</ce:cross-ref>]. <ce:bold>Baricitinib</ce:bold> (<ce:bold>3</ce:bold>), co-developed by Incyte and Eli Lilly, was currently approved by FDA on July, 2018, under the trade name Olumiant for moderate to severe RA or RA which is insufficient or intolerant to methotrexate (MTX) [<ce:cross-ref id="crosref0445" refid="bib61">61</ce:cross-ref>]. <ce:bold>Peficitinib</ce:bold> (<ce:bold>4</ce:bold>) was developed by Astellas Pharma and launched in Japan for RA on July, 2019 as a pan-inhibitor for four JAKs enzyme family [<ce:cross-ref id="crosref0450" refid="bib62">62</ce:cross-ref>]. However, all these four JAKs inhibitor approved are JAKs pan-inhibitors and much of the interest in these first-generation inhibitors was due to their impressive efficacy in preclinical models which are shown in <ce:cross-ref id="crosref0455" refid="tbl2">TableÂ 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor> [<ce:cross-ref id="crosref0460" refid="bib4">4</ce:cross-ref>].</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0090">Tofacitinib</ce:section-title>
                        <ce:para id="p0115" view="all">
                           <ce:bold>1</ce:bold> was the first compound developed for the treatment of inflammatory indications and received its first regulatory approval for the treatment of moderate to severe RA by the FDA on November 6, 2012, under the trade name Xeljanz. The discovery of <ce:bold>1</ce:bold> began with a high throughput screen, which resulted in the identification of <ce:bold>5</ce:bold> that possessed a pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine pharmacophoric subunit shown in <ce:cross-ref id="crosref0465" refid="fig7">Fig.Â 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor> [<ce:cross-ref id="crosref0470" refid="bib36">36</ce:cross-ref>,<ce:cross-ref id="crosref0475" refid="bib63">63</ce:cross-ref>]. Great efforts had been made for searching <ce:bold>1</ce:bold> through medicinal chemistry optimization that greater than 1000 synthetic analogues of the original lead compound (<ce:bold>5</ce:bold>) were prepared and evaluated over an approximately three years period. The pyrrolopyrimidine ring was assumed to be the hinge-binding element of the molecule for the reason of changing or adding substitutions around the ring could lead to reduced potency. Consequently, the pyrrolopyrimidine ring was retained and relationships between amino headgroup with the combined cavity of JAKs enzyme were explored in order to achieve program objectives. Improved potency was observed when benzene ring of the lead compound <ce:bold>5</ce:bold> was removed which suggested an advantage for molecules processing an <ce:italic>N</ce:italic>-methylcycloalkyl headgroup motif as illustrated by compound <ce:bold>6</ce:bold>. Biological evaluation results of analogues indicated that methyl of the cycloalkyl was essential and the natural terpenoids, âcarvonesâ, was introduced to address the problem of the optimal stereochemistry affording the structure <ce:bold>7</ce:bold>. Moreover, the need to decrease stereochemical complexity inspired a move to the corresponding piperidine scaffold <ce:bold>8</ce:bold> and the piperidine analogues also improved the druglike properties and facilitated synthetic access to the active site pocket, which is now known as the P-loop of JAKs kinases. Eventually, it was the cyanoacetamide side chain that imparted the best attributes and <ce:bold>1</ce:bold> was obtained.</ce:para>
                        <ce:para id="p0120" view="all">Great efforts were made for the synthesis of <ce:bold>1</ce:bold> since it was discovered as a potent and potential therapeutic way for the treatment of autoimmune diseases such as RA. <ce:bold>1</ce:bold> can be fragmented into two main synthons via retrosynthetic analysis which were shown in <ce:cross-ref id="crosref0480" refid="fig8">Fig.Â 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>: the 4-substituted pyrrolo[2,3-d]pyrimidine (blue part) and a piperidine analogue (yellow part). Challenge of the synthesis of <ce:bold>1</ce:bold> is concentrated on the demand for the piperidine moiety (yellow part) with two asymmetric centers on a kilogram scale. As a result, it can be noticed the plethora of starting materials that were used to attain this intermediate which were shown in <ce:cross-ref id="crosref0485" refid="fig8">Fig.Â 8</ce:cross-ref>. The first description of the synthesis of <ce:bold>1</ce:bold> was disclosed in 2001 by Pfizer and they reported the chiral resolution methods to afford the optically pure products one year later. Ripin etÂ al. reported the synthesis of piperidine moiety from alternative starting material picoline such as picoline, pipecoline and 3-amino-4-methyl pyridine. <ce:small-caps>l</ce:small-caps>-serine is also applied for the preparation of <ce:bold>1</ce:bold> aimed at developing various enantiopure stereoisomers. In general, these synthetic efforts indicate the growing importance of this active pharmaceutical ingredient (API), which is still extensively studied towards several pathologies [<ce:cross-ref id="crosref0490" refid="bib59">59</ce:cross-ref>,<ce:cross-ref id="crosref0495" refid="bib64">64</ce:cross-ref>].</ce:para>
                        <ce:para id="p0125" view="all">
                           <ce:bold>1</ce:bold> was approved by the FDA for the treatment of RA In 2012 and remains in the clinic for additional indications including Ankylosing Spondylitis (NCT03502616, Phase III, recruiting), Ulcerative Colitis (NCT01458951, Phase III, completed), Arthritis Juvenile Idiopathic (NCT03000439, Phase III, recruiting), Psoriatic Arthritis (NCT03486457)psoriatic arthritis (NCT01976364, Phase III, recruiting), AA (NCT03800979, Phase IV, recruiting) and Spondyloarthritis (NCT03504072, Phase IV, recruiting).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0095">Ruxolitinib</ce:section-title>
                        <ce:para id="p0130" view="all">
                           <ce:bold>2</ce:bold>, known as INCB018424, developed by Incyte and Novartis is a potent and selective JAK1/JAK2 inhibitor with 130-fold selectivity for JAK1/JAK2 over JAK3 [<ce:cross-ref id="crosref0500" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0505" refid="bib65">65</ce:cross-ref>]. <ce:bold>2</ce:bold> was approved by the US FDA for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis under the trade name Jakafi in 2011 [<ce:cross-ref id="crosref0510" refid="bib60">60</ce:cross-ref>]. Several groups reported the presence of an activating mutation in the JAK2 gene, which results in a valine to phenyalanine substitution at codon 617 (JAK2<ce:sup loc="post">V617F</ce:sup>) in a substantial proportion of patients with various MPNs in 2005 [<ce:cross-ref id="crosref0515" refid="bib66">66</ce:cross-ref>]. Subsequent experiments prove that ectopic expression of JAK2<ce:sup loc="post">V617F</ce:sup> in mice results in MPN-like phenotypes which supports an important role for this mutation in human MPNs. Oral administration of <ce:bold>2</ce:bold> markedly reduced splenomegaly, levels of circulating inflammatory cytokines and preferentially eliminated JAK2<ce:sup loc="post">V617F</ce:sup>-mutant cells and increased survival in a mouse model of JAK2<ce:sup loc="post">V617F</ce:sup>-positive MPNs.</ce:para>
                        <ce:para id="p0135" view="all">A multi-institution Phase I trial of <ce:bold>2</ce:bold> in patients with Chronic Myelomonocytic Leukemia (CMML) demonstrates that <ce:bold>2</ce:bold> has promising activity in CMML with particular benefit in those with disease-related B symptoms that warrants further study [<ce:cross-ref id="crosref0520" refid="bib67">67</ce:cross-ref>]. In this clinical study, 20 patients were enrolled and treated with <ce:bold>2</ce:bold> during March 2013 and January 2015. Four patients had hematologic improvement and one patient had a partial response per 2006 International Working Group (IWG) criteria. Five of 9 patients with splenomegaly had a reduction in spleen size. Additionally, Ten of 11 patients with reported disease-related symptoms had clinically meaningful or complete resolution. Importantly, no dose limiting toxicities for <ce:bold>2</ce:bold> were identified and correlative analysis demonstrated a reduction in inflammatory cytokines and GM-CSFâdependent STAT5 phosphorylation. In general, this clinical study provides the first clinical evidence that <ce:bold>2</ce:bold> is a targetable and clinically relevant vulnerability in CMML extending the JAK/STAT pathway.</ce:para>
                        <ce:para id="p0140" view="all">The JAK-STAT signaling pathway also plays a key role in the systemic inflammatory response in many cancers including colorectal cancer (CRC). As a result, a multicenter Phase II study evaluated the addition of <ce:bold>2</ce:bold> to Regorafenib in patients with relapsed/refractory metastatic CRC [<ce:cross-ref id="crosref0525" refid="bib68">68</ce:cross-ref>]. Although the study was terminated early for the reason of futility at interim analysis and sponsor decision and addition of <ce:bold>2</ce:bold> to Regorafenib did not improve overall survival/progression-free survival vs. regorafenib plus placebo. They did not show increased safety concerns in patients with relapsed/refractory metastatic CRC which indicated another therapeutic strategy for these conditions. Another drug combination therapeutic way was the combination of Afatinib and <ce:bold>2</ce:bold> in EGFR mutant NSCLC with progression on EGFR-TKIs [<ce:cross-ref id="crosref0530" refid="bib69">69</ce:cross-ref>]. They evaluated the safety and efficacy of the combination therapy of Afatinib and <ce:bold>2</ce:bold> in patients with EGFR mutant NSCLC progressing on at least one kind of EGFR-TKI in a phase I open-label study (NCT02145637). The clinical results indicated that the combination of Afatinib and <ce:bold>2</ce:bold> was tolerated by patients, with modest clinical activity observed in NSCLC with acquired resistance to EGFR-TKIs. <ce:bold>2</ce:bold> in combination with corticosteroids for the treatment of steroid-refractory Acute Graft-Vs-Host Disease (aGVHD) was evaluated in a clinical Phase II trial (NCT02953678) [<ce:cross-ref id="crosref0535" refid="bib70">70</ce:cross-ref>]. aGVHD is a serious complication of allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with less than 50% of patients achieve sustained responses with first-line corticosteroid treatment. The results disclosed that overall response rate (ORR) was 54.9% by day 28 and 73.2% at any time during treatment in this first prospective trial of <ce:bold>2</ce:bold> in Steroid-Refractory (SR) aGVHD. The AE profile was consistent with expectations for <ce:bold>2</ce:bold> and patients with SR aGVHD which indicated that <ce:bold>2</ce:bold> represents a promising therapeutic strategy.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0100">Baricitinib</ce:section-title>
                        <ce:para id="p0145" view="all">
                           <ce:bold>3</ce:bold>, also called INCB028050 or LY3009104, developed by Incyte and Lilly is a potent and selective JAK1/JAK2 inhibitor with 100-fold selectivity for JAK1/JAK2 over JAK3 [<ce:cross-ref id="crosref0540" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0545" refid="bib71">71</ce:cross-ref>]. <ce:bold>3</ce:bold> was currently approved by the US FDA for the treatment of patients with moderate to severe RA or RA which is insufficient or intolerant to MTX under the trade name Olumiant in 2018 [<ce:cross-ref id="crosref0550" refid="bib72">72</ce:cross-ref>]. <ce:bold>3</ce:bold> proves to be a potent inhibitor of JAK signaling and function in cell-based assays. It inhibits IL-6-stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC<ce:inf loc="post">50</ce:inf> values of 44Â nM and 40Â nM respectively In PBMCs. It also inhibits pSTAT3 stimulated by IL-23 with IC<ce:inf loc="post">50</ce:inf> value of 20Â nM in isolated naive T-cells. Importantly, this inhibition prevented the production of two pathogenic cytokines (IL-17 and IL-22) produced by Th17 cells-a subtype of helper T cells with demonstrable inflammatory and pathogenic properties-with an IC<ce:inf loc="post">50</ce:inf> value of 50Â nM [<ce:cross-ref id="crosref0555" refid="bib73">73</ce:cross-ref>]. <ce:bold>3</ce:bold> inhibits the increase in hind paw volumes during the 2 weeks of treatment by 50% at a dose of 1Â mg/kg and >95% at doses of 3 or 10Â mg/kg compare with vehicle. Mice treated with <ce:bold>3</ce:bold> (0.7Â mg/day) exhibits substantially reduced inflammation as assessed by H&E staining, reduced CD8 infiltration and reduced MHC class I and class II expression when compared with vehicle-control treated mice. Additionally, CD8+NKG2DÂ +Â cells which are critical effectors of disease in murine and human alopecia areata (AA) are greatly diminished in <ce:bold>3</ce:bold> treated mice compare with vehicle control treated mice [<ce:cross-ref id="crosref0560" refid="bib74">74</ce:cross-ref>].</ce:para>
                        <ce:para id="p0150" view="all">Autoimmune diseases such as SLE is still associated with significant mortality and severe burden despite improvements in diagnostics and therapy over the past few decades [<ce:cross-ref id="crosref0565" refid="bib75">75</ce:cross-ref>]. Recent results from a double-blind, placebo-controlled Phase II randomized controlled trial of <ce:bold>3</ce:bold> in patients with SLE indicated that Patients receiving <ce:bold>Baricitinib</ce:bold> 4Â mg reached the primary endpoint of resolution of arthritis or rash [<ce:cross-ref id="crosref0570" refid="bib76">76</ce:cross-ref>]. There were also no notable safety concerns and the predefined secondary endpoints of SLE Responder Index-4 response, Lupus Low Disease Activity Score and flares of any severity were significantly improved in the <ce:bold>Baricitinib</ce:bold> 4Â mg group versus the placebo group. This first trial and the positive findings indicate that <ce:bold>3</ce:bold> could be a favorable drug for SLE [<ce:cross-ref id="crosref0575" refid="bib77">77</ce:cross-ref>].</ce:para>
                        <ce:para id="p0155" view="all">
                           <ce:bold>3</ce:bold> is also applied for the treatment of Atopic Dermatitis (AD) which is the most common chronic inflammatory skin disease. A Phase II parallel, double-blinded, randomized placebo-controlled multiple-dose study of <ce:bold>3</ce:bold> in adult patients with moderate-to-severe AD was carried out [<ce:cross-ref id="crosref0580" refid="bib78">78</ce:cross-ref>]. 124 patients with moderate-to-severe AD applied topical corticosteroids (TCSs) for 4 weeks before randomization to once daily placebo, 2Â mg of <ce:bold>Baricitinib</ce:bold> and 4Â mg of <ce:bold>Baricitinib</ce:bold> for 16 weeks in this Phase II study. The primary outcome was the proportion of patients achieving at least a 50% reduction in the Eczema Area and Severity Index (EASI-50) compared with placebo. The study results shown that significantly more patients who received <ce:bold>3</ce:bold> (4Â mg) achieved EASI-50 than patients receiving placebo (61% vs 37% [PÂ =Â 0.027]) at 16 weeks and <ce:bold>3</ce:bold> also improved pruritus and sleep loss. In general, <ce:bold>3</ce:bold> used with TCSs reduced inflammation and pruritus in patients with moderate to severe AD but longer studies are required to confirm <ce:bold>3</ce:bold>âs efficacy and safety.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0105">Peficitinib</ce:section-title>
                        <ce:para id="p0160" view="all">
                           <ce:bold>4</ce:bold>, also known as ASP015K, was the latest JAKs pan-inhibitor developed for the treatment of inflammatory indications and received its regulatory approval for the treatment of RA by the PMDA on July 10, 2019, under the trade name Smyraf [<ce:cross-ref id="crosref0585" refid="bib79">79</ce:cross-ref>]. Hisao, H etÂ al. reported the discovery of <ce:bold>4</ce:bold> as a novel and potent JAKs inhibitor in 2018 [<ce:cross-ref id="crosref0590" refid="bib62">62</ce:cross-ref>]. In their previous research, 1<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>b</ce:italic>]pyridine-5-carboxamide derivative <ce:bold>9</ce:bold> shown in <ce:cross-ref id="crosref0595" refid="fig9">Fig.Â 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor> was identified as a lead compound and a potent and moderately selective JAK3 inhibitor while poor metabolic stability in liver microsomes and <ce:italic>inÂ vivo</ce:italic> Pharmacokinetic (PK) profiles due to high molecule lipophilicity prevented the progress of these analogues as efficient JAKs enzyme inhibitors. To enhance the affinity of the hydrophobic cavity, they investigated the conversion of the cyclohexane ring of <ce:bold>9</ce:bold> to a bridged ring like adamantane because docking calculations of <ce:bold>9</ce:bold> to JAK3 indicated that the cyclohexane ring was directed towards the hydrophobic cavity and bulkiness of the substituent was favorable to JAK3 inhibitory activity. After that, efforts were made for the purpose of decreasing the molecule lipophilicity of these series of molecules and previous study indicated the introduction of a polar functional group could reduce metabolic clearance and improve oral absorption. As a result, a polar functional group like hydroxy was introduced in the adamantyl moiety to decrease the molecule lipophilicity of compound <ce:bold>10</ce:bold> and a very potential pan-inhibitor <ce:bold>4</ce:bold> of JAKs enzyme was obtained. The introduction of the hydroxy of the adamantyl moiety lead to the formation of a hydrogen bond between polar residues exhibited in <ce:cross-refs id="crosrefs0015" refid="fig4 fig9">Figs.Â 9 and 4</ce:cross-refs> showed high metabolic stability in human liver microsomes (CL<ce:inf loc="post">int</ce:inf>Â =Â 26Â mL/min/kg) which was consistent with the initial medicinal chemistry optimization planning.</ce:para>
                        <ce:para id="p0165" view="all">
                           <ce:bold>4</ce:bold> inhibited IL-2-induced rat (IC<ce:inf loc="post">50</ce:inf>Â =Â 10Â nM) and human T cell proliferation (IC<ce:inf loc="post">50</ce:inf>Â =Â 18Â nM) with similar potency additionally. Furthermore, <ce:bold>4</ce:bold> prevented EPO-induced proliferation of the human erythroleukemia cell line TF-1 (IC<ce:inf loc="post">50</ce:inf>Â =Â 248Â nM), which involves JAK2 activity, with 14-fold less potency than that against human T cell proliferation and the milder inhibition of JAK2 by <ce:bold>4</ce:bold> may contribute to the alleviation of JAK2-mediated adverse hematopoietic effects [<ce:cross-ref id="crosref0600" refid="bib80">80</ce:cross-ref>]. PK study of <ce:bold>4</ce:bold> was performed in rats, and the results following oral and intravenous administration showed good oral bioavailability (45.9%) which was displayed in <ce:cross-ref id="crosref0605" refid="tbl3">TableÂ 3</ce:cross-ref>
                           <ce:float-anchor refid="tbl3"/></ce:float-anchor>. Moreover, <ce:bold>4</ce:bold> exhibited dose-dependent efficacies by oral administration in prophylactic and therapeutic dosing regimens in an adjuvant-induced arthritis rat model which suggested that <ce:bold>4</ce:bold> could be a potentially effective small molecule for the oral treatment of RA and other autoimmune disorders.</ce:para>
                        <ce:para id="p0170" view="all">A Phase IIb study in Japanese patients with moderate to severe RA treated with <ce:bold>4</ce:bold> monotherapy for 12 weeks demonstrated that <ce:bold>4</ce:bold> was efficacious and had an acceptable safety profile [<ce:cross-ref id="crosref0610" refid="bib81">81</ce:cross-ref>]. Two other Phase IIb studies of <ce:bold>4</ce:bold> have also been conducted in non-Japanese populations and a separate study of <ce:bold>4</ce:bold> (RAJ3) has recently completed in patients with an inadequate response to Disease Modifying Antirheumatic Drugs (DMARDs) [<ce:cross-ref id="crosref0615" refid="bib82">82</ce:cross-ref>,<ce:cross-ref id="crosref0620" refid="bib83">83</ce:cross-ref>]. Recently, the results of the RAJ4 study (NCT02305849) of <ce:bold>4</ce:bold> with two dosage regimens in combination with MTX, compared with placebo, in Japanese patients with RA and an inadequate response to MTX had been published [<ce:cross-ref id="crosref0625" refid="bib84">84</ce:cross-ref>]. This Phase III study assessed the efficacy and safety of <ce:bold>4</ce:bold> and two doses (100 and 150Â mg/day) were selected for this study based on previous efficacy and safety findings. The evidence that once-daily <ce:bold>4</ce:bold> 100 and 150Â mg demonstrates robust clinical and structural efficacy in patients with RA who have an inadequate response to MTX is provided by this clinical study. An extension study is also ongoing to further evaluate safety and efficacy of <ce:bold>4</ce:bold> (NCT01638013), specifically to confirm the persistence of treatment response and to ascertain that <ce:bold>4</ce:bold>âs safety profile does not differ greatly from the safety profile of other JAK inhibitors over long-term treatment. In general, <ce:bold>4</ce:bold> demonstrated significant superiority versus placebo in reducing RA symptoms and suppressing joint destruction in Japanese patients with RA and inadequate response to MTX and had an acceptable safety and tolerability profile, with no new safety signals compared with other JAK inhibitors.</ce:para>
                        <ce:para id="p0175" view="all">A Phase II study (NCT01959282) of <ce:bold>4</ce:bold> as an oral JAKs inhibitor for the treatment of moderate to severe Ulcerative Colitis (UC) had been completed [<ce:cross-ref id="crosref0630" refid="bib85">85</ce:cross-ref>]. In this Phase IIb study, dose-ranging trial, <ce:bold>4</ce:bold> was evaluated at 25Â mg once daily, 75Â mg once daily, 150Â mg once daily, and 75Â mg twice daily versus placebo for efficacy and safety in 219 patients with moderate to severe UC. The primary outcome was dose-response of <ce:bold>4</ce:bold>Â atÂ Week 8 assessed using Mayo score change from baseline. Secondary endpoints were clinical response, clinical remission, mucosal healing, change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ), and normalization of inflammatory biomarkers at Week 8 and other secondary endpoints were treatment response through Week 16 and 32 for patients in clinical response at Week 8. Safety was assessed through Week 36 or four weeks after the last dose. A statistically significant <ce:bold>4</ce:bold> dose-response was not demonstrated at Week 8 while a numerically greater proportion of patients receiving <ce:bold>4</ce:bold>Â â¥Â 75Â mg once daily achieved clinical response, remission, and mucosal healing at Week 8. The clinical response, remission, and mucosal healing were supported by IBDQ improvement and inflammatory biomarker normalization. In general, evidence of efficacy was suggested at doses â¥75Â mg once daily although no dose-response in patients with moderate to severe UC was demonstrated with <ce:bold>4</ce:bold> and the safety profile of <ce:bold>4</ce:bold> was consistent with current information. Future development of <ce:bold>4</ce:bold> in UC should consider more frequent or higher once daily doses and a primary endpoint >8 weeks for optimal efficacy.</ce:para>
                        <ce:para id="p0180" view="all">
                           <ce:bold>4</ce:bold> was also evaluated in a Phase II, double-blinded, placebo-controlled study (NCT01096862) in patients with moderate to severe Psoriasis for the purpose of exploring the efficacy and safety of multiple, escalating doses of <ce:bold>4</ce:bold> when compared to placebo [<ce:cross-ref id="crosref0635" refid="bib86">86</ce:cross-ref>]. Five sequential <ce:bold>4</ce:bold> cohorts were enrolled, consisting of 4 twice daily dosing groups (10, 25, 60, 100Â mg) and 1 once daily dosing group (50Â mg) for 6 weeks. The primary efficacy endpoint significantly favored <ce:bold>4</ce:bold> versus placebo, with greater improvements at higher doses. The secondary endpoints Physician Static Global Assessment (PSGA) score, percentage of patients achieving PSGA success, change in percent body surface area (%BSA) improved and epidermal thickness and proliferation decreased from baseline with <ce:bold>4</ce:bold>, versus placebo by the end of treatment. Generally, <ce:bold>4</ce:bold> was well tolerated, with no serious adverse events reported at all doses and demonstrated dose dependent improvements in clinical and histologic measures of severity over 6 weeks of treatment in patients with moderate to severe psoriasis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0110">Other pan-inhibitors of JAKs enzyme family under clinical or preclinical study</ce:section-title>
                        <ce:para id="p0185" view="all">There are many other pan-inhibitors of JAKs enzyme family except the four marketed inhibitors discussed above due to the important roles of the JAKs in the functional regulating of autoimmune diseases (<ce:cross-ref id="crosref0640" refid="fig10">Fig.Â 10</ce:cross-ref>
                           <ce:float-anchor refid="fig10"/></ce:float-anchor>). <ce:bold>Oclacitinib</ce:bold> (<ce:bold>11</ce:bold>) had been approved only in dogs by FDA in 2013 for treatment of itching and AD caused by canine allergic dermatitis [<ce:cross-ref id="crosref0645" refid="bib87">87</ce:cross-ref>]. <ce:bold>Momelotinib</ce:bold> (<ce:bold>12</ce:bold>), also known as <ce:bold>CYT387</ce:bold>, was developed by Gilead and is currently in Phase III clinical stage as a potential JAK1/JAK2 inhibitor for the treatment of myelofibrosis, polycythemia and thrombocytopenia [<ce:cross-ref id="crosref0650" refid="bib88">88</ce:cross-ref>]. <ce:bold>PF-06700841</ce:bold> (<ce:bold>13</ce:bold>) was developed by Pfizer as a JAK1/TYK2 inhibitor for the treatment of psoriasis and other autoimmune indications in Phase II trials [<ce:cross-ref id="crosref0655" refid="bib89">89</ce:cross-ref>]. <ce:bold>AT9283</ce:bold> (<ce:bold>14</ce:bold>) is a JAK2/JAK3 inhibitor as well as aurora kinase inhibitor developed by Astex Therapeutics Ltd. and is recently in Phase II clinical study for the treatment of Multiple Myeloma [<ce:cross-ref id="crosref0660" refid="bib90">90</ce:cross-ref>]. <ce:bold>Cerdulatinib</ce:bold> (<ce:bold>15</ce:bold>) was developed by Portola Pharmaceuticals as a pan-inhibitor of JAKs enzyme family and is recruiting Phase II study for the treatment of patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) [<ce:cross-ref id="crosref0665" refid="bib91">91</ce:cross-ref>]. Pyridion <ce:bold>6</ce:bold> (<ce:bold>16</ce:bold>) is a pan-inhibitor, which potently inhibits the JAKs enzyme family, with IC<ce:inf loc="post">50</ce:inf> of 1Â nM for JAK2 and TYK2, 5Â nM for JAK3 and 15Â nM for JAK1 while displaying significantly weaker affinities for other protein tyrosine kinases [<ce:cross-ref id="crosref0670" refid="bib92">92</ce:cross-ref>]. <ce:bold>Delgocitinib</ce:bold> (<ce:bold>17</ce:bold>) potently inhibits all of the JAKs subtypes with IC<ce:inf loc="post">50</ce:inf> values of 2.8, 2.6, 13 and 58Â nM for JAK1, JAK2, JAK3 and TYK2 respectively in the enzymatic assays and is currently in Phase II study for the treatment of Chronic Hand Eczema and Discoid Lupus Erythematosus [<ce:cross-ref id="crosref0675" refid="bib93">93</ce:cross-ref>]. <ce:bold>AZD-1480</ce:bold>, developed by AstraZeneca, is a potent inhibitor of JAK1 and JAK2 with IC<ce:inf loc="post">50</ce:inf> of 1.3 andÂ <Â 0.4Â nM respectively and is in Phase I study for the treatment of Solid Malignancies and Primary Myelofibrosis since 2010 [<ce:cross-ref id="crosref0680" refid="bib94">94</ce:cross-ref>].</ce:para>
                        <ce:para id="p0190" view="all">
                           <ce:bold>11</ce:bold> was developed by Pfizer as a novel JAKs inhibitor with IC<ce:inf loc="post">50</ce:inf> values of 10, 18, 99 and 84Â nM for JAK1, JAK2, JAK3 and TYK2 respectively [<ce:cross-ref id="crosref0685" refid="bib87">87</ce:cross-ref>,<ce:cross-ref id="crosref0690" refid="bib95">95</ce:cross-ref>]. It also inhibits the function of JAK1-dependent cytokines in some anti-allergic, inflammatory and pruritic reactions. Studies have confirmed that experimental animals (dogs) are orally administered twice a day at a dose of 0.4â0.6Â mg/kg, which is safe and effective for the treatment of itching due to AD [<ce:cross-ref id="crosref0695" refid="bib96">96</ce:cross-ref>]. During the treatment, <ce:bold>11</ce:bold> was relieved of itching within 24Â h, and more than 70% of the experimental animals alleviated more than 50% of the pruritus reaction on day 7.<ce:bold>11</ce:bold> had been approved by FDA in 2013 only for dogs to control itching and AD caused by canine allergic dermatitis. However, although oclacitinib has a good effect on allergic skin diseases in dogs, its effect is narrow. It cannot fundamentally directly block the binding of allergic mediators to related receptors, and thus does not fundamentally block the development of allergic skin diseases.</ce:para>
                        <ce:para id="p0195" view="all">
                           <ce:bold>12</ce:bold> was originally developed by Cytopia, an Australian biotechnology company, then acquired by Gilead in 2013 as an orally JAK1/JAK2 inhibitor. Two completed clinical Phase III trials and other clinical Phase II trials have shown that the drug has distinctive treatment characteristics in the treatment of myelofibrosis including a series of improvements that are meaningful for anemia, eliminating or reducing frequent blood transfusions and achieving substantial control of the spleen and systemic symptoms [<ce:cross-ref id="crosref0700" refid="bib97">97</ce:cross-ref>]. <ce:bold>12</ce:bold> also has clear and predictable security that more than 180 patients are still receiving long-term treatment, some of whom have benefited from this treatment for more than seven years, which once again proves its potential long-lasting efficacy and good long-term tolerance [<ce:cross-ref id="crosref0705" refid="bib98">98</ce:cross-ref>].</ce:para>
                        <ce:para id="p0200" view="all">
                           <ce:bold>13</ce:bold> is a dual JAK1 and TYK2 inhibitor with IC<ce:inf loc="post">50</ce:inf> of 17 and 23Â nM respectively developed by Pfizer. Early bicyclic leads identified from the Pfizer compound collection were developed into a series of 3,8-diazabicyclo-[3.2.1]octane substituted pyrimidines shown in <ce:cross-ref id="crosref0710" refid="fig11">Fig.Â 11</ce:cross-ref>
                           <ce:float-anchor refid="fig11"/></ce:float-anchor>
                           <ce:float-anchor refid="fig12"/></ce:float-anchor>, which delivered potent dual TYK2 and JAK1 potency with appropriate in-family selectivity against JAK2 and JAK3 [<ce:cross-ref id="crosref0715" refid="bib89">89</ce:cross-ref>]. The potential compound from this series, <ce:bold>13</ce:bold>, has an excellent off-target polypharmacology profile and ADME profile consistent with once daily dosing in humans. <ce:bold>13</ce:bold> has completed a Phase I clinical study in healthy volunteers and psoriasis patients and is currently being studied in multiple indications in Phase II trials (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</ce:para>
                        <ce:para id="p0205" view="all">
                           <ce:bold>14</ce:bold> is a multitargeted kinase inhibitor which potently inhibits JAK2/3 (IC50Â =Â 1.2Â nM, 1.1Â nM) respectively. <ce:bold>14</ce:bold>, a clinical candidate, was identified via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Interestingly, <ce:bold>14</ce:bold> was initial developed for a potent inhibitor of Aurora kinase while exhibited efficient inhibition toward JAK2 and JAK3 kinases [<ce:cross-ref id="crosref0720" refid="bib99">99</ce:cross-ref>]. On the basis of the good balance between inÂ vitro potency and physicochemical properties, <ce:bold>14</ce:bold> was chosen for further studies <ce:italic>inÂ vivo</ce:italic>. Pharmacokinetics study of <ce:bold>14</ce:bold> was considered suitable for development of it as an iv agent with the potential for oral administration. Compound <ce:bold>14</ce:bold> was evaluated for its <ce:italic>inÂ vivo</ce:italic> antitumor activity in immunocompromised BALB/c nude mice bearing early stage HCT116 human colon carcinoma xenografts with the tumor growth inhibition of 67% and 76% in the doses of 15 and 20Â mg/kg respectively [<ce:cross-ref id="crosref0725" refid="bib100">100</ce:cross-ref>]. As a result, <ce:bold>14</ce:bold> is recently in Phase II clinical study for the treatment of Multiple Myeloma and other cancer.</ce:para>
                        <ce:para id="p0210" view="all">
                           <ce:bold>15</ce:bold> was developed by Portola Pharmaceuticals as a JAKs and SYK double inhibitor and the company announced that FDA has granted the orphan drug status of <ce:bold>15</ce:bold> for the treatment of PTCL recently. <ce:bold>15</ce:bold> inhibits two key cellular signaling pathways associated with certain hematological malignancies and autoimmune diseases which play important roles in PTCL tumor survival. In addition to PTCL, Portola is also conducting a Phase II clinical trial evaluating <ce:bold>15</ce:bold> for other specific subtypes of B-cell and T-cell non-Hodgkinâs lymphoma (NHL), including relapsed/refractory Follicular Lymphoma (FL) and Chronic Lymphocytic Lymphoma/Small Cell Lymphoma (CLL/SLL) [<ce:cross-ref id="crosref0730" refid="bib101">101</ce:cross-ref>]. The results showed that <ce:bold>15</ce:bold> showed extensive clinical activity, with an objective response rate of 47% in all patients and was tolerated. In addition, in the PTCL, 7 patients in 20 achieved complete remission.</ce:para>
                        <ce:para id="p0215" view="all">
                           <ce:bold>16</ce:bold> is a potent also a selective JAK inhibitor and showed IC<ce:inf loc="post">50</ce:inf> values of more than 130Â nM when tested against other kinases. In B9 cells, treatment of <ce:bold>16</ce:bold>Â at concentration of 250Â nM significantly decreased the phosphorylation of STAT3 induced by IL-6. Treatment of 1Â Î¼M almost completely inhibited the phosphorylation of STAT3. Besides that, <ce:bold>16</ce:bold> suppressed cell proliferation with IC<ce:inf loc="post">50</ce:inf> value of 250Â nM in U266Â cells and caused a modest cell growth reduction and G1 arrest. However, a polylactic acid formulation of <ce:bold>16</ce:bold> and glycolic acid has been applied in animal model Due to the low water solubility of <ce:bold>16</ce:bold>. In mice model of AD, administration of <ce:bold>16</ce:bold> is found to have therapeutic activity through modifying Th cell differentiation and inhibiting mast cell function [<ce:cross-ref id="crosref0735" refid="bib102">102</ce:cross-ref>].</ce:para>
                        <ce:para id="p0220" view="all">
                           <ce:bold>17</ce:bold>, also called JTE-052, is a pan-inhibitor of JAKs enzyme family developed by Japan Tobacco Inc. In cell-based cytokine signaling assays, <ce:bold>17</ce:bold> inhibits the phosphorylation of STAT proteins induced by IL-2, IL-6, IL-23, GM-CSF, and IFN-Î± with IC<ce:inf loc="post">50</ce:inf> values of 40, 33, 84, 304 and 18Â nM respectively. <ce:bold>17</ce:bold> also inhibits IL-2-induced proliferation of T cells in a concentration-dependent manner with IC<ce:inf loc="post">50</ce:inf> values of 8.9Â nM and its potency is similar to that of <ce:bold>1</ce:bold> (IC<ce:inf loc="post">50</ce:inf>Â =Â 16Â nM) [<ce:cross-ref id="crosref0740" refid="bib83">83</ce:cross-ref>]. <ce:bold>17</ce:bold> is currently being studied in multiple indications in Phase I and Phase II trials (NCT 03826901, NCT 03958955 and NCT 03683719).</ce:para>
                        <ce:para id="p0225" view="all">
                           <ce:bold>18</ce:bold> is an inhibitor of JAK1 and JAK2 developed by AstraZeneca and the Phase I study of <ce:bold>18</ce:bold> for the patients with Myeloproliferative diseases had completed while two Phase I studies of <ce:bold>18</ce:bold> for the treatment of solid tumor had been terminated the discontinued compound development. <ce:bold>18</ce:bold> is capable of inhibiting STAT3 phosphorylation and tumor growth in a STAT3-dependent manner it can also inhibit tumor angiogenesis and metastasis in part by affecting the tumor microenvironment [<ce:cross-ref id="crosref0745" refid="bib103">103</ce:cross-ref>]. <ce:italic>InÂ vivo</ce:italic>, <ce:bold>18</ce:bold> inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial glioblastoma (GBM) tumors by inhibiting STAT3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by <ce:bold>18</ce:bold> should be considered for study in the treatment of patients with GBM tumors [<ce:cross-ref id="crosref0750" refid="bib103">103</ce:cross-ref>,<ce:cross-ref id="crosref0755" refid="bib104">104</ce:cross-ref>]. <ce:bold>18</ce:bold> blocks lung infiltration of myeloid cells and formation of pulmonary metastases in both mouse syngeneic experimental and spontaneous metastatic models. Furthermore, <ce:bold>18</ce:bold> reduces angiogenesis and metastasis in a human xenograft tumor model [<ce:cross-ref id="crosref0760" refid="bib105">105</ce:cross-ref>].</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0115">Advances in the second-generation JAKs inhibitors with selectivity to JAKs enzyme family for the treatment of autoimmune diseases and myeloproliferative disorders</ce:section-title>
                     <ce:para id="p0230" view="all">A new wave of more selective JAK inhibitors have been recently reported as a result of our increasing knowledge of the importance of kinase selectivity for safety along with the desire to understand the roles and impact of the individual JAK family members on disease [<ce:cross-ref id="crosref0765" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0770" refid="bib36">36</ce:cross-ref>]. As we discussed above, JAK2 is exclusively associated with the receptors for various cytokines and growth factors (IL-3, IL-5, granulocyte macrophage colony-stimulating factor, EPO, and TPO) and functions as a homodimer to play a very important role in red blood cell formation. As a result, side effects including anemia, neutropenia and thrombopenia has been ascribed to the concomitant inhibition of JAK2 when treated with pan-inhibitors of JAKs enzyme family like <ce:bold>3</ce:bold> or <ce:bold>2</ce:bold> [<ce:cross-ref id="crosref0775" refid="bib106">106</ce:cross-ref>]. Recent study has made it clear that inhibition of multiple JAK isozymes is not a prerequisite for the clinical efficacy of JAK inhibitors and an isozyme-selective inhibitor would show improved efficacy and safety profiles [<ce:cross-ref id="crosref0780" refid="bib107">107</ce:cross-ref>]. Consequently, there is a compelling need for the development of selective JAK1 or JAK3 inhibitors and JAK1 inhibition could provide an increased therapeutic window, allowing higher dosing and efficacy while avoiding dose-limited pharmacology observed with pan JAK inhibitors. JAK2 selective inhibitors are developed for the treatment of myeloproliferative disorders because a unique gain-of-function JAK2 point mutation (V617F) could result in these kinds of disorders in humans [<ce:cross-ref id="crosref0785" refid="bib108">108</ce:cross-ref>]. Selective TYK2 inhibitors are explored in the hope of establishing clinical efficacy in autoimmune diseases such as Psoriasis, Crohnâs disease and SLE while demonstrating an improved safety profile [<ce:cross-ref id="crosref0790" refid="bib109">109</ce:cross-ref>].</ce:para>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0120">JAK1 selectivity inhibitors</ce:section-title>
                        <ce:para id="p0235" view="all">
                           <ce:bold>Upadacitinib (25)</ce:bold>, also called <ce:bold>ABT-494</ce:bold>, was developed by AbbVie as an efficient JAK1 selectivity inhibitors for the treatment of moderate to severe RA and is currently in multiple Phase III studies across indications including Crohnâs Disease (NCT03345849, NCT03345823 and NCT03345836), AD (NCT03569293, NCT03568318, NCT03661138, NCT03607422 and NCT03738397), Psoriatic Arthritis (NCT03104400 and NCT03104374) and UC (NCT03653026 and NCT03006068) <ce:cross-ref id="optCjnZhvLB8R" refid="fig12">Fig.Â 12</ce:cross-ref>. <ce:bold>25</ce:bold> is 4.6-fold selective for JAK1 compared with JAK2 which is involved in erythropoiesis (IC<ce:inf loc="post">50</ce:inf> for JAK1: 43Â nM; JAK2: 200Â nM; JAK3: 2300Â nM; TYK2: 4700Â nM) and has no effects on EPO signaling or peripheral NK cell counts, which are often seen at comparable anti-arthritic doses of <ce:bold>1</ce:bold> [<ce:cross-ref id="crosref0795" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0800" refid="bib110">110</ce:cross-ref>]. The medicinal chemistry discovery story for <ce:bold>25</ce:bold> has not been described in the literature to date. Importantly, unlike <ce:bold>1</ce:bold>, <ce:bold>3</ce:bold> and <ce:bold>2</ce:bold>, <ce:bold>25</ce:bold> takes advantage of an imidazopyrrolopyridine hinge binding heterocycle as a pharmacophoric subunit and it was engineered to enhance selectivity for JAK1 by exploiting interactions outside the ATP-binding site. As illustrated in <ce:cross-ref id="crosref0805" refid="fig13">Fig.Â 13</ce:cross-ref>
                           <ce:float-anchor refid="fig13"/></ce:float-anchor>, the residue structure of trifluoroethylamine plays a key role in the binding mode of <ce:bold>25</ce:bold> and JAK1 that they can form hydrogen binding with Arg 1007. However, there are none of these hydrogen binding interactions existing in the binding mode of <ce:bold>25</ce:bold> and JAK2 enzyme which may contribute to the more selectivity for JAK1 than JAK2 of <ce:bold>25</ce:bold> [<ce:cross-ref id="crosref0810" refid="bib111">111</ce:cross-ref>,<ce:cross-ref id="crosref0815" refid="bib112">112</ce:cross-ref>].</ce:para>
                        <ce:para id="p0240" view="all">The efficacy, including inhibition of radiographic progression, and safety of <ce:bold>25</ce:bold> vs placebo and adalimumab in patients with RA and an inadequate response to methotrexate had been evaluated [<ce:cross-ref id="crosref0825" refid="bib113">113</ce:cross-ref>]. In this Phase III study (NCT02629159), 1629 patients with inadequate response to methotrexate were randomized (2:2:1) to once daily <ce:bold>25</ce:bold> 15Â mg, placebo, or adalimumab 40Â mg. Primary endpoints were ACR20 and DAS28CRP<2.6 versus placebo at Week12 and inhibition of radiographic progression was evaluated at Week26 (ACR20 was defined by American College of Rheumatology which represents 20% improvement in swelling and tender joint counts; DAS28CRP is the abbreviation of Disease Activity Score 28Â C-Reactive Protein). This study was designed and powered to test for non-inferiority and superiority of upadacitinib versus adalimumab clinically and functionally. Both primary endpoints that ACR20 was achieved by 71% versus 36%, and DAS28CRP<2.6 by 29% versus 6% were met for <ce:bold>25</ce:bold> versus placebo (pÂ â¤Â 0.001) at Week12. Additionally, <ce:bold>25</ce:bold> was superior to adalimumab for ACR50, DAS28CRPâ¤3.2, ÎPain and ÎHAQ-DI. More patients on <ce:bold>25</ce:bold> vs placebo or adalimumab achieved low disease activity or remission (pÂ â¤Â 0.001) at Week26 and radiographic progression was less and observed in fewer patients receiving <ce:bold>25</ce:bold> versus placebo (pÂ â¤Â 0.001). (AEs) including serious infections were comparable for <ce:bold>25</ce:bold> and adalimumab up to Week26. In conclusion, <ce:bold>25</ce:bold> was superior to placebo and adalimumab for improving signs, symptoms and physical function in RA patients on background MTX, and significantly inhibited radiographic progression versus placebo, while the overall safety profile was generally similar to adalimumab. Recently, <ce:bold>25</ce:bold> had received its approval in august 2019 for the treatment of adults with moderately to severely active RA and an inadequate response or intolerance to methotrexate.</ce:para>
                        <ce:para id="p0245" view="all">
                           <ce:bold>Filgotinib</ce:bold> (<ce:bold>26</ce:bold>), also known as <ce:bold>GLPG0634</ce:bold>, was discovered and developed by Galapagos and then transferred to Gilead for co-development as a potent JAK1 selective inhibitor. <ce:bold>26</ce:bold> was identified as a lead compound belonging to a novel class of JAK inhibitors. It displayed a JAK1/JAK2 inhibitor profile in biochemical assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of 30-fold for JAK1 over JAK2 dependent signaling [<ce:cross-ref id="crosref0830" refid="bib56">56</ce:cross-ref>]. <ce:bold>26</ce:bold> dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17Â cells inÂ vitro. Oral dosing of <ce:bold>26</ce:bold> in a therapeutic set-up in a CIA model in rodents resulted in a significant dose-dependent reduction of the disease progression and paw swelling, bone and cartilage degradation, levels of inflammatory cytokines were reduced by <ce:bold>26</ce:bold> treatment which indicated the JAK1 selective inhibitor <ce:bold>26</ce:bold> is a promising novel therapeutic with potential for oral treatment of RA and possibly other immune-inflammatory diseases [<ce:cross-ref id="crosref0835" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0840" refid="bib36">36</ce:cross-ref>,<ce:cross-ref id="crosref0845" refid="bib114">114</ce:cross-ref>]. There are a series of clinical Phase III studies of <ce:bold>26</ce:bold> in progress including the treatment of Crohnâs Disease (NCT02914600, NCT02914561) and UC (NCT02914522, NCT02914535).</ce:para>
                        <ce:para id="p0250" view="all">Lead compound triazolo[1,5-<ce:italic>a</ce:italic>]pyridine <ce:bold>30</ce:bold> was identified through the screen of the BioFocus kinase-focused library collection against the kinase domain of JAK1 in an inÂ vitro biochemical assay at 10Â Î¼M initially. Compound <ce:bold>30</ce:bold> exhibited encouraging JAK1 inhibitory activity (70Â nM), and owing to its modular nature, emerged as a good platform to initiate chemistry. The procedure of medicinal chemistry optimization of lead compound <ce:bold>30</ce:bold> is illustrated in <ce:cross-ref id="crosref0850" refid="fig14">Fig.Â 14</ce:cross-ref>
                           <ce:float-anchor refid="fig14"/></ce:float-anchor> and Four sites of the original lead molecule <ce:bold>30</ce:bold> were optimized leading to <ce:bold>26</ce:bold>. The 2-position of the triazolopyridine was first investigated through replacement of the cyclopropylamide of the original hit <ce:bold>30</ce:bold>. Synthesized compounds without a free hydrogen atom on the amine at the 2-position essentially lost all activity on JAK1. Modeling studies indicate that an H-bond is formed with the main chain carbonyl of Leu 959 of the hinge region and the H-bond interaction in this position plays a key role in the activity and selectivity of the compounds. Next attention to the SAR was around the phenyl group at the 5-position of the triazolo[1,5-a]pyridine core and replacement of phenyl by more polar heterocycles resulted in a substantial reduction in potency which was consistent with modeling studies that the phenyl ring sits in a hydrophobic subpocket of JAK1, forming hydrophobic contacts with Leu 881, Val 938, Ser 963, Leu 1010 and Gly 1020. The scaffold of the lead compound <ce:bold>30</ce:bold> was also considered to be modified while modification of the scaffold by addition of an extra nitrogen atom showed no inhibition of JAK1. As a result, the pyrazolopyridine scaffold are optimal for binding in the JAK ATP pocket. The last optimization leading to <ce:bold>26</ce:bold> was focused on the region of glycine rich loop and large substitutions were introduced to increase the contact with the P-loop. Finally, the cyclic sulfone moiety was found to offer a good balance of selectivity and ADME properties which led to the discovery of <ce:bold>26</ce:bold> with good oral bioavailability, long half-life and low total plasma clearance. Additionally, <ce:italic>InÂ vivo</ce:italic> and vitro experiments have identified <ce:bold>26</ce:bold> as a potential orally JAK1 inhibitor for the treatment of RA and other autoimmune diseases [<ce:cross-ref id="crosref0855" refid="bib56">56</ce:cross-ref>].</ce:para>
                        <ce:para id="p0255" view="all">
                           <ce:bold>PF-04965842</ce:bold> (<ce:bold>27</ce:bold>), known as <ce:bold>Abrocitinib</ce:bold>, was developed by Pfizer as a selective JAK1 inhibitor for the treatment of AD (Phase III, NCT03796676, NCT03796676, NCT03575871, NCT03349060, NCT03422822) and Plaque Psoriasis (Phase II, NCT02201524). In preclinical studies, <ce:bold>27</ce:bold> demonstrated a 28-fold selectivity for JAK1 over JAK2 in kinase inhibition assay and nanomolar potency together with highly JAK1 selectivity in an HWB assay which was shown in <ce:cross-ref id="crosref0860" refid="tbl4">TableÂ 4</ce:cross-ref>
                           <ce:float-anchor refid="tbl4"/></ce:float-anchor> [<ce:cross-ref id="crosref0865" refid="bib115">115</ce:cross-ref>]. The effect of JAK1 inhibition by <ce:bold>27</ce:bold> 
                           <ce:italic>inÂ vivo</ce:italic> was evaluated using a therapeutic dosing paradigm in a rat AIA disease model and a significant reduction in paw swelling was observed for all doses which proved the efficacy of <ce:bold>27</ce:bold> in a rat AIA model.</ce:para>
                        <ce:para id="p0260" view="all">
                           <ce:bold>27</ce:bold> was discovered based on compound <ce:bold>1</ce:bold> through the modification of the 3-aminopiperidine linker. The pyrrolopyrimidine scaffold was retained due to the excellent overall kinome selectivity of <ce:bold>1</ce:bold> and a variety of diamine linkers were systematically evaluated as alternatives to the 3-aminopiperidine group of <ce:bold>1</ce:bold> [<ce:cross-ref id="crosref0870" refid="bib115">115</ce:cross-ref>]. As a result, sulfonamides bearing a <ce:italic>cis</ce:italic>-1,3-cyclobutane diamine linker turned out to confer not only excellent potency in the low nanomolar range but more importantly excellent selectivity within the JAKs enzyme family. After that, more efforts were made for the optimization of the ADME properties of these analogues to afford the clinical candidate <ce:bold>27</ce:bold>. To explore the reason for excellent potency and potent selectivity within the JAKs enzyme family of <ce:bold>27</ce:bold> X-ray crystallographic studies were carried out. The Glu 966 (JAK1)/Asp 939 (JAK2) residue difference that lies toward the solvent-exposed region of the binding site shown in <ce:cross-ref id="crosref0875" refid="fig15">Fig.Â 15</ce:cross-ref>
                           <ce:float-anchor refid="fig15"/></ce:float-anchor>
                           <ce:float-anchor refid="fig16"/></ce:float-anchor> prove to be a differential hydrogen bonding interaction with favorable improvement in JAK1 selectivity, which is supported by cocrystal structures of both JAK1 and JAK2. Additionally, A comparison of the crystal structures of <ce:bold>27</ce:bold> bound to JAK1 and JAK2 suggested that the P-loop in JAK2 is clamped down slightly more onto the active site than the relatively more open JAK1 P-loop which means that a shift in the P-loop position observed between the JAK1 and JAK2 X-ray structures may also explain the selectivity of <ce:bold>27</ce:bold>. Importantly, the strategies used in the optimization of leading to the discovery of <ce:bold>27</ce:bold> gave us efficient methods for the design of selective JAK1 inhibitors.</ce:para>
                        <ce:para id="p0265" view="all">
                           <ce:bold>Itacitinib</ce:bold> (<ce:bold>28</ce:bold>) was developed by Incyte as a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2. <ce:bold>28</ce:bold> is now under recruitment status of clinical phase III tries (NCT03584516) for the treatment of Chronic Graft-Versus-Host Disease and several clinical phase II tries are underway for the treatment of MPNs, Plaque Psoriasis, B-Cell Malignancies, Non-Small Cell Lung Cancer, Moderate to Severe UC and RA [<ce:cross-ref id="crosref0880" refid="bib116">116</ce:cross-ref>]. The efficacy and safety of three dose levels of <ce:bold>28</ce:bold> were evaluated in an open-label Phase II study (NCT01633372) in patients with intermediate to high risk myelofibrosis. 35.7% and 28.6% of patients in the 200Â mg twice-daily cohort, 32.3% and 35.5% in the 600Â mg once-daily cohort and two patients (20%) in the 100Â mg twice-daily cohort achieved a â¥50% reduction in total symptom score at week 12 (primary end point) and 24 respectively which indicated that treatment with <ce:bold>28</ce:bold> resulted in clinically meaningful symptom relief, modest spleen volume reduction, and limited myelosuppression.</ce:para>
                        <ce:para id="p0270" view="all">
                           <ce:bold>Solcitinib</ce:bold> (<ce:bold>29</ce:bold>), known as <ce:bold>GSK-2586184</ce:bold> or <ce:bold>GLPG-0778</ce:bold>, is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC<ce:inf loc="post">50</ce:inf> of 9.8Â nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2 respectively. <ce:bold>29</ce:bold> is used in the research of moderate to severe Plaque-type Psoriasis. A randomized placebo-controlled phase II study (NCT01782664) was carried out of <ce:bold>29</ce:bold> to assess the relationship between dose of <ce:bold>29</ce:bold> and clinical response for the treatment of Psoriasis. A 75% reduction in Psoriasis Area Severity Index (PASI) response rates in the intent-to-treat population were 13%, 25% and 57% in the 100Â mg, 200Â mg and 400Â mg <ce:bold>29</ce:bold> twice-daily groups respectively at week 12. Improvement in itch and quality of life were observed at all doses relative to placebo with the greatest improvement seen in the 400-mg dose group which demonstrates that 12 weeks of treatment with <ce:bold>29</ce:bold> resulted in clinical improvement and was generally well tolerated in patients with moderate to severe Plaque-type Psoriasis [<ce:cross-ref id="crosref0885" refid="bib117">117</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0125">JAK2 selectivity inhibitors</ce:section-title>
                        <ce:para id="p0275" view="all">MPNs are a subunit of myeloid malignancies that encompass polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF) [<ce:cross-ref id="crosref0890" refid="bib118">118</ce:cross-ref>]. Research data show that acquisition of the constitutively active JAK2 V617F mutation occurs in almost all patients with PV and in a significant number of patients with ET and PMF. The causal role of JAK2 in MPNs is supported by significant genetic and pharmacological data [<ce:cross-ref id="crosref0895" refid="bib119">119</ce:cross-ref>]. As a result, the discovery of this single activating somatic mutation (V617F) in the pseudokinase JH2 (Janus Homology 2) domain of JAK2 stimulated significant interest in developing selective JAK2 inhibitors for the treatment of MPNs.</ce:para>
                        <ce:para id="p0280" view="all">
                           <ce:bold>Pacritinib</ce:bold> (<ce:bold>30</ce:bold>), known as <ce:bold>SB1518</ce:bold>, was developed by SâBIO Pte. Ltd. as a potent inhibitor of both wild-type JAK2 (IC<ce:inf loc="post">50</ce:inf>Â =Â 23Â nM) and JAK2<ce:sup loc="post">V617F</ce:sup> mutant (IC<ce:inf loc="post">50</ce:inf>Â =Â 19Â nM) for the treatment of myeloid diseases and now is currently in a series of clinical Phase II and III tries (NCT03645824, NCT00745550 and NCT01263899) for the conditions like Myelofibrosis and Advanced Lymphoid Malignancies ( <ce:cross-ref id="opt7H7duFhi4L" refid="fig16">Fig.Â 16</ce:cross-ref>). <ce:bold>30</ce:bold> was the first macrocycle explored for the inhibitor of JAKs enzyme family with the aim to identify a distinct core structure with clear novelty and structural rigidity which would in turn reduce conformational freedom, potentially increasing the likelihood of finding compounds with specific selectivity profiles. The initial optimization of these compounds was focused on the linkers retaining the double bond which were displayed in <ce:cross-ref id="crosref0905" refid="fig17">Fig.Â 17</ce:cross-ref>
                           <ce:float-anchor refid="fig17"/></ce:float-anchor> and various linkers demonstrated that these templates inhibited JAK2 with selectivity against JAK1/3 and CDK2. In general, the most potent JAK2 linkers were 8 atoms in length with at least one benzylic ether. However, very low solubility in these high cLogP compounds promoted the search for installing a solubilizing group of these analogues. Compounds docking studies indicated that groups from the R1 position pointing were toward to a channel out to the solvent directly and may offer potential for additional interactions as well as increase in solubility by installation of a basic center. Improved solubility and potency were achieved with oxygen-linked substituents represented by the side chain of pyrrole which afford the clinical candidate <ce:bold>30</ce:bold> [<ce:cross-ref id="crosref0910" refid="bib120">120</ce:cross-ref>].</ce:para>
                        <ce:para id="p0285" view="all">
                           <ce:bold>Lestaurtinib</ce:bold> (<ce:bold>31</ce:bold>), also called <ce:bold>CEP-701</ce:bold> or <ce:bold>KT-5555</ce:bold>, is a multi-kinase inhibitor with potent activity against the TRK family of receptor tyrosine kinases and <ce:bold>31</ce:bold> inhibits JAK2, FLT3 and TRKA with IC<ce:inf loc="post">50</ce:inf> of 0.9, 3 and less than 25Â nM respectively [<ce:cross-ref id="crosref0915" refid="bib121">121</ce:cross-ref>]. <ce:bold>31</ce:bold> was developed and first tested in patients with a subset of acute myelogenous leukemia (AML) bearing activating mutations in FLT3 as a potent orally available FLT3 inhibitor [<ce:cross-ref id="crosref0920" refid="bib122">122</ce:cross-ref>]. The compound has clinical activity in Phase I/II studies of relapsed, FLT3 mutationâpositive AML patients [<ce:cross-ref id="crosref0925" refid="bib123">123</ce:cross-ref>,<ce:cross-ref id="crosref0930" refid="bib124">124</ce:cross-ref>]. Additionally, studies have further shown that <ce:bold>31</ce:bold>âs inhibitory activity is not only limited to FLT3 but also to a potent V617F JAK2 inhibitor that can suppress the growth and JAK/STAT signaling in primary erythroid cells from subjects with MPDs [<ce:cross-ref id="crosref0935" refid="bib125">125</ce:cross-ref>]. However, a Phase II study (NCT00668421) designed to evaluate the safety and efficacy of <ce:bold>31</ce:bold>Â 140Â mg twice daily in patients with JAK2V617F-positive Myelofibrosis demonstrated a dose-limiting gastrointestinal AEs and the narrow therapeutic index of <ce:bold>31</ce:bold> precludes most patients from deriving clinical benefit which suggests this agent should not be developed further for the treatment of Myelofibrosis [<ce:cross-ref id="crosref0940" refid="bib126">126</ce:cross-ref>]. Although <ce:bold>31</ce:bold> was disclosed for a long time, toxic and side effect appeared in the clinical tries have limited the progress of it.</ce:para>
                        <ce:para id="p0290" view="all">
                           <ce:bold>Fedratinib</ce:bold> (<ce:bold>32</ce:bold>) is an anilinopyrimidine derivative, also known as <ce:bold>TG-101348</ce:bold> or <ce:bold>SAR 302503</ce:bold>, developed by Sanofi as a selective inhibitor of JAK2 with an IC<ce:inf loc="post">50</ce:inf> of 3Â nM showing 35- and 334-fold selectivity over JAK1 and JAK3 respectively [<ce:cross-ref id="crosref0945" refid="bib127">127</ce:cross-ref>]. <ce:bold>32</ce:bold> inhibits proliferation of human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F) with IC<ce:inf loc="post">50</ce:inf> of 305Â nM and 270Â nM respectively. It also inhibits proliferation of parental Ba/F3 cells to a comparable level with IC<ce:inf loc="post">50</ce:inf> of approximate 420Â nM and the treatment of <ce:bold>32</ce:bold> reduces STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation [<ce:cross-ref id="crosref0950" refid="bib128">128</ce:cross-ref>]. A clinical Phase III study (NCT01437787) that evaluated the safety and efficacy of <ce:bold>32</ce:bold> in patients with primary or secondary Myelofibrosis had completed. The primary end point was achieved by 35 of 96 and 39 of 97 patients in the <ce:bold>32</ce:bold>Â 400-mg and 500-mg groups vs 1 of 96 in the placebo group (PÂ <Â 0.001). Symptom response rates were 33 of 91, 31 of 91 and 6 of 85 in the <ce:bold>32</ce:bold>Â 400-mg, 500-mg and placebo groups respectively (PÂ <Â 0.001) at week 24 [<ce:cross-ref id="crosref0955" refid="bib129">129</ce:cross-ref>]. <ce:bold>32</ce:bold> therapy significantly reduced splenomegaly and symptom burden in patients with Myelofibrosis [<ce:cross-ref id="crosref0960" refid="bib130">130</ce:cross-ref>]. Recently, <ce:bold>32</ce:bold> hydrochloride received its approval in august 2019 in the U.S. for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis as an oral dual-acting JAK2/FLT3 small molecule kinase inhibitor.</ce:para>
                        <ce:para id="p0295" view="all">
                           <ce:bold>SB1317</ce:bold> (<ce:bold>33</ce:bold>) was also developed by SâBIO Pte. Ltd. as a potent inhibitor of JAK2 together with CDK2 and FLT3 for the treatment of cancer with IC<ce:inf loc="post">50</ce:inf> of 73, 13, and 56Â nM for JAK2, CDK2 and FLT3 respectively [<ce:cross-ref id="crosref0965" refid="bib131">131</ce:cross-ref>]. The medicinal chemistry discovery procedure of <ce:bold>33</ce:bold> is similar to the discovery of <ce:bold>30</ce:bold> while <ce:bold>33</ce:bold> possess more targets effecting inhibiting 17 kinases from a panel of 63 and 11 of which are JAK/CDK/FLT family members which are implicated in inflammatory and proliferative processes [<ce:cross-ref id="crosref0970" refid="bib132">132</ce:cross-ref>]. <ce:bold>33</ce:bold> is currently under the research of clinical studies and is more favorable for the treatment of tumors rather than other JAK2 inhibitors including the Phase I study (NCT01699152) for the treatment of CLL and SLL and Phase II study (NCT02942264, recruiting status) for the treatment of Recurrent Anaplastic Astrocytoma and Glioblastoma.</ce:para>
                        <ce:para id="p0300" view="all">
                           <ce:bold>Gandotinib</ce:bold> (<ce:bold>34</ce:bold>), known as <ce:bold>LY2784544</ce:bold>, was developed by Lilly as a potent JAK2 inhibitor with IC<ce:inf loc="post">50</ce:inf> of 3Â nM. Screening of the Lilly compound library resulted in the identification of potent JAK2 inhibitor compound <ce:bold>40</ce:bold> exhibited in <ce:cross-ref id="crosref0975" refid="fig18">Fig.Â 18</ce:cross-ref>
                           <ce:float-anchor refid="fig18"/></ce:float-anchor> that followed with the medicinal chemistry optimization afforded <ce:bold>34</ce:bold>.<ce:bold>34</ce:bold> inhibits JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells with IC<ce:inf loc="post">50</ce:inf> of 20 and 55Â nM respectively effectively while is much less potent at inhibiting interleukin-3-stimulated wild-type JAK2-mediated signaling and cell proliferation with IC<ce:inf loc="post">50</ce:inf> of 1183 and 1309Â nM respectively. <ce:italic>InÂ vivo</ce:italic> studies also indicate that <ce:bold>34</ce:bold> is very potent against JAK2V617-induced mouse hematological diseases in addition to no effect on erythroid progenitors, reticulocytes or platelets [<ce:cross-ref id="crosref0980" refid="bib132">132</ce:cross-ref>]. Currently, two Phase I trials (NCT01134120 and NCT01520220) to investigate dose and schedule in Myeloproliferative Neoplasms patients of <ce:bold>34</ce:bold> had been completed and a Phase II study to investigate efficacy (NCT01594723) of <ce:bold>34</ce:bold> in Myeloproliferative Neoplasms patients is under the status of recruiting.</ce:para>
                        <ce:para id="p0305" view="all">
                           <ce:bold>BMS-911543</ce:bold> (<ce:bold>35</ce:bold>) developed by Bristol-Myers Squibb R&D is a potent selective JAK2 inhibitor with IC<ce:inf loc="post">50</ce:inf> of 1.1Â nM and less selective at JAK1, JAK3 and TYK2 with IC<ce:inf loc="post">50</ce:inf> of 75, 360, 66Â nM respectively. The discovery of this clinical candidate <ce:bold>35</ce:bold> was through X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole <ce:bold>41</ce:bold> displayed in <ce:cross-ref id="crosref0985" refid="fig19">Fig.Â 19</ce:cross-ref>
                           <ce:float-anchor refid="fig19"/></ce:float-anchor>
                           <ce:float-anchor refid="fig20"/></ce:float-anchor>. Groups such as methyl or amides introduced in C-4 position led to either rapidly metabolization or loss in selectivity which were explained in <ce:cross-ref id="crosref0990" refid="fig19">Fig.Â 19</ce:cross-ref>B and C. Accordingly, other closely related five-membered isosteric dialkylthiazole ring isosteres that would dispose alkyl groups in the extended hinge region similar to <ce:bold>41</ce:bold> were substituted resulting the affording of <ce:bold>35</ce:bold>.<ce:bold>35</ce:bold> showed potent antiproliferative activity in the SET-2 as well as BaF3âV617F engineered cell lines (both dependent upon JAK2 pathway) with IC<ce:inf loc="post">50</ce:inf> values of 60 and 70Â nM respectively in cellular assays [<ce:cross-ref id="crosref0995" refid="bib55">55</ce:cross-ref>,<ce:cross-ref id="crosref1000" refid="bib133">133</ce:cross-ref>]. At the same time, <ce:bold>35</ce:bold> showed good metabolic stability, excellent intrinsic permeability and moderate drugâdrug interaction potential based upon CYP inhibition of the CYP3A4 and CYP1A2 isoforms in inÂ vitro ADMET profiling assays. Nevertheless, the clinical Phase I/II study (NCT01236352) of <ce:bold>35</ce:bold> to determine if <ce:bold>35</ce:bold> is safe, tolerable and efficacy in symptomatic Myelofibrosis patients had been terminated due to portfolio/business decisions by the sponsor.</ce:para>
                        <ce:para id="p0310" view="all">
                           <ce:bold>CEP-33779</ce:bold> (<ce:bold>36</ce:bold>) was developed by Cephalon, Inc. as novel selective and orally bioavailable inhibitor of JAK2 with an IC<ce:inf loc="post">50</ce:inf> of 1.8Â nM. Optimization of the 1,2,4-triazolo[1,5-a]pyridine scaffold as a kinase hinge binding element led to the discovery of <ce:bold>36</ce:bold> which exhibited excellent JAK2 potency, selectivity and oral bioavailability in mouse in addition to antitumor efficacy in multiple JAK2-driven tumor xenografts and efficacy in inflammation models in mouse and has potential as a preclinical development candidate for the treatment of Myeloid diseases [<ce:cross-ref id="crosref1005" refid="bib134">134</ce:cross-ref>].</ce:para>
                        <ce:para id="p0315" view="all">
                           <ce:bold>TG101209</ce:bold> (<ce:bold>37</ce:bold>) is a selective JAK2 inhibitor with IC<ce:inf loc="post">50</ce:inf> of 6Â nM less potent to FLT3 and RET with IC<ce:inf loc="post">50</ce:inf> of 25Â nM and 17Â nM and approximate 30-fold selective for JAK2 than JAK3. Additionally, <ce:bold>37</ce:bold> is sensitive to JAK2V617F mutations and inhibits growth of Ba/F3 cells expressing JAK2V617F mutations with an IC<ce:inf loc="post">50</ce:inf> of 200Â nM. <ce:bold>37</ce:bold> induces cell cycle arrest and apoptosis in a human JAK2V617F-expressing AML cell line and inhibits phosphorylation of JAK2V617F, STAT5 and STAT3 in JAK/STAT signaling pathway [<ce:cross-ref id="crosref1010" refid="bib135">135</ce:cross-ref>].</ce:para>
                        <ce:para id="p0320" view="all">
                           <ce:bold>Ilginatinib</ce:bold> (<ce:bold>38</ce:bold>), known as <ce:bold>NS-018</ce:bold>, is a highly active JAK2 inhibitor developed by NS Pharma, Inc. with an IC<ce:inf loc="post">50</ce:inf> of 0.72Â nM 46-, 54- and 31-fold selectivity for JAK2 over JAK1 (IC<ce:inf loc="post">50</ce:inf>Â =Â 33Â nM), JAK3 (IC<ce:inf loc="post">50</ce:inf>Â =Â 39Â nM), and Tyk2 (IC<ce:inf loc="post">50</ce:inf>Â =Â 22Â nM) [<ce:cross-ref id="crosref1015" refid="bib136">136</ce:cross-ref>]. <ce:bold>38</ce:bold> shows potent inhibitory activity against cell lines JAK2V617F mutations or the TEL-JAK2 fusion gene (expressing a constitutively activated JAK2) with IC<ce:inf loc="post">50</ce:inf> of 11â120Â nM [<ce:cross-ref id="crosref1020" refid="bib137">137</ce:cross-ref>]. The clinical Phase I/II studies (NCT01423851, NCT01423851 and NCT01423851) of <ce:bold>38</ce:bold> are under the status of active, not recruiting for the treatment of Myelofibrosis.</ce:para>
                        <ce:para id="p0325" view="all">
                           <ce:bold>NVP-BSK805</ce:bold> (<ce:bold>39</ce:bold>), also called <ce:bold>BSK805</ce:bold>, is an ATP-competitive JAK2 inhibitor, with IC<ce:inf loc="post">50</ce:inf> of 0.48Â nM, 31.63Â nM, 18.68Â nM and 10.76Â nM for JAK2, JAK1, JAK3 and TYK2 respectively. <ce:bold>39</ce:bold> inhibits the full-length wild-type JAK2 (FL JAK2 wt) and FL JAK2 V617F activity with IC<ce:inf loc="post">50</ce:inf> of 0.58 and 0.56Â nM. Additionally, <ce:bold>30</ce:bold> suppresses the growth of JAK2V617F-bearing acute myeloid leukemia cell lines with GI<ce:inf loc="post">50</ce:inf> of <100Â nM and blocks the STAT5 phosphorylation at â¥100Â nM concentrations [<ce:cross-ref id="crosref1025" refid="bib138">138</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0130">JAK3 selectivity inhibitors</ce:section-title>
                        <ce:para id="p0330" view="all">
                           <ce:bold>PF-06651600</ce:bold> (<ce:bold>47</ce:bold>), developed by Pfizer, is a newly discovered potent JAK3-selective inhibitor which is highly efficacious at inhibiting Î³c cytokine signaling dependent on both JAK1 and JAK <ce:cross-ref id="opt27mhDMIUhU" refid="fig20">Fig.Â 20</ce:cross-ref>. InÂ vitro, <ce:bold>47</ce:bold> inhibits Th1 and Th17Â cell differentiation and function and <ce:italic>inÂ vivo</ce:italic>, it reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models [<ce:cross-ref id="crosref1030" refid="bib139">139</ce:cross-ref>]. The favorable efficacy and safety profile of this JAK3-specific inhibitor <ce:bold>47</ce:bold> led to its evaluation in several human clinical studies including the treatment of AA (NCT03732807, NCT02974868 and NCT04006457), Crohnâs Disease (NCT03395184), RA (NCT02969044) and UC (NCT02958865). .</ce:para>
                        <ce:para id="p0335" view="all">The importance of the individual JAKs in cytokine signaling has resulted in significant efforts to identify isoform selective inhibitors and the discovery of <ce:bold>47</ce:bold> addresses the problem that how to design JAK3 selective inhibitors. Sequence alignment of the ATP binding site for the JAKs enzyme family illustrates that there are only two unique residues that could be utilized to design selective inhibitors in JAK3. The most important one is the unique residue Cys-909 in JAK3 which provides an opportunity to engineer selectivity for JAK3 in a covalent manner to overcome the high sequence and shape similarity within the ATP binding cavity [<ce:cross-ref id="crosref1040" refid="bib140">140</ce:cross-ref>]. Obviously, <ce:bold>47</ce:bold> achieves JAK3 isoform specificity through covalent interaction with this unique JAK3 residue Cys-909 displayed in <ce:cross-ref id="crosref1045" refid="fig21">Fig.Â 21</ce:cross-ref>
                           <ce:float-anchor refid="fig21"/></ce:float-anchor> and much of JAK3 selective inhibitors under research now are designed through this principle.</ce:para>
                        <ce:para id="p0340" view="all">
                           <ce:bold>Decernotinib</ce:bold> (<ce:bold>48</ce:bold>), known as <ce:bold>VX-509</ce:bold>, is a potent inhibitor of JAK3-associated events in cells and that it is selective over other JAK isotypes developed by Vertex Pharmaceuticals. In inÂ vitro assays, <ce:bold>48</ce:bold> inhibits JAK3 in enzyme assays (K<ce:inf loc="post">i</ce:inf>Â =Â 2.5Â nM) and cellular assays dependent on JAK3 activity (IC50 range, 50â170Â nM) with limited or no measurable potency against other JAK isotypes. In <ce:italic>inÂ vivo</ce:italic> assays, treatment of <ce:bold>48</ce:bold> resulted in dose-dependent reduction in ankle swelling, paw weight and improved paw histopathology scores in the rat CIA model which demonstrate that <ce:bold>48</ce:bold> could modulate proinflammatory response in models of immune-mediated diseases, such as CIA and delayed-type hypersensitivity. Additionally, evaluation of <ce:bold>48</ce:bold> for treatment of patients with autoimmune and inflammatory diseases such as RA is feasible [<ce:cross-ref id="crosref1050" refid="bib141">141</ce:cross-ref>]. A Phase II/III open-label extension study (NCT01830985) to evaluate long-term safety and efficacy with <ce:bold>48</ce:bold> in subjects with RA had been completed while no results were posted.</ce:para>
                        <ce:para id="p0345" view="all">
                           <ce:bold>FM381</ce:bold> (<ce:bold>49</ce:bold>) is a potent covalent reversible inhibitor of JAK3 with an IC<ce:inf loc="post">50</ce:inf> of 0.13Â nM for JAK3, with 410-, 2700- and 3600-fold selectivity over JAK1, JAK2 and TYK2 respectively. <ce:bold>49</ce:bold> has no relevant effect on the activity of any tested kinases except JAK3 at a concentration of 100Â nM when screened against a panel of 410 kinases at concentrations of 100Â nM and 500Â nM. At the same time, <ce:bold>49</ce:bold> selectively inhibit JAK3 signaling in human CD4<ce:sup loc="post">+</ce:sup> T cells and blocks IL2 stimulated (JAK3/JAK1 dependent) STAT5 phosphorylation at 100Â nM. However, <ce:bold>49</ce:bold> does not block IL6 stimulated (JAK1/JAK2/TYK2 dependent) STAT3 signaling in human CD4<ce:sup loc="post">+</ce:sup> T cells with IC<ce:inf loc="post">50</ce:inf> of 1Â Î¼M [<ce:cross-ref id="crosref1055" refid="bib142">142</ce:cross-ref>]. In general, <ce:bold>49</ce:bold> is a promising tool, complementing the existing irreversible acrylamide-based inhibitors by a covalent-reversible mode of action and may be suitable to investigate the effects of highly selective JAK3 inhibition <ce:italic>inÂ vivo</ce:italic>.</ce:para>
                        <ce:para id="p0350" view="all">
                           <ce:bold>Compound 32</ce:bold> (<ce:bold>50</ce:bold>), developed by Pfizer, is a newly reported selective JAK3 inhibitor with an IC<ce:inf loc="post">50</ce:inf> of 11Â nM and shows 246-fold selectivity vs other JAKs. Design of novel covalent inhibitors that engage Cys909 through a cyanamide moiety, a structurally and mechanistically differentiated electrophile from the acrylamide moiety in <ce:bold>47</ce:bold> led to the discovery of this selective JAK3 inhibitor <ce:bold>50</ce:bold>.<ce:bold>50</ce:bold> also shows high kinome selectivity in a panel of 40 kinases and in a panel of 10 kinases that contain a Cys residue at the equivalent position of Cys909 in JAK3. Furthermore, evaluation of <ce:bold>50</ce:bold> in IL-15-stimulated PBMC assays demonstrated that selective inhibition of JAK3 is sufficient to drive cellular activity in pathways signaled through the JAK1/JAK3 heterodimer (IL-15 PBMC IC<ce:inf loc="post">50</ce:inf>Â =Â 331Â nM) [<ce:cross-ref id="crosref1060" refid="bib143">143</ce:cross-ref>]. Importantly, the procedure of the discovery of <ce:bold>50</ce:bold> gives key insights into a productive approach to decrease glutathione/glutathione <ce:italic>S</ce:italic>-transferase-mediated clearance, a challenge typically encountered during the discovery of covalent kinase inhibitors.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0135">TYK2 selectivity inhibitors</ce:section-title>
                        <ce:para id="p0355" view="all">
                           <ce:bold>BMS-986165</ce:bold> (<ce:bold>51</ce:bold>), developed by Bristol-Myers Squibb, is a selective orally bioavailable and allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC<ce:inf loc="post">50</ce:inf>Â =Â 1.0Â nM) and blocks receptor-mediated TYK2 activation by stabilizing the regulatory JH2 domain. To data, the small molecule JAKs enzyme inhibitors progressed into development are active site-directed mediators that bind to the adenosine triphosphate (ATP) site of the catalytic domain which are referred to as JH1 domain of the JAK proteins. In contrast, the TYK2 JH2 shown in <ce:cross-ref id="crosref1065" refid="fig22">Fig.Â 22</ce:cross-ref>
                           <ce:float-anchor refid="fig22"/></ce:float-anchor> is capable of binding ATP while it is catalytically incompetent and it has been shown to play an important regulatory role in TYK2 function. In addition, the TYK2 JH2 could be targeted is due to the TYK2 JH2 domain closely resembles its JH1 domain and contains an ATP binding site much like the JH1 domain and specific residue differences within JH2 precludes any catalytic function. As a result, a high level of selectivity over the kinome, especially with respect to the other JAKs could been obtained easily through the wide differences between TYK2 JH2 and the JH1 of other JAKs enzyme. The discovery of <ce:bold>51</ce:bold> was via the optimization of a preclinical proof-of-concept analog and a structure-guided design and water displacement strategy were applied for the afford of <ce:bold>51</ce:bold>.<ce:bold>51</ce:bold> displays unprecedented JAK isoform and kinome selectivity due to the binding of TYK2 JH2 and shows excellent pharmacokinetic properties with minimal profiling liabilities. Additionally, it is efficacious in several murine models of autoimmune disease and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases [<ce:cross-ref id="crosref1070" refid="bib144">144</ce:cross-ref>]. Several Phase I clinical studies of <ce:bold>51</ce:bold> for the treatment of autoimmune diseases including Psoriasis (NCT03004768), SLE (NCT03541564) and Arthritic Psoriasis (NCT03262727) had been completed and Phase II clinical studies for these conditions are under the status of recruiting.</ce:para>
                        <ce:para id="p0360" view="all">
                           <ce:bold>Tyk2-IN-5</ce:bold> (<ce:bold>52</ce:bold>), also developed by Bristol-Myers Squibb, is a highly potent, selective and orally active TYK2 inhibitor and targets the JH2 domain with a K<ce:inf loc="post">i</ce:inf> of 0.086Â nM for TYK2 JH2 and an IC<ce:inf loc="post">50</ce:inf> of 25Â nM for IFNÎ±. <ce:bold>52</ce:bold> was disclosed through an optimization of 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo-[1,2-b]pyridazine analogues which were found to display dramatically improved metabolic stability. TYK2 JH2 inhibitor <ce:bold>52</ce:bold> proves to be highly effective in inhibiting IFNÎ³ production in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model. Not only that, <ce:bold>52</ce:bold> also displays good to excellent PK profiles among the species of mouse, rat, cyno and dog [<ce:cross-ref id="crosref1075" refid="bib145">145</ce:cross-ref>]. As a result, <ce:bold>52</ce:bold> is supposed to be an efficient TYK2 JH2 inhibitor for the treatment of autoimmune diseases such as Psoriasis and RA.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" role="conclusion" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0140">Conclusion</ce:section-title>
                  <ce:para id="p0365" view="all">Almost three decades had passed through since the JAKs kinase family was discovered and six small molecular drugs including <ce:bold>Tofacitinib</ce:bold>, <ce:bold>Ruxolitinib</ce:bold>, <ce:bold>Baricitinib</ce:bold>, <ce:bold>Peficitinib</ce:bold>, <ce:bold>Upadacitinib</ce:bold> and <ce:bold>Fedratinib</ce:bold> targeted JAKs had been approved for the treatment of autoimmune diseases such as RA and myelofibrosis. The approval of <ce:bold>Tofacitinib</ce:bold>, the first kinase inhibitor used for the treatment of RA, represents a milestone for this kinase target and the effects observed in the clinical studies confirm the utility of JAK inhibition in the clinic. In addition to autoimmune diseases, approved JAKs inhibitor <ce:bold>Ruxolitinib</ce:bold> is applied for the treatment of myelofibrosis because a most commonly mutation that valine substitutes for phenylalanine at amino acid position 617 (V617F) in the pseudokinase domain (JH2) of JAK2 was observed in myeloproliferative neoplasms patients [<ce:cross-ref id="crosref1080" refid="bib146">146</ce:cross-ref>]. This mutation turns off the autoinhibitory function of the pseudokinase domain, causing constitutive activation of the (JH2) of the JAK2 protein which appears to be the logical target for therapeutic intervention. However, <ce:bold>Ruxolitinib</ce:bold> is not specific for the mutated form of JAK2, and inhibits both the wild type and JAK2V617F. <ce:bold>Baricitinib</ce:bold> and <ce:bold>Peficitinib</ce:bold> were recently approved by FDA and PMDA for the treatment of RA as pan-inhibitors of JAKs kinase family.</ce:para>
                  <ce:para id="p0370" view="all">JAKs enzyme inhibitors on the market are all pan-inhibitors which could result in severe side effects such as anemia, infection and neutrophils due to the inhibition of JAK2 which plays an essential role in hematopoietic system until the approval of the JAK1 selective inhibitor <ce:bold>Upadacitinib</ce:bold> and JAK2 selective inhibitor <ce:bold>Fedratinib</ce:bold> in 2019. As suggested in <ce:cross-ref id="crosref1085" refid="fig3">Fig.Â 3</ce:cross-ref>, The activation step occurs when a cytokine binds to its receptor, inducing a multimerization (dimerization or higher order complexes) of receptor subunits which brings the JAKs associated with each subunit proximal to one another and ultimately resulting in the phosphorylation and activation of STAT proteins. As a result, inhibiting only one of the JAKs enzymes is able to suppress the whole JAK-STAT signing pathway in autoimmune diseases. Successfully, <ce:bold>Upadacitinib</ce:bold>, a JAK1 selective inhibitor received the approval for the treatment of RA in august 2019. It was reported by AbbVie, which could inhibit the Î³-common dependent cytokines and IL-6 without inhibiting JAK2 dependent EPO and TPO signaling so as to modulate the immune response without having negative effects on EPO signaling. However, the JAK1 selective inhibitor <ce:bold>Upadacitinib</ce:bold> still has kinds of side effects such as infection which indicates us whether it is necessary to rise the selectivity for JAKs enzyme family is still need to be settled. The JAK2 selective inhibitor <ce:bold>Fedratinib</ce:bold> was approved for the diseases like myelofibrosis, which confirmed the efficient for this target for the treatment of MPNs. Additionally, orally active JAK3 specific covalent inhibitor, <ce:bold>PF-06651600</ce:bold>, is sufficient to inhibit JAK3 only as the partner in the heterodimeric pair of JAK1/JAK3 kinase mediated cytokine signaling though the Î³-common chain receptors. Additionally, selective TYK2 pseudokinase (JH2) domain inhibitor, <ce:bold>BMS-986165</ce:bold>, has been utilized to illustrate the consequences on TYK2 inhibition in a range of inÂ vitro and <ce:italic>inÂ vivo</ce:italic> systems. Moreover, JAK1 is the isoform most broadly found in these signaling pairs, and therefore JAK1 inhibitors will inhibit the JAK1/TYK2 dependent type I interferons. The IFNÎ± receptor antibody Anifrolumab has recently shown efficacy in a Phase II trial in SLE which supports targeting TYK2. As a result, in a subset of diseases with a strong interferon and/or IL-12 or IL-23 component to the pathogenesis of disease, we may therefore be able to enhance the activity of a JAK1 inhibitor by simultaneously targeting TYK2 [<ce:cross-ref id="crosref1090" refid="bib89">89</ce:cross-ref>]. In general, the second generation JAKs enzyme family inhibitors which possess selectivity for single JAK protein have been proved to be efficient for the treatment of autoimmune diseases and avoid the side effects due to the over inhibition of JAKs kinases.</ce:para>
                  <ce:para id="p0375" view="all">In recent years, the combination strategy is also gotten attention for the reason of development of molecules that have dual, or multiple, inhibition capabilities against two different classes of enzyme are more efficient than the optimization of the best combinations of two drugs. Inhibition of JAKs directly leads to reduction of intracellular levels of STATs. Inhibition of HDACs has also been reported to reduce STAT levels with the HDAC inhibitor Pracinostat demonstrating modest activity in a myelofibrosis clinical trial [<ce:cross-ref id="crosref1095" refid="bib147">147</ce:cross-ref>,<ce:cross-ref id="crosref1100" refid="bib148">148</ce:cross-ref>]. Therefore, dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) are under the development for the treatment of proliferative disorders [<ce:cross-ref id="crosref1105" refid="bib149">149</ce:cross-ref>]. Besides, The Brutonâs tyrosine kinase (BTK) and JAK3 receptors dual inhibitors are also under the development for the treatment of B-cell lymphomas due to the critical roles of these receptors played in the signal transduction pathways that regulate the growth, differentiation and survival of B-lineage lymphoid cells [<ce:cross-ref id="crosref1110" refid="bib150">150</ce:cross-ref>]. Combination of JAKs enzymes with other protein tyrosine kinases (PTKs) could be a potential strategy for the treatment of different kinds of autoimmune diseases, which were proved by inÂ vitro and vivo assays although there are no this kind of inhibitor approved.</ce:para>
                  <ce:para id="p0380" view="all">The huge therapeutic potential of JAKs enzyme family has led the drug discovery on it. Six pan-inhibitors had been approved and launched on the market for the treatment of autoimmune diseases such as RA. However, a new wave of more selective JAK inhibitors have been recently reported as a result of our increasing knowledge of the importance of kinase selectivity for safety along with the desire to understand the roles and impact of the individual JAK family members on diseases. Furthermore, how to generate exquisitely selective inhibitors for individual JAK family members and whether this kind of selective inhibitors are more efficient or safer than pan-inhibitors still remains to be settled by the cooperation of medicinal and biological chemistry.</ce:para>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:section-title id="sectitle0145">Funding</ce:section-title>
                  <ce:para id="p0385" view="all">We gratefully acknowledge financial support for the <ce:grant-sponsor id="gs6" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (no. <ce:grant-number refid="gs6">818772746</ce:grant-number>, <ce:grant-number refid="gs6">81703347</ce:grant-number> and <ce:grant-number refid="gs6">21372260</ce:grant-number>), the financial support of the National <ce:grant-sponsor id="gs7" sponsor-id="https://doi.org/10.13039/501100004608" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Natural Science Foundation of Jiangsu Province</ce:grant-sponsor> of China (no. <ce:grant-number refid="gs7">BK20170743</ce:grant-number> and <ce:grant-number refid="gs7">BK20171393</ce:grant-number>), a <ce:grant-sponsor id="gs3" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Innovation and Entrepreneurship Training Program</ce:grant-sponsor> For College Students (<ce:grant-number refid="gs3">201910316030S</ce:grant-number>) the <ce:grant-sponsor id="gs4" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">âDouble First-Classâ University Project</ce:grant-sponsor> (<ce:grant-number refid="gs4">CPU2018GY07</ce:grant-number>), and the <ce:grant-sponsor id="gs5" sponsor-id="https://doi.org/10.13039/501100011198" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">State Key Laboratory of Drug Research</ce:grant-sponsor> (<ce:grant-number refid="gs5">SIMM1903KF-03</ce:grant-number>) and <ce:grant-sponsor id="gs8" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Postgraduate Research & Practice Innovation Program of Jiangsu Province</ce:grant-sponsor> (<ce:grant-number refid="gs8">KYCX18_0770</ce:grant-number>).</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0150">Declaration of competing interest</ce:section-title>
               <ce:para id="p0390" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="all">
                  <ce:section-title id="sectitle0155">List of Abbreviations</ce:section-title>
                  <ce:para id="p0395" view="all">
                     <ce:def-list id="dlist0010">
                        <ce:def-term id="d0010">JAKs</ce:def-term>
                        <ce:def-description id="defdis0010">
                           <ce:para id="p0400" view="all">janus kinases</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0015">STAT</ce:def-term>
                        <ce:def-description id="defdis0015">
                           <ce:para id="p0405" view="all">signal transducer and activator of transcription</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0020">RA</ce:def-term>
                        <ce:def-description id="defdis0020">
                           <ce:para id="p0410" view="all">rheumatoid arthritis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0025">PTKs</ce:def-term>
                        <ce:def-description id="defdis0025">
                           <ce:para id="p0415" view="all">protein tyrosine kinases</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0030">NRTKs</ce:def-term>
                        <ce:def-description id="defdis0030">
                           <ce:para id="p0420" view="all">non-receptor tyrosine kinases</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0035">RPTKs</ce:def-term>
                        <ce:def-description id="defdis0035">
                           <ce:para id="p0425" view="all">receptor tyrosine kinases</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0040">iNOS</ce:def-term>
                        <ce:def-description id="defdis0040">
                           <ce:para id="p0430" view="all">inducible nitric oxide synthase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0045">COX-2</ce:def-term>
                        <ce:def-description id="defdis0045">
                           <ce:para id="p0435" view="all">cyclooxygenase 2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0050">SLE</ce:def-term>
                        <ce:def-description id="defdis0050">
                           <ce:para id="p0440" view="all">systemic lupus erythematosus</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0055">SSc</ce:def-term>
                        <ce:def-description id="defdis0055">
                           <ce:para id="p0445" view="all">systemic sclerosis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0060">FDA</ce:def-term>
                        <ce:def-description id="defdis0060">
                           <ce:para id="p0450" view="all">U.S. Food and Drug Administration</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0065">JAK1</ce:def-term>
                        <ce:def-description id="defdis0065">
                           <ce:para id="p0455" view="all">janus kinase 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0070">JAK2</ce:def-term>
                        <ce:def-description id="defdis0070">
                           <ce:para id="p0460" view="all">janus kinase 2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0075">JAK3</ce:def-term>
                        <ce:def-description id="defdis0075">
                           <ce:para id="p0465" view="all">janus kinase 3</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0080">TYK2</ce:def-term>
                        <ce:def-description id="defdis0080">
                           <ce:para id="p0470" view="all">tyrosine kinase 2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0085">SH2</ce:def-term>
                        <ce:def-description id="defdis0085">
                           <ce:para id="p0475" view="all">src homology domain</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0090">JH</ce:def-term>
                        <ce:def-description id="defdis0090">
                           <ce:para id="p0480" view="all">Janus Homology</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0095">P-loop</ce:def-term>
                        <ce:def-description id="defdis0095">
                           <ce:para id="p0485" view="all">glycine rich loop</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0100">TNF</ce:def-term>
                        <ce:def-description id="defdis0100">
                           <ce:para id="p0490" view="all">tumor necrosis factor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0105">MPNs</ce:def-term>
                        <ce:def-description id="defdis0105">
                           <ce:para id="p0495" view="all">myeloproliferative neoplasms</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0110">CIA</ce:def-term>
                        <ce:def-description id="defdis0110">
                           <ce:para id="p0500" view="all">collagen-induced arthritis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0115">EAE</ce:def-term>
                        <ce:def-description id="defdis0115">
                           <ce:para id="p0505" view="all">experimental autoimmune encephalomyelitis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0120">HTRF</ce:def-term>
                        <ce:def-description id="defdis0120">
                           <ce:para id="p0510" view="all">homogeneous time-resolved fluorescence</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0125">PPI</ce:def-term>
                        <ce:def-description id="defdis0125">
                           <ce:para id="p0515" view="all">protein-protein interaction</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0130">HWB</ce:def-term>
                        <ce:def-description id="defdis0130">
                           <ce:para id="p0520" view="all">human whole blood</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0135">PBMCs</ce:def-term>
                        <ce:def-description id="defdis0135">
                           <ce:para id="p0525" view="all">peripheral blood mononuclear cells</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0140">RFU</ce:def-term>
                        <ce:def-description id="defdis0140">
                           <ce:para id="p0530" view="all">relative fluorescence unit</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0145">AIA</ce:def-term>
                        <ce:def-description id="defdis0145">
                           <ce:para id="p0535" view="all">adjuvant-induced arthritis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0150">CFA</ce:def-term>
                        <ce:def-description id="defdis0150">
                           <ce:para id="p0540" view="all">complete freund adjuvant</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0155">MTX</ce:def-term>
                        <ce:def-description id="defdis0155">
                           <ce:para id="p0545" view="all">methotrexate</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0160">API</ce:def-term>
                        <ce:def-description id="defdis0160">
                           <ce:para id="p0550" view="all">active pharmaceutical ingredient</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0165">IWG</ce:def-term>
                        <ce:def-description id="defdis0165">
                           <ce:para id="p0555" view="all">international working group</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0170">CRC</ce:def-term>
                        <ce:def-description id="defdis0170">
                           <ce:para id="p0560" view="all">colorectal cancer</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0175">aGVHD</ce:def-term>
                        <ce:def-description id="defdis0175">
                           <ce:para id="p0565" view="all">acute graft-vs-host disease</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0180">allo-HSCT</ce:def-term>
                        <ce:def-description id="defdis0180">
                           <ce:para id="p0570" view="all">allogeneic hematopoietic stem cell transplantation</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0185">ORR</ce:def-term>
                        <ce:def-description id="defdis0185">
                           <ce:para id="p0575" view="all">overall response rate</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0190">SR</ce:def-term>
                        <ce:def-description id="defdis0190">
                           <ce:para id="p0580" view="all">steroid-refractory</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0195">AA</ce:def-term>
                        <ce:def-description id="defdis0195">
                           <ce:para id="p0585" view="all">alopecia areata</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0200">AD</ce:def-term>
                        <ce:def-description id="defdis0200">
                           <ce:para id="p0590" view="all">atopic dermatitis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0205">TCSs</ce:def-term>
                        <ce:def-description id="defdis0205">
                           <ce:para id="p0595" view="all">topical corticosteroids</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0210">EASI-50</ce:def-term>
                        <ce:def-description id="defdis0210">
                           <ce:para id="p0600" view="all">eczema area and severity index</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0215">PK</ce:def-term>
                        <ce:def-description id="defdis0215">
                           <ce:para id="p0605" view="all">pharmacokinetic</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0220">DMARDs</ce:def-term>
                        <ce:def-description id="defdis0220">
                           <ce:para id="p0610" view="all">disease modifying antirheumatic drugs</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0225">UC</ce:def-term>
                        <ce:def-description id="defdis0225">
                           <ce:para id="p0615" view="all">ulcerative colitis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0230">IBDQ</ce:def-term>
                        <ce:def-description id="defdis0230">
                           <ce:para id="p0620" view="all">inflammatory bowel disease questionnaire</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0235">PSGA</ce:def-term>
                        <ce:def-description id="defdis0235">
                           <ce:para id="p0625" view="all">physician static global assessment</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0240">BSA</ce:def-term>
                        <ce:def-description id="defdis0240">
                           <ce:para id="p0630" view="all">body surface area</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0245">PTCL</ce:def-term>
                        <ce:def-description id="defdis0245">
                           <ce:para id="p0635" view="all">peripheral T-cell lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0250">NHL</ce:def-term>
                        <ce:def-description id="defdis0250">
                           <ce:para id="p0640" view="all">non-hodgkinâs lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0255">FL</ce:def-term>
                        <ce:def-description id="defdis0255">
                           <ce:para id="p0645" view="all">follicular lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0260">CLL</ce:def-term>
                        <ce:def-description id="defdis0260">
                           <ce:para id="p0650" view="all">chronic lymphocytic lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0265">SLL</ce:def-term>
                        <ce:def-description id="defdis0265">
                           <ce:para id="p0655" view="all">small cell lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0270">GBM</ce:def-term>
                        <ce:def-description id="defdis0270">
                           <ce:para id="p0660" view="all">glioblastoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0275">ACR20</ce:def-term>
                        <ce:def-description id="defdis0275">
                           <ce:para id="p0665" view="all">American College of Rheumatology 20%</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0280">DAS28CRP</ce:def-term>
                        <ce:def-description id="defdis0280">
                           <ce:para id="p0670" view="all">Disease Activity Score 28Â C-Reactive Protein</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0285">PASI</ce:def-term>
                        <ce:def-description id="defdis0285">
                           <ce:para id="p0675" view="all">psoriasis area severity index</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0290">PV</ce:def-term>
                        <ce:def-description id="defdis0290">
                           <ce:para id="p0680" view="all">polycythemia vera</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0295">ET</ce:def-term>
                        <ce:def-description id="defdis0295">
                           <ce:para id="p0685" view="all">essential thrombocytopenia</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0300">PMF</ce:def-term>
                        <ce:def-description id="defdis0300">
                           <ce:para id="p0690" view="all">primary myelofibrosis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0305">AML</ce:def-term>
                        <ce:def-description id="defdis0305">
                           <ce:para id="p0695" view="all">acute myelogenous leukemia</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0310">HEL</ce:def-term>
                        <ce:def-description id="defdis0310">
                           <ce:para id="p0700" view="all">human erythroblast leukemia</ce:para>
                        </ce:def-description>
                     </ce:def-list>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0160">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Amatya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Andreotti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dynamic regulatory features of the protein tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Soc. Trans.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1101</sb:first-page>
                              <sb:last-page>1116</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1042/BST20180590</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">N. Amatya, D. Y. Lin, A. H. Andreotti, Dynamic regulatory features of the protein tyrosine kinases, Biochem. Soc. Trans. 47 (2019) 1101-1116. https://doi.org/10.1042/BST20180590.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Solouki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>August</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>201</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.pharmthera.2019.05.008</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">S. Solouki, A. August, W. Huang, Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications, Pharmacol. Ther. 201 (2019) 39-50. https://doi.org/10.1016/j.pharmthera.2019.05.008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonizing cytokine-mediated JAK-STAT signaling by porcine reproductive and respiratory syndrome virus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Vet. Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>209</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>65</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.vetmic.2016.12.036</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">L. Yang, Y. J. Zhang, Antagonizing cytokine-mediated JAK-STAT signaling by porcine reproductive and respiratory syndrome virus, Vet. Microbiol. 209 (2017) 57-65. https://doi.org/10.1016/j.vetmic.2016.12.036.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Bryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Rajapaksa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors for the treatment of immunological disorders: recent advances</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9030</sb:first-page>
                              <sb:last-page>9058</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b00667</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">M. C. Bryan, N. S. Rajapaksa, Kinase inhibitors for the treatment of immunological disorders: recent advances, J. Med. Chem. 61 (2018) 9030-9058. https://doi.org/10.1021/acs.jmedchem.8b00667.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Balboa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>de Pablo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Meana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Balsinde</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of lipins in innate immunity and inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Mol. Cell Biol. Lipids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1864</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1328</sb:first-page>
                              <sb:last-page>1337</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bbalip.2019.06.003</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">M. A. Balboa, N. de Pablo, C. Meana, J. Balsinde, The role of lipins in innate immunity and inflammation, Biochim. Biophys. Acta. Mol. Cell. Biol. Lipids. 1864 (2019) 1328-1337. https://doi.org/10.1016/j.bbalip.2019.06.003.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>ÄernÃ½</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>StÅÃ­Å¾</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adaptive innate immunity or innate adaptive immunity?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Sci. (Lond.)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>133</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1549</sb:first-page>
                              <sb:last-page>1565</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1042/CS20180548</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J. Cerny, I. Striz, Adaptive innate immunity or innate adaptive immunity? Clin. Sci. (Lond). 133 (2019) 1549-1565. https://doi.org/10.1042/CS20180548.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>SchÃ¶n</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adaptive and innate immunity in psoriasis and other inflammatory disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1323</sb:first-page>
                              <sb:last-page>1337</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3389/fimmu.2019.01764</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">M. P. Schon, Adaptive and innate immunity in psoriasis and other inflammatory disorders, Front. Immunol. 9 (2019) 1323-1337. https://doi.org/10.3389/fimmu.2019.01764.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Alunno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Padjen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Fanouriakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Boumpas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cells</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>898</sb:first-page>
                              <sb:last-page>911</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3390/cells8080898</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">A. Alunno, I. Padjen, A. Fanouriakis, D. T. Boumpas, Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent, Cells. 8 (2019) 898-911. https://doi.org/10.3390/cells8080898.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TNF-alpha and IL-6: the link between immune and bone system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Targets</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <ce:doi>10.2174/1389450120666190821161259</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">T. Wang, C. He, TNF-alpha and IL-6: the link between immune and bone system, Curr. Drug Targets. 2019. https://doi.org/10.2174/1389450120666190821161259.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gremesea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ferracciolia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tofacitinib for rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>381</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>25</sb:first-page>
                              <sb:last-page>31</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S0140-6736(13)61114-9</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">E. Gremesea, G. Ferracciolia, Tofacitinib for rheumatoid arthritis. Lancet. 381 (2013) 25-31. https://doi.org/10.1016/S0140-6736(13)61114-9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ciechanowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Rakowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sikora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rudnicka</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK-inhibitors in dermatology: current evidence and future applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Dermatol. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>648</sb:first-page>
                              <sb:last-page>658</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/09546634.2018.1546043</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">P. Ciechanowicz, A. Rakowska, M. Sikora, L. Rudnicka, JAK-inhibitors in dermatology: current evidence and future applications, J. Dermatolog. Treat. 30 (2018) 648-658. https://doi.org/10.1080/09546634.2018.1546043.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Serra LÃ³pez-Matencio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Morell BaladrÃ³n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>CastaÃ±eda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK-STAT inhibitors for the treatment of immunomediated diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Clin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>152</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>353</sb:first-page>
                              <sb:last-page>360</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.medcli.2018.10.020</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">J. M. Serra Lopez-Matencio, A. Morell Baladron, S. Castaneda, JAK-STAT inhibitors for the treatment of immunomediated diseases, Med. Clin. (Barc). 152 (2019) 353-360. https://doi.org/10.1016/j.medcli.2018.10.020.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Nash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Omotuyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ogbadu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Artocarpus altilis CG-901 alters critical nodes in the JH1-kinase domain of Janus kinase 2 affecting upstream JAK/STAT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Mol. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>280</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00894-015-2821-z</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">O. Nash, O. Omotuyi, J. Lee, B. M. Kwon, L. Ogbadu, Artocarpus altilis CG-901 alters critical nodes in the JH1-kinase domain of Janus kinase 2 affecting upstream JAK/STAT3 signaling, J. Mol. Model. 21 (2015) 280. https://doi.org/10.1007/s00894-015-2821-z.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sanz Sanz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Niranjan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>HammarÃ©n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ungureanu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ruijtenbeek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.P.</ce:given-name>
                                 <ce:surname>Touw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hilhorst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The JH2 domain and SH2-JH2 linker regulate JAK2 activity: a detailed kinetic analysis of wild type and V617F mutant kinase domains</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1844</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1835</sb:first-page>
                              <sb:last-page>1841</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bbapap.2014.07.003</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">A. Sanz Sanz, Y. Niranjan, H. Hammaren, D. Ungureanu, R. Ruijtenbeek, I. P. Touw, O. Silvennoinen, R. Hilhorst, The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains, Biochim. Biophys. Acta. 1844 (2014) 1835-1841. https://doi.org/10.1016/j.bbapap.2014.07.003.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Saharinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Takaluoma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of the Jak2 tyrosine kinase by its pseudokinase domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3387</sb:first-page>
                              <sb:last-page>3395</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1128/mcb.20.10.3387-3395.2000</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">P. Saharinen, K. Takaluoma, O. Silvennoinen, Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell Biol. 20 (2000) 3387-3395. https://doi.org/10.1128/mcb.20.10.3387-3395.2000.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Saharinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vihinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Biol. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1448</sb:first-page>
                              <sb:last-page>1459</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1091/mbc.e02-06-0342</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">P. Saharinen, M. Vihinen, O. Silvennoinen, Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Molecular biology of the cell 14 (2003) 1448-1459. https://doi.org/10.1091/mbc.e02-06-0342.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Saharinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>47954</sb:first-page>
                              <sb:last-page>47963</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1074/jbc.M205156200</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">P. Saharinen, O. Silvennoinen, The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277 (2002) 47954-47963. https://doi.org/10.1074/jbc.M205156200.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kralovics</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Passamonti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Buser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Tiedt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Passweg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tichelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cazzola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Skoda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ gain-of-function mutation of JAK2 in myeloproliferative disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>352</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1779</sb:first-page>
                              <sb:last-page>1790</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1056/NEJMoa051113</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">R. Kralovics, F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola, R. C. Skoda, A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790. https://doi.org/10.1056/NEJMoa051113.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Levine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Loriaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Huntly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Loh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Beran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Stoffregen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Willis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Flores</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Estey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gattermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Armstrong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Look</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3377</sb:first-page>
                              <sb:last-page>3379</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2005-05-1898</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">R. L. Levine, M. Loriaux, B. J. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, N. J. Flores, E. Estey, N. Gattermann, S. Armstrong, A. T. Look, J. D. Griffin, O. A. Bernard, M. C. Heinrich, D. G. Gilliland, B. Druker, M. W. Deininger, The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106 (2005) 3377-3379. https://doi.org/10.1182/blood-2005-05-1898.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Staerk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kallin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Demoulin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vainchenker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Constantinescu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41893</sb:first-page>
                              <sb:last-page>41899</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1074/jbc.C500358200</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">J. Staerk, A. Kallin, J. B. Demoulin, W. Vainchenker, S. N. Constantinescu, JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 280 (2005) 41893-41899. https://doi.org/10.1074/jbc.C500358200.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Dondi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Uze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pellegrini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8991</sb:first-page>
                              <sb:last-page>8996</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1073/pnas.160130297</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">T. C. Yeh, E. Dondi, G. Uze, S. Pellegrini, A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc. Natl. Acad. Sci. USA 97 (2000) 8991-8996. https://doi.org/10.1073/pnas.160130297.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gakovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ragimbeau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Eloranta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ronnblom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Michel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pellegrini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>190</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2335</sb:first-page>
                              <sb:last-page>2344</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4049/jimmunol.1203118</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Z. Li, M. Gakovic, J. Ragimbeau, M. L. Eloranta, L. Ronnblom, F. Michel, S. Pellegrini, Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J. Immunol. 190 (2013) 2335-2344. https://doi.org/10.4049/jimmunol.1203118.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Bandaranayake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ungureanu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Struct. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>754</sb:first-page>
                              <sb:last-page>759</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nsmb.2348</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">R. M. Bandaranayake, D. Ungureanu, Y. Shan, D. E. Shaw, O. Silvennoinen, S. R. Hubbard, Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19 (2012) 754-759. https://doi.org/10.1038/nsmb.2348.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Goldsmith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mikami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pharr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Longmore</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Absence of cytokine receptor-dependent specificity in red blood cell differentiation inÂ vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7006</sb:first-page>
                              <sb:last-page>7011</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1073/pnas.95.12.7006</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">M. A. Goldsmith, A. Mikami, Y. You, K. D. Liu, L. Thomas, P. Pharr, G. D. Longmore, Absence of cytokine receptor-dependent specificity in red blood cell differentiation inÂ vivo. Proc. Natl. Acad. Sci. USA. 95 (1998) 7006-7011. https://doi.org/10.1073/pnas.95.12.7006.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Lupardus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ultsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wallweber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bir Kohli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Eigenbrot</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8025</sb:first-page>
                              <sb:last-page>8030</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1073/pnas.1401180111</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">P. J. Lupardus, M. Ultsch, H. Wallweber, P. Bir Kohli, A. R. Johnson, C. Eigenbrot, Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition, Proc. Natl. Acad. Sci. U S A. 111 (2014) 8025-8030. https://doi.org/10.1073/pnas.1401180111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Boggon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Manley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure of the JAK3 kinase domain in complex with a staurosporine analog</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>996</sb:first-page>
                              <sb:last-page>1002</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2005-02-0707</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">T. J. Boggon, Y. Li, P. W. Manley, M. J. Eck, Crystal structure of the JAK3 kinase domain in complex with a staurosporine analog, Blood. 106 (2005) 996-1002. https://doi.org/10.1182/blood-2005-02-0707.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Lucet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Styles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bamert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Broughton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Walter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Treutlein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Wilks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rossjohn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>176</sb:first-page>
                              <sb:last-page>183</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2005-06-2413</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">I. S. Lucet, E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, J. Rossjohn, The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor, Blood. 107 (2006) 176-183. https://doi.org/10.1182/blood-2005-06-2413.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Bamert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Walden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Wilks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rossjohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Lucet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dissecting Specificity in the Janus Kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>219</sb:first-page>
                              <sb:last-page>232</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.jmb.2009.01.041</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">N. K. Williams, R. S. Bamert, O. Patel, C. Wang, P. M. Walden, A. F. Wilks, E. Fantino, J. Rossjohn, I. S. Lucet, Dissecting Specificity in the Janus Kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains, J. Mol. Biol. 387 (2009) 219-232. https://doi.org/10.1016/j.jmb.2009.01.041.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Chrencik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.K.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Korniski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Emmons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Weinberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Gormley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Day</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Hirsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Kiefer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Leone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Sommers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Jacobsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Tenbrink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Tomasselli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Benson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>400</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>413</sb:first-page>
                              <sb:last-page>433</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.jmb.2010.05.020</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">J. E. Chrencik, A. Patny, I. K. Leung, B. Korniski, T. L. Emmons, T. Hall, R. A. Weinberg, J. A. Gormley, J. M. Williams, J. E. Day, J. L. Hirsch, J. R. Kiefer, J. W. Leone, H. D. Fischer, C. D. Sommers, H. Huang, E. J. Jacobsen, R. E. Tenbrink, A. G. Tomasselli, T. E. Benson, Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6, J. Mol. Biol. 400 (2010), 413-433. https://doi.org/10.1016/j.jmb.2010.05.020.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bechman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yates</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Galloway</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>147</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104392</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.phrs.2019.104392</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">K. Bechman, M. Yates, J. B. Galloway, The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors, Pharmacol. Res. 2019, 147: 104392. https://doi.org/10.1016/j.phrs.2019.104392.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Christiano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy of selective next-generation JAK inhibitors in the treatment of alopecia areata</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Invest. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>186</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.jid.2018.03.1111</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Z. Dai, W. Zeng, A. M. Christiano, Efficacy of selective next-generation JAK inhibitors in the treatment of alopecia areata, J. Invest. Dermatol. 138 (2018) 186. https://doi.org/10.1016/j.jid.2018.03.1111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Q.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.G.</ce:given-name>
                                 <ce:surname>Fand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.X.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Tao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.F.</ce:given-name>
                                 <ce:surname>Pand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>P2X7 receptor: a potential therapeutic target for autoimmune diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Autoimmun. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>767</sb:first-page>
                              <sb:last-page>777</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.autrev.2019.06.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">F. Cao, L. Q. Hu, S. R. Yao, Y. Hu, D. G. Wang, Y. G. Fand, G. X. Pan, S. S. Tao, Q. Zhang, H. F. Pand, G. C. Wu, P2X7 receptor: A potential therapeutic target for autoimmune diseases, Autoimmun. Rev. 18 (2019) 767-777. https://doi.org/10.1016/j.autrev.2019.06.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Van den Bosch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.K.</ce:given-name>
                                 <ce:surname>Ostor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wassenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Garg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kalabic</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Impact of participation in the adalimumab (Humira) patient support program on rheumatoid arthritis treatment course: results from the PASSION study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rheumatol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>96</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s40744-017-0061-7</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">F. Van den Bosch, A. J. K. Ostor, S. Wassenberg, N. Chen, C. Wang, V. Garg, J. Kalabic, Impact of participation in the adalimumab (Humira) patient support program on rheumatoid arthritis treatment course: results from the PASSION study, Rheumatol. Ther. 4 (2017) 85-96. https://doi.org/10.1007/s40744-017-0061-7.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.X.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of SIRT1/Akt pathway on chronic inflammatory response and lung function in patients with asthma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Rev. Med. Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4948</sb:first-page>
                              <sb:last-page>4953</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.26355/eurrev_201906_18085</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Y. Z. Zhang, Q. J. Wu, X. Yang, X. X. Xing, Y. Y. Chen, H. Wang, Effects of SIRT1/Akt pathway on chronic inflammatory response and lung function in patients with asthma, Eur. Rev. Med. Pharmacol. Sci. 11 (2019) 4948-4953. https://doi.org/10.26355/eurrev_201906_18085.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>HammarÃ©n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Virtanen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Raivola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The regulation of JAKs in cytokine signaling and its breakdown in disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>63</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cyto.2018.03.041</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">H. M. Hammaren, A. T. Virtanen, J. Raivola, O. Silvennoinen, The regulation of JAKs in cytokine signaling and its breakdown in disease, Cytokine. 118 (2019) 48-63. https://doi.org/10.1016/j.cyto.2018.03.041.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5023</sb:first-page>
                              <sb:last-page>5038</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm401490p</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">J. D. Clark, M. E. Flanagan, J. B. Telliez, Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases, J. Med. Chem. 57 (2014) 5023â5038. https://doi.org/10.1021/jm401490p.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Cha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.Y.</ce:given-name>
                                 <ce:surname>Yen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Zha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.O.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.K.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.H.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Amin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Kaseb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Hung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3324</sb:first-page>
                              <sb:last-page>3338</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1172/JCI126022</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">L. C. Chan, C. W. Li, W. Y. Xia, J. M. Hsu, H. H. Lee, J. H. Cha, H. L. Wang, W. H. Yang, E. Y. Yen, W. C. Chang, Z. Y. Zha, S. O. Lim, Y. J. Lai, C. X. Liu, J. L. Liu, Q. Z. Dong, Y. Yang, L. L. Sun, Y. K. Wei, L. Nie, J. L. Hsu, H. Li, Q. H. Ye, M. M. Hassan, H. M. Amin, A. O. Kaseb, X. Lin, S. C. Wang, M. C. Hung, IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion, J. Clin. Invest. 129 (2019) 3324-3338. https://doi.org/10.1172/JCI126022.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.A.</ce:given-name>
                                 <ce:surname>Elsayed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pommier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Agama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Low</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cushman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Application of sequential palladium catalysis for the discovery of janus kinase inhibitors in the benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) series</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10440</sb:first-page>
                              <sb:last-page>10462</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b00510</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">M. S. A. Elsayed, J. J. Nielsen, S. Park, J. Park, Q. Liu, C. H. Kim, Y. Pommier, K. Agama, P. S. Low, M. Cushman, Application of sequential palladium catalysis for the discovery of janus kinase inhibitors in the benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) series, J. Med. Chem. 61 (2018) 10440â10462. https://doi.org/10.1021/acs.jmedchem.8b00510.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Karantanosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Moliternob</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: opportunities for targeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>426</sb:first-page>
                              <sb:last-page>432</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.blre.2018.03.007</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">T. Karantanosa, A. R. Moliternob, The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy, Blood Rev. 32 (2018) 426-432. https://doi.org/10.1016/j.blre.2018.03.007.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Baxter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Campbell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>East</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fourouclas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Swanton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Vassiliou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Bench</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Boyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Curtin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.N.</ce:given-name>
                                 <ce:surname>Erber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>365</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1054</sb:first-page>
                              <sb:last-page>1061</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S0140-6736(05)71142-9</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">E. J. Baxter, L. M. Scott, P. J. Campbell, C. East, N. Fourouclas, S. Swanton, G. S. Vassiliou, A. J. Bench, E. M. Boyd, N. Curtin, M. A. Scott, W. N. Erber, A. R. Green, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet. 365 (2005) 1054-1061. https://doi.org/10.1016/S0140-6736(05)71142-9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Taoka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Otte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Spencer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Dinsmore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Altman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rosenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Szewczak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zugay-Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Marshall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7334</sb:first-page>
                              <sb:last-page>7349</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm200909u</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">J. Lim, B. Taoka, R. D. Otte, K. Spencer, C. J. Dinsmore, M. D. Altman, G. Chan, C. Rosenstein, S. Sharma, H. Su, A. A. Szewczak, L. Xu, H. Yin, J. Zugay-Murphy, C. G. Marshall, J. R. Young, Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders, J. Med. Chem. 54 (2011) 7334-7349. https://doi.org/10.1021/jm200909u.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Schenkel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Deak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Doherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Emkey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gunaydin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Loberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Olivieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pistillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Geuns-Meyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent and highly selective thienopyridine janus kinase 2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8440</sb:first-page>
                              <sb:last-page>8450</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm200911r</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">L. B. Schenkel, X. Huang, A. Cheng, H. L. Deak, E. Doherty, R. Emkey, Y. Gu, H. Gunaydin, J. L. Kim, J. Lee, R. Loberg, P. Olivieri, J. Pistillo, J. Tang, Q. Wan, H. Wang, S. Wang, M. C. Wells, B. Wu, V. Yu, L. Liu, S. Geuns-Meyer, Discovery of potent and highly selective thienopyridine janus kinase 2 inhibitors, J. Med. Chem. 54 (2011) 8440â8450. https://doi.org/10.1021/jm200911r.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Hanan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>van Abbema</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Barrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Blair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Eigenbrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Flynn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gibbons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Hurley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Kenny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kulagowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Magnuson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Morris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Pastor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Rawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Siu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ultsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sampath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Lyssikatos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10090</sb:first-page>
                              <sb:last-page>10107</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm3012239</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">E. J. Hanan, A. van Abbema, K. Barrett, W. S. Blair, J. Blaney, C. Chang, C. Eigenbrot, S. Flynn, P. Gibbons, C. A. Hurley, J. R. Kenny, J. Kulagowski, L. Lee, S. R. Magnuson, C. Morris, J. Murray, R. M. Pastor, T. Rawson, M. Siu, M. Ultsch, A. Zhou, D. Sampath, J. P. Lyssikatos, Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors, J. Med. Chem. 55 (2012) 10090â10107. https://doi.org/10.1021/jm3012239.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Roskoski</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>784</sb:first-page>
                              <sb:last-page>803</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.phrs.2016.07.038</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">R. Jr. Roskoski, Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases, Pharmacol. Res. 111 (2016) 784-803. https://doi.org/10.1016/j.phrs.2016.07.038.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Decker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK-STAT signaling: from interferons to cytokines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>282</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20059</sb:first-page>
                              <sb:last-page>20063</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1074/jbc.R700016200</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">C. Schindler, D. E. Levy, T. Decker, JAK-STAT signaling: from interferons to cytokines, J. Biol. Chem. 282 (2007) 20059-20063. https://doi.org/10.1074/jbc.R700016200.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>137</sb:first-page>
                              <sb:last-page>149</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/13543776.2019.1567713</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">X. He, X. Chen, H. Zhang, T. Xie, X. Y. Ye, Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018), Expert. Opin. Ther. Pat. 29 (2019) 137-149. https://doi.org/10.1080/13543776.2019.1567713.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Tsui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Van Abbema</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Barrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Beresini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Berezhkovskiy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Blair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Driscoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Eigenbrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ghilardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gibbons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Halladay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bir Kohli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liimatta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Mantik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Menghrajani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sambrone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Stanley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ultsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Magnuson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lead identification of novel and selective TYK2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>67</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>175</sb:first-page>
                              <sb:last-page>187</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2013.03.070</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">J. Liang, V. Tsui, A. Van Abbema, L. Bao, K. Barrett, M. Beresini, L. Berezhkovskiy, W. S. Blair, C. Chang, J. Driscoll, C. Eigenbrot, N. Ghilardi, P. Gibbons, J. Halladay, A. Johnson, P. Bir Kohli, Y. Lai, M. Liimatta, P. Mantik, K. Menghrajani, J. Murray, A. Sambrone, Y. Xiao, S. Shia, Y. Shin, J. Smith, S. Sohn, M. Stanley, M. Ultsch, B. Zhang, L. C. Wu, S. Magnuson, Lead identification of novel and selective TYK2 inhibitors, Eur. J. Med. Chem. 67 (2013) 175-187. https://doi.org/10.1016/j.ejmech.2013.03.070.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Muckelbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chaudhry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Elzinga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dâarienzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Gillooly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>SalterCid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aranibar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of imidazo[1,2-b]pyridazine derivatives as potent, selective, and orally active TYK2 JH2 Inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>388</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.9b00035</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">C. Liu, J. Lin, R. Moslin, J. S Tokarski, J. K. Muckelbauer, C. Chang, J. Tredup, D. Xie, H. Park, P. Li, D. Wu, J. Strnad, A. Zupa-Fernandez, L. Cheng, C. Chaudhry, J. Chen, C. Chen, H. Sun, P. Elzinga, C. Dâarienzo, K. M. Gillooly, T. L. Taylor, K. W. McIntyre, L. SalterCid, L. J Lombardo, P. H Carter, N. Aranibar, J. R. Burke, D. S. Weinstein, Identification of imidazo[1,2-b]pyridazine derivatives as potent, selective, and orally active TYK2 JH2 Inhibitors, ACS Med. Chem. Lett. 10 (2019) 383-388. https://doi.org/10.1021/acsmedchemlett.9b00035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shuai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of JAK-STAT signalling in the immune system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>900</sb:first-page>
                              <sb:last-page>911</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nri1226</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">K. Shuai, B. Liu, Regulation of JAK-STAT signalling in the immune system, Nat. Rev. Immunol. 3 (2003) 900-911. https://doi.org/10.1038/nri1226.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Deacon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Horiuchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The challenge of selecting protein kinase assays for lead discovery optimization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>607</sb:first-page>
                              <sb:last-page>621</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1517/17460441.3.6.607</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">H. Ma, S. Deacon, K. Horiuchi, The challenge of selecting protein kinase assays for lead discovery optimization, Expert. Opin. Drug Discov. 3 (2008) 607-621. https://doi.org/10.1517/17460441.3.6.607.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Quinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kwak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.V.</ce:given-name>
                                 <ce:surname>Talanian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Current inÂ vitro kinase assay technologies: the quest for a universal format</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Discov. Technol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>69</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.2174/157016308783769414</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">Y. Jia, C. M. Quinn, S. Kwak, R. V. Talanian, Current inÂ vitro kinase assay technologies: the quest for a universal format, Curr. Drug Discov. Technol. 5 (2008) 59-69. https://doi.org/10.2174/157016308783769414.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Perrin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>FrÃ©maux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Besson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biomol. Screen</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>996</sb:first-page>
                              <sb:last-page>1004</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1177/1087057106294094</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">D. Perrin, C. Fremaux, D. Besson, A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors, J. Biomol. Screen. 11 (2006) 996-1004. https://doi.org/10.1177/1087057106294094.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Benicchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lozzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Svahn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biomol. Screen</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>933</sb:first-page>
                              <sb:last-page>945</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1177/1087057112447873</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">T. Benicchi, S. Lozzi, A. Svahn, A homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interaction, J. Biomol. Screen. 17 (2012) 933-945. https://doi.org/10.1177/1087057112447873.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Brubaker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally bioavailable JAK1 inhibitor for validation of JAK1-selective hypothesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:title>
                                 <sb:maintitle>Presented at Applied Pharmaceutical Chemistry Conference; Boston, MA</sb:maintitle>
                              </sb:title>
                              <sb:date>March 4, 2014</sb:date>
                           </sb:edited-book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">J. Brubaker, Discovery of an orally bioavailable JAK1 inhibitor for validation of JAK1-selective hypothesis. Presented at Applied Pharmaceutical Chemistry Conference; Boston, MA, March 4, 2014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Inghrim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Grebinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Lorenzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mcdevitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Penhallow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Vuppugalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Iyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Trainor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ruepp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lippy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Blat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Sack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Stefanski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sleczka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mathur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.N.</ce:given-name>
                                 <ce:surname>Arunachalam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pragalathan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Narayanan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Nanjundaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kuppusamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Purandare</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>850</sb:first-page>
                              <sb:last-page>855</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.5b00226</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">H. Wan, G. M. Schroeder, A. C. Hart, J. Inghrim, J. Grebinski, J. S. Tokarski, M. V. Lorenzi, D. You, T. Mcdevitt, B. Penhallow, R. Vuppugalla, Y. Zhang, X. Gu, R. Iyer, L. J. Lombardo, G. L. Trainor, S. Ruepp, J. Lippy, Y. Blat, J. S. Sack, J. A. Khan, K. Stefanski, B. Sleczka, A. Mathur, J. Sun, M. K. Wong, D. Wu, P. Li, A. Gupta, P. N. Arunachalam, B. Pragalathan, S. Narayanan, K.C. Nanjundaswamy, P. Kuppusamy, A. V. Purandare, Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms, ACS Med. Chem. Lett. 6 (2015) 850â855. https://doi.org/10.1021/acsmedchemlett.5b00226.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Menet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Van Lommen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Geney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blanc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Smits</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jouannigot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Deprez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>van der Aar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Clement-Lacroix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lepescheux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Galien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vayssiere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nelles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Christophe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Brys</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Uhring</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ciesielski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Van Rompaey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9323</sb:first-page>
                              <sb:last-page>9342</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm501262q</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">C. J. Menet, S. R. Fletcher, G. Van Lommen, R. Geney, J. Blanc, K. Smits, N. Jouannigot, P. Deprez, E. M. van der Aar, P. Clement-Lacroix, L. Lepescheux, R. Galien, B. Vayssiere, L. Nelles, T. Christophe, R. Brys, M. Uhring, F. Ciesielski, L. Van Rompaey. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634, J. Med. Chem. 57 (2014) 9323-9342. https://doi.org/10.1021/jm501262q.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Purandare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>McDevitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Penhallow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Vuppugalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.U.</ce:given-name>
                                 <ce:surname>Ruepp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Trainor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pedicord</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Gottardis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ross-Macdonald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>de Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hosbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Emanuel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Blat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fitzpatrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Michaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Mulligan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Woolfson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Lasho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pardanani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tefferi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Lorenzi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>280</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/leu.2011.292</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">A. V. Purandare, T. M. McDevitt, H. Wan, D. You, B. Penhallow, X. Han, R. Vuppugalla, Y. Zhang, S. U. Ruepp, G. L. Trainor, L. Lombardo, D. Pedicord, M. M. Gottardis, P. Ross-Macdonald, H. de Silva, J. Hosbach, S. L. Emanuel, Y. Blat, E. Fitzpatrick, T. L. Taylor, K. W. McIntyre, E. Michaud, C. Mulligan, F. Y. Lee, A. Woolfson, T. L. Lasho, A. Pardanani, A. Tefferi, M. V. Lorenzi, Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2, Leukemia. 26 (2012) 280-288. https://doi.org/10.1038/leu.2011.292.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Keith</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Collins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Nickerson-Nutter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Rheum. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>67</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1505</sb:first-page>
                              <sb:last-page>1515</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1136/ard.2007.076430</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">M. Hegen, J. C. Jr. Keith, M. Collins, C. L. Nickerson-Nutter, Utility of animal models for identification of potential therapeutics for rheumatoid arthritis, Ann. Rheum. Dis. 67 (2008)1505-1515. https://doi.org/10.1136/ard.2007.076430.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.C.R.</ce:given-name>
                                 <ce:surname>Carvalho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>LourenÃ§o</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Ferreira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Branco</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tofacitinib synthesis â an asymmetric challenge</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Org Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>615</sb:first-page>
                              <sb:last-page>624</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/ejoc.201801180</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">L. C. R. Carvalho, A. Lourenco, L. M. Ferreira, P. S. Branco, Tofacitinib synthesis - an asymmetric challenge, Eur. J. Org. Chem. 4 (2019) 615-624. https://doi.org/10.1002/ejoc.201801180.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Mesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Yasothan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kirkpatrick</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ruxolitinib. Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>103</sb:first-page>
                              <sb:last-page>104</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrd3652</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">R. A. Mesa, U. Yasothan, P. Kirkpatrick, Ruxolitinib. Nat. Rev. Drug Discov. 11 (2012) 103-104. https://doi.org/10.1038/nrd3652.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.A.M.</ce:given-name>
                                 <ce:surname>Sanchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Reinhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ramsey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wittkowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Hashkes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Berkun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schalm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Murias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Dare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Klausmeier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Foell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>De Jesus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Chapelle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Colbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Failla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kost</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>OâBrien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Reynolds</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Folio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Calvo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Paul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Weir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Brofferio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Soldatos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Biancotto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.W.</ce:given-name>
                                 <ce:surname>Cowen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Digiovanna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gadina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Lipton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hadigan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Holland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fontana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Alawad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Rother</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Heller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Brooks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Brooks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Waldman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.K.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Nickeleit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Silk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Prakash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Janes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ozen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Wakim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Brogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.L.</ce:given-name>
                                 <ce:surname>Macias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Goldbach-Mansky</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3041</sb:first-page>
                              <sb:last-page>3052</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1172/JCI98814</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">G. A. M. Sanchez, A. Reinhardt, S. Ramsey, H. Wittkowski, P. J. Hashkes, Y. Berkun, S. Schalm, S. Murias, J. A. Dare, D. Brown, D. L. Stone, L. Gao, T. Klausmeier, D. Foell, A. A. De Jesus, D. C. Chapelle, H. Kim, S. Dill, R. A. Colbert, L. Failla, B. Kost, M. OâBrien, J. C. Reynolds, L. R. Folio, K. R. Calvo, S. M. Paul, N. Weir, A. Brofferio, A. Soldatos, A. Biancotto, E. W. Cowen, J. J. Digiovanna, M. Gadina, A. J. Lipton, C. Hadigan, S. M. Holland, J. Fontana, A. S. Alawad, R. J. Brown, K. I. Rother, T. Heller, K. M. Brooks, P. Kumar, S. R. Brooks, M. Waldman, H. K. Singh, V. Nickeleit, M. Silk, A. Prakash, J. M. Janes, S. Ozen, P. G. Wakim, P. A. Brogan, W. L. Macias, R. Goldbach-Mansky, JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies, J. Clin. Invest. 128 (2018) 3041-3052. https://doi.org/10.1172/JCI98814.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hamaguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Amano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Moritomo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shirakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nakai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nomura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Higashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4971</sb:first-page>
                              <sb:last-page>4983</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2018.08.005</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">H. Hamaguchi, Y. Amano, A. Moritomo, S. Shirakami, Y. Nakajima, K. Nakai, N. Nomura, M. Ito, Y. Higashi, T. Inoue, Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor, Bioorg. Med. Chem. 26 (2018) 4971-4983. https://doi.org/10.1016/j.bmc.2018.08.005.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Blumenkopf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Brissette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Casavant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Shang-Poa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Doty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Elliott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hines</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Kudlacz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Lillie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Magnuson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>McCurdy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Munchhof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Perry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Strelevitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Subramanyam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Whipple</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Changelian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8468</sb:first-page>
                              <sb:last-page>8484</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm1004286</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">M. E. Flanagan, T. A. Blumenkopf, W. H. Brissette, M. F. Brown, J. M. Casavant, C. Shang-Poa, J. L. Doty, E. A. Elliott, M. B. Fisher, M. Hines, C. Kent, E. M. Kudlacz, B. M. Lillie, K. S. Magnuson, S. P. McCurdy, M. J. Munchhof, B. D. Perry, P. S. Sawyer, T. J. Strelevitz, C. Subramanyam, J. Sun, D. A. Whipple, P. S. Changelian, Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection, J. Med. Chem. 53 (2010) 8468-8484. https://doi.org/10.1021/jm1004286.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>MaricÃ¡n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Simirgiotis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Asymmetric total synthesis of tofacitinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5096</sb:first-page>
                              <sb:last-page>5098</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.tetlet.2013.07.042</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">A. Marican, M. J. Simirgiotis, L. S. Santos, Asymmetric total synthesis of tofacitinib, Tetrahedron Lett. 54 (2013) 5096-5098. https://doi.org/10.1016/j.tetlet.2013.07.042.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Jacobson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Baumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ismail</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Kratzke</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Gene Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>411</sb:first-page>
                              <sb:last-page>418</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41417-018-0074-6</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">M. R. Patel, A. Dash, B. A. Jacobson, Y. Ji, D. Baumann, K. Ismail, R. A. Kratzke, JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models, Cancer Gene Ther. 26 (2019) 411-418. https://doi.org/10.1038/s41417-018-0074-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>QuintaÂ´s-Cardama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Vaddi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Manshouri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Scherle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Caulder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Waeltz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rupar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Burn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kelley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Covington</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shepard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Rodgers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Haley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Fridman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3109</sb:first-page>
                              <sb:last-page>3117</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2009-04-214957</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">A. QuintaÂ´s-Cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li, P. A. Scherle, E. Caulder, X. Wen, Y. Li, P. Waeltz, M. Rupar, T. Burn, Y. Lo, J. Kelley, M. Covington, S. Shepard, J. D. Rodgers, P. Haley, H. Kantarjian, J. S. Fridman, S. Verstovsek, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, Blood. 115 (2010) 3109-3117. https://doi.org/10.1182/blood-2009-04-214957.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Padron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dezern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andrade-Campos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Vaddi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Scherle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Balasis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tinsley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ramadan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zimmerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Steensma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Roboz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Lancet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>List</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Sekeres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Komrokji</ce:surname>
                              </sb:author>
                              <sb:collaboration>on behalf of the Myelodysplastic Syndrome Clinical Research Consortium</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3746</sb:first-page>
                              <sb:last-page>3754</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-15-2781</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">E. Padron, A. Dezern, M. Andrade-Campos, K. Vaddi, P. Scherle, Q. Zhang, Y. Ma, M. E. Balasis, S. Tinsley, H. Ramadan, C. Zimmerman, D. P. Steensma, G. J. Roboz, J. E. Lancet, A. F. List, M. A. Sekeres, R. S. Komrokji on behalf of the Myelodysplastic Syndrome Clinical Research Consortium. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML), Clin. Cancer Res. 22 (2016) 3746-3754. https://doi.org/10.1158/1078-0432.CCR-15-2781.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Fogelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cubillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>GarcÃ­a-Alfonso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.L.</ce:given-name>
                                 <ce:surname>MirÃ³n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nemunaitis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Flora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Borg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mineur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Vieitez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Saylors</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Assad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Switzky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bendell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5382</sb:first-page>
                              <sb:last-page>5393</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/cam4.1703</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">D. Fogelman, A. Cubillo, P. Garcia-Alfonso, M. L. L. Miron, J. Nemunaitis, D. Flora, C. Borg, L. Mineur, J. M. Vieitez, A. Cohn, G. Saylors, A. Assad, J. Switzky, L. Zhou, J. Bendell, Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer, Cancer Med. 7 (2018) 5382-5393. https://doi.org/10.1002/cam4.1703.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Honga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Chuna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Kima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lung Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>134</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>46</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.lungcan.2019.05.030</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">J. S. Park, M. H. Honga, Y. J. Chuna, H. R. Kima, B. C. Cho, A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs, Lung Cancer. 134 (2019) 46-51. https://doi.org/10.1016/j.lungcan.2019.05.030.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jagasia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.N.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Dawkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Arbushites</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Perales</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 reach 1 trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Blood Marrow Transplant.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>52</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bbmt.2018.12.130</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">M. Jagasia, H. Ali, M. A. Schroeder, N. N. Shah, Y. Chen, F. Dawkins, M. Arbushites, C. Tian, M. Perales, Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 reach1 trial, Biol. Blood Marrow Transplant. 25 (2019) 52. https://doi.org/10.1016/j.bbmt.2018.12.130.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Fridman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Scherle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Collins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Burn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Covington</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Collier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Favata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McGee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Haley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shepard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Rodgers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yeleswaram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Newton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Metcalf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Vaddi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>184</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5298</sb:first-page>
                              <sb:last-page>5307</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4049/jimmunol.0902819</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">J. S. Fridman, P. A. Scherle, R. Collins, T. C. Burn, Y. Li, J. Li, M. B. Covington, B. Thomas, P. Collier, M. F. Favata, X. Wen, J. Shi, R. McGee, P. J. Haley, S. Shepard, J. D. Rodgers, S. Yeleswaram, G. Hollis, R. C. Newton, B. Metcalf, S. M. Friedman, K. Vaddi, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050, J. Immunol. 184 (2010) 5298-5307. https://doi.org/10.4049/jimmunol.0902819.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mullard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FDA approves Eli Lillyâs baricitinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <ce:doi>10.1038/nrd.2018.112</ce:doi>
                        </sb:host>
                        <sb:comment>460-460</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0380">A. Mullard, FDA approves Eli Lillyâs baricitinib, Nat. Rev. Drug Discov. 17 (2018) 460-460. https://doi.org/10.1038/nrd.2018.112.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jabbari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cerise</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ramot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Berkun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Sanchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Goldbach-Mansky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Christiano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Clynes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zlotogorski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EBioMedicine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>351</sb:first-page>
                              <sb:last-page>355</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ebiom.2015.02.015</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">A. Jabbari, Z. Dai, L. Xing, J. E. Cerise, Y. Ramot, Y. Berkun, G. A. Sanchez, R. Goldbach-Mansky, A. M. Christiano, R. Clynes, A. Zlotogorski, Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib, EBioMedicine. 26 (2015) 351-355. https://doi.org/10.1016/j.ebiom.2015.02.015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.M.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Perrard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Brunner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Sparks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Z.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Ballantyne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Obes.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1607</sb:first-page>
                              <sb:last-page>1618</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/ijo.2015.104</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">I. M. Khan, X. Y. Perrard, G. Brunner, H. Lui, L. M. Sparks, S. R. Smith, X. Wang, Z. Z. Shi, D. E. Lewis, H. Wu, C. M. Ballantyne, Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance, Int. J. Obes. (Lond). 39 (2015) 1607-1618. https://doi.org/10.1038/ijo.2015.104.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Current mechanistic insights into the role of infection in systemic lupus erythematosus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomed. Pharmacother.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>109122</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.biopha.2019.109122</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">Q. Pan, Z. Liu, S. Liao, L. Ye, X. Lu, X. Chen, Z. Li, X. Li, Y. Z. Xu, H. Liu, Current mechanistic insights into the role of infection in systemic lupus erythematosus, Biomed. Pharmacother. 117 (2019) 109122. https://doi.org/10.1016/j.biopha.2019.109122.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Wallace</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Furie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>de Bono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Baricitinib for systemic lupus erythematosus reply</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>393</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>402</sb:first-page>
                              <sb:last-page>403</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S0140-6736(18)32749-1</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">D. J. Wallace, R. A. Furie, Y. Tanaka, S. de Bono, R. W. Hoffman, Baricitinib for systemic lupus erythematosus reply, Lancet. 393 (2019) 402-403. https://doi.org/10.1016/S0140-6736(18)32749-1.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Baricitinib for systemic lupus erythematosus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>393</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <ce:doi>10.1016/S0140-6736(18)32763-6</ce:doi>
                        </sb:host>
                        <sb:comment>402-402</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0405">K. Yuan, G. Huang, X. Sang, A. Xu, Baricitinib for systemic lupus erythematosus, Lancet. 393 (2019) 402-402. https://doi.org/10.1016/S0140-6736(18)32763-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Guttman-Yassky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Silverberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Nemoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Forman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wilke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Prescilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de la Pena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.P.</ce:given-name>
                                 <ce:surname>Nunes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Janes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gamalo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Donley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Paik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>DeLozier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Nickoloff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Simpson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Am. Acad. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>913</sb:first-page>
                              <sb:last-page>921</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.jaad.2018.01.018</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">E. Guttman-Yassky, J. I. Silverberg, O. Nemoto, S. B. Forman, A. Wilke, R. Prescilla, A. de la Pena, F. P. Nunes, J. Janes, M. Gamalo, D. Donley, J. Paik, A. M. DeLozier, B. J. Nickoloff, E. L. Simpson, Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study, J. Am. Acad. Dermatol. 80 (2019) 913-921. https://doi.org/10.1016/j.jaad.2018.01.018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yamazaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamagami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Morita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Chida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Inami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shirakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Higashi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>133</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>25</sb:first-page>
                              <sb:last-page>33</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.jphs.2016.12.001</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">M. Ito, S. Yamazaki, K. Yamagami, M. Kuno, Y. Morita, K. Okuma, K. Nakamura, N. Chida, M. Inami, T. Inoue, S. Shirakami, Y. Higashi, A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model, J. Pharmacol. Sci. 133 (2017) 25-33. https://doi.org/10.1016/j.jphs.2016.12.001.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Isaacs</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, crohnâs disease and ulcerative colitis?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Rheum. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>175</sb:first-page>
                              <sb:last-page>187</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1136/annrheumdis-2017-211555</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">K. F. Baker, J. D. Isaacs, Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, crohnâs disease and ulcerative colitis? Ann. Rheum. Dis. 77 (2017) 175-187. https://doi.org/10.1136/annrheumdis-2017-211555.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>iwasaki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effcacy and safety of the oral Janus kinase inhibitor pefcitinib (asP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebocontrolled phase iib study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Rheum. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1057</sb:first-page>
                              <sb:last-page>1064</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1136/annrheumdis-2015-208279</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">T. Takeuchi, Y. Tanaka, M. iwasaki, Effcacy and safety of the oral Janus kinase inhibitor pefcitinib (asP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebocontrolled phase iib study, Ann. Rheum. Dis. 75 (2016)1057-1064. https://doi.org/10.1136/annrheumdis-2015-208279.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Genovese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Greenwald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Codding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pefcitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arthritis Rheum.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>932</sb:first-page>
                              <sb:last-page>942</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/art.40054</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">M. C. Genovese, M. Greenwald, C. Codding, Pefcitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis, Arthritis Rheumatol. 69 (2017) 932-942. https://doi.org/10.1002/art.40054.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Kivitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Gutierrez-UreÃ±a</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Poiley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Genovese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kristy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Garg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zubrzycka-Sienkiewicz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pefcitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arthritis Rheum.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>709</sb:first-page>
                              <sb:last-page>719</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/art.39955</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">A. J. Kivitz, S. R. Gutierrez-Urena, J. Poiley, M. C. Genovese, R. Kristy, K. Shay, X. Wang, J. P. Garg, A. Zubrzycka-Sienkiewicz, Pefcitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate, Arthritis Rheumatol. 69 (2017) 709-719. https://doi.org/10.1002/art.39955.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kawakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>iwasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Katayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rokuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>izutsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ushijima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kaneko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>shiomi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Yamada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>van der Heijde</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effcacy and safety of pefcitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Rheum. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1305</sb:first-page>
                              <sb:last-page>1309</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1136/annrheumdis-2019-215164</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">T. Takeuchi, Y. Tanaka, S. Tanaka, A. Kawakami, M. iwasaki, K. Katayama, M. Rokuda, H. izutsu, S. Ushijima, Y. Kaneko, T. shiomi, E. Yamada, D. van der Heijde, Effcacy and safety of pefcitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan, Ann. Rheum. Dis. 78 (2019) 1305-1309. https://doi.org/10.1136/annrheumdis-2019-215164.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Sands</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Sandborn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.G.</ce:given-name>
                                 <ce:surname>Feagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Lichtenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Strauss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Szapary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Johanns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Panes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vermeire</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>OâBrien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bertelsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Marano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Peficitinib-UC Study Group. Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, phase 2 study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Crohns. Colitis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1158</sb:first-page>
                              <sb:last-page>1169</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/ecco-jcc/jjy085</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">B. E. Sands, W. J. Sandborn, B. G. Feagan, G. R. Lichtenstein, H. Zhang, R. Strauss, P. Szapary, J. Johanns, J. Panes, S. Vermeire, C. D. OâBrien, Z. Yang, K. Bertelsen, C. Marano, Peficitinib-UC Study Group. Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, phase 2 study, J. Crohns. Colitis. 12 (2018) 1158-1169. https://doi.org/10.1093/ecco-jcc/jjy085.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Papp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pariser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Catlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wierz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Akinlade</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zeiher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Krueger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 2a randomised, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel janus kinase (JAK) inhibitor, in patients with moderate to severe psoriasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>173</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>767</sb:first-page>
                              <sb:last-page>776</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/bjd.13745</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">K. Papp, D. Pariser, M. Catlin, G. Wierz, G. Ball, B. Akinlade, B. Zeiher, J.G. Krueger, Phase 2a randomised, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel janus kinase (JAK) inhibitor, in patients with moderate to severe psoriasis, Br. J. Dermatol. 173 (2015) 767-776. https://doi.org/10.1111/bjd.13745.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Gonzales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Fici</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Mann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mitton-Fry</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Vet. Pharmacol. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>317</sb:first-page>
                              <sb:last-page>324</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/jvp.12101</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">A. J. Gonzales, J. W. Bowman, G. J. Fici, M. Zhang, D. W. Mann, M. Mitton-Fry, Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy, J. Vet. Pharmacol. Ther. 4 (2014) 317-324. https://doi.org/10.1111/jvp.12101.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Mesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kiladjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Catalano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Devos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Egyed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hellmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McLornan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shimoda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Winton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Dubowy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Maltzman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cervantes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gotlib</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitorânÃ¤Ä±ve patients with myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3844</sb:first-page>
                              <sb:last-page>3850</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1200/JCO.2017.73.4418</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">R. A. Mesa, J. Kiladjian, J. V. Catalano, T. Devos, M. Egyed, A. Hellmann, D. McLornan, K. Shimoda, E. F. Winton, W. Deng, R. L. Dubowy, J. D. Maltzman, F. Cervantes, J. Gotlib, SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naÂ¨ive patients with myelofibrosis, J. Clin. Oncol. 35 (2017) 3844-3850. https://doi.org/10.1200/JCO.2017.73.4418.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Fensome</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Ambler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Arnold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chrencik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.V.</ce:given-name>
                                 <ce:surname>Efremov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Flick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Gerstenberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gopalsamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Hayward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Hollingshead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Knafels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Limburg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Pierce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Saiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Symanowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-sifluorocyclopropyl)((1R,5S)-3-(2-((1- methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8597</sb:first-page>
                              <sb:last-page>8612</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b00917</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">A. Fensome, C. M. Ambler, E. Arnold, M. E. Banker, M. F. Brown, J. Chrencik, J. D. Clark, M. E. Dowty, I. V. Efremov, A. Flick, B. S. Gerstenberger, A. Gopalsamy, M. M. Hayward, M. Hegen, B. D. Hollingshead, J. Jussif, J. D. Knafels, D. C. Limburg, D. Lin, T. H. Lin, B. S. Pierce, E. Saiah, R. Sharma, P. T. Symanowicz, J. Telliez, J. I. Trujillo, F. F. Vajdos, F. Vincent, Z. Wan, L. Xing, X. Yang, X. Yang, L. Zhang, Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-sifluorocyclopropyl)((1R,5S)-3-(2-((1- methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841), J. Med. Chem. 61 (2018) 8597â8612. https://doi.org/10.1021/acs.jmedchem.8b00917.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Berdini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Boulstridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Carr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Curry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Devine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Early</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fazal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Gill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Heathcote</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Maman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Matthews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>McMenamin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Navarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>OâBrien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>OâReilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Rees</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>VinkovicÂ´</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Wyatt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>379</sb:first-page>
                              <sb:last-page>388</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm800984v</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">S. Howard, V. Berdini, J. A. Boulstridge, M. G. Carr, D. M. Cross, J. Curry, L. A. Devine, T. R. Early, L. Fazal, A. L. Gill, M. Heathcote, S. Maman, J. E. Matthews, R. L. McMenamin, E. F. Navarro, M. A. OâBrien, M. OâReilly, D. C. Rees, M. Reule, D. Tisi, G. Williams, M. VinkovicÂ´, P. G. Wyatt. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity, J. Med. Chem. 52 (2009) 379-388. https://doi.org/10.1021/jm800984v.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.P.</ce:given-name>
                                 <ce:surname>Coffey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Betz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Birrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Leeds</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Der</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kadri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Segal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Michelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Curnutte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Conley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1174</sb:first-page>
                              <sb:last-page>1184</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-18-1047</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">G. P. Coffey, J. Feng, A. Betz, A. Pandey, M. Birrell, J. M. Leeds, K. Der, S. Kadri, P. Lu, J. Segal, Y. L. Wang, G. Michelson, J. T. Curnutte, P. B. Conley, Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignancies, Clin. Cancer Res. 25 (2019) 1174-1184. https://doi.org/10.1158/1078-0432.CCR-18-1047.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Cubbon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Cummings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Wicker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Frankshun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Cunningham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Cameron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Meinke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Liverton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Weng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>DeMartino</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1219</sb:first-page>
                              <sb:last-page>1223</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/s0960-894x(02)00106-3</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">J. E. Thompson, R. M. Cubbon, R. T. Cummings, L. S. Wicker, R. Frankshun, B. R. Cunningham, P. M. Cameron, P. T. Meinke, N. Liverton, Y. Weng, J. A. DeMartino, Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor, Bioorg. Med. Chem. Lett. 12 (2002) 1219-1223. https://doi.org/10.1016/s0960-894x(02)00106-3.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tanimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ogawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Oki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nozawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Amano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Noji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shiozaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Matsuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shinozaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Matsushita</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses inÂ vitro and inÂ vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Inflamm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00011-014-0782-9</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">A. Tanimoto, Y. Ogawa, C. Oki, Y. Kimoto, K. Nozawa, W. Amano, S. Noji, M. Shiozaki, A. Matsuo, Y. Shinozaki, M. Matsushita, Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses inÂ vitro and inÂ vivo, Inflamm. Res. 64 (2015) 41-51. https://doi.org/10.1007/s00011-014-0782-9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ioannidis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chuaqui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Almeida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alimzhanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bebernitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Block</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huszar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Read</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rivard Costa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zinda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 1-methyl-1H-imidazole derivatives as potent JAK2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>144</sb:first-page>
                              <sb:last-page>158</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm401546n</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">Q. Su, S. Ioannidis, C. Chuaqui, L. Almeida, M. Alimzhanov, G. Bebernitz, K. Bell, M. Block, T. Howard, S. Huang, D. Huszar, J. A. Read, C. Rivard Costa, J. Shi, M. Su, M. Ye, M. Zinda, Discovery of 1-methyl-1H-imidazole derivatives as potent JAK2 inhibitors, J. Med. Chem. 57 (2014) 144â158. https://doi.org/10.1021/jm401546n.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fukuyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ehling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Cook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>BÃ¤umer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Pharmacol. Exp. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>394</sb:first-page>
                              <sb:last-page>405</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1124/jpet.115.223784</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">T. Fukuyama, S. Ehling, E. Cook, W. Baumer, Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis, J. Pharmacol. Exp. Ther. 3 (2015) 394-405. https://doi.org/10.1124/jpet.115.223784.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Cosgrove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Wren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cleaver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Walsh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Harfst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Follis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Boucher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Stegemann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Vet. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <ce:doi>10.1111/vde.12047</ce:doi>
                        </sb:host>
                        <sb:comment>479-e114</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0500">S. B. Cosgrove, J. A. Wren, D. M. Cleaver, D. D. Martin, K. F. Walsh, J. A. Harfst, S. L. Follis, V. L. King, J. F. Boucher, M. R. Stegemann, Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis, Vet. Dermatol. 5 (2013) 479-e114. https://doi.org/10.1111/vde.12047.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Tyner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Bumm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Aichberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Loriaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5232</sb:first-page>
                              <sb:last-page>5240</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2009-05-223727</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">J. W. Tyner, T. G. Bumm, J. Deininger, L. Wood, K. J. Aichberger, M. M. Loriaux, B. J. Druker, C. J. Burns, E. Fantino, M. W. Deininger. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms, Blood. 25 (2010) 5232-5240. https://doi.org/10.1182/blood-2009-05-223727.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tefferi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barraco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Lasho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Begna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Al-Kali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Hogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Litzow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Hanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Ketterling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gangat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pardanani</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Momelotinib therapy for myelofibrosis: a 7-year follow-up</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Canc. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29</sb:first-page>
                              <sb:last-page>34</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41408-018-0067-6</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">A. Tefferi, D. Barraco, T. L. Lasho, S. Shah, K. H. Begna, A. Al-Kali, W. J. Hogan, M. R. Litzow, C. A. Hanson, R. P. Ketterling, N. Gangat, A. Pardanani, Momelotinib therapy for myelofibrosis: a 7-year follow-up, Blood Cancer J. 8 (2018) 29-34. https://doi.org/10.1038/s41408-018-0067-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Cooke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.O.</ce:given-name>
                                 <ce:surname>Persky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Squires</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mahadevan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2997</sb:first-page>
                              <sb:last-page>3005</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/ijc.26324</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0515">W. Qi, X. Liu, L. S. Cooke, D. O. Persky, T. P. Miller, M. Squires, D. Mahadevan, AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas, Int. J. Cancer. 12 (2012) 2997-3005. https://doi.org/10.1002/ijc.26324.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Santo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hideshima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cirstea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gorgun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rodig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vallet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pozzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Unitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Squires</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chauhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mahindra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.C.</ce:given-name>
                                 <ce:surname>Munshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Raje</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3259</sb:first-page>
                              <sb:last-page>3271</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-10-3012</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0520">L. Santo, T. Hideshima, D. Cirstea, M. Bandi, E. A. Nelson, G. Gorgun, S. Rodig, S. Vallet, S. Pozzi, K. Patel, C. Unitt, M. Squires, Y. Hu, D. Chauhan, A. Mahindra, N. C. Munshi, K. C. Anderson, N. Raje, Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide, Clin. Cancer Res. 10 (2011) 3259-3271. https://doi.org/10.1158/1078-0432.CCR-10-3012.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Blunt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koehrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dobson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Larrayoz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wilmore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hayman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Parnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Conley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Strefford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.K.</ce:given-name>
                                 <ce:surname>Stevenson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Packham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Forconi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Coffey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Burger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Steele</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The dual SYK/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2313</sb:first-page>
                              <sb:last-page>2324</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-16-1662</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0525">M. D. Blunt, S. Koehrer, R. Dobson, M. Larrayoz, S. Wilmore, A. Hayman, J. Parnell, L. Smith, A. Davies, P. W. Johnson, P. B. Conley, A. Pandey, J. C. Strefford, F. K. Stevenson, G. Packham, F. Forconi, G. Coffey, J. A Burger, A. J. Steele, The dual SYK/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia, Clin Cancer Res. 9 (2017) 2313-2324. https://doi.org/10.1158/1078-0432.CCR-16-1662.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nakagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Asakawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tamiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Morita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nakao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yoshimura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>187</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4611</sb:first-page>
                              <sb:last-page>4620</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4049/jimmunol.1100649</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0530">R. Nakagawa, H. Yoshida, M. Asakawa, T. Tamiya, N. Inoue, R. Morita, H. Inoue, A. Nakao, A. Yoshimura, Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17, J. Immunol. 187 (2011) 4611-4620. https://doi.org/10.4049/jimmunol.1100649.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Derenzini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lemoine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Buglio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Katayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Younes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The JAK inhibitor AZD1480 regulates proliferation and immunity in hodgkin lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Canc. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e46</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/bcj.2011.46</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0535">E. Derenzini, M. Lemoine, D. Buglio, H. Katayama, Y. Ji, R. E. Davis, S. Sen, A. Younes, The JAK inhibitor AZD1480 regulates proliferation and immunity in hodgkin lymphoma, Blood Cancer J. 12 (2011) e46. https://doi.org/10.1038/bcj.2011.46.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hedvat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huszar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Gozgit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sheehy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Proia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Kowolik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Armstrong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bebernitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Weng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Morosini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alimzhanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ioannidis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>McCoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.A.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zinda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The JAK2 inhibitor AZD1480 potently blocks STAT3 signaling and oncogenesis in solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>487</sb:first-page>
                              <sb:last-page>497</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccr.2009.10.015</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0540">M. Hedvat, D. Huszar, A. Herrmann, J. M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C. M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z. A. Cao, H. Yu, R. Jove, M. Zinda, The JAK2 inhibitor AZD1480 potently blocks STAT3 signaling and oncogenesis in solid tumors, Cancer Cell. 6 (2009) 487-497. https://doi.org/10.1016/j.ccr.2009.10.015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Ramkissoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Luu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bandopadhayay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Beroukhim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Stiles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Segal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Ligon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Hahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine receptor kinase B is a drug target in astrocytomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>22</sb:first-page>
                              <sb:last-page>30</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/neuonc/now139</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0545">J. Ni, S. Xie, S. H. Ramkissoon, V. Luu, Y. Sun, P. Bandopadhayay, R. Beroukhim, T. M. Roberts, C. D. Stiles, R. A. Segal, K. L. Ligon, W. C. Hahn, J. J. Zhao, Tyrosine receptor kinase B is a drug target in astrocytomas, Neuro. Oncol. 19 (2017) 22-30. https://doi.org/10.1093/neuonc/now139.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Grimster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alimzhanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bebernitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chuaqui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Deegan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Ferguson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Gero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Harsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huszar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kawatkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Kettle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lyne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Read</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Costa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ruston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Throner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Toader</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vasbinder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Woessner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zinda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5235</sb:first-page>
                              <sb:last-page>5244</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b00076</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0550">N. P. Grimster, E. Anderson, M. Alimzhanov, G. Bebernitz, K. Bell, C. Chuaqui, T. Deegan, A. D. Ferguson, T. Gero, A. Harsch, D. Huszar, A. Kawatkar, J. G. Kettle, P. Lyne, J. A. Read, C. R. Costa, L. Ruston, P. Schroeder, J. Shi, Q. Su, S. Throner, D. Toader, M. Vasbinder, R. Woessner, H. Wang, A. Wu, M. Ye, W. Zheng, M. Zinda, Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors, J. Med. Chem. 61 (2018) 5235â5244. https://doi.org/10.1021/acs.jmedchem.8b00076.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Guro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Tore</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New-generation JAK inhibitors: how selective can they be?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2477</sb:first-page>
                              <sb:last-page>2478</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S0140-6736(18)31325-4</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0555">G. L. Guro, T. K. Tore, New-generation JAK inhibitors: how selective can they be? Lancet. 391 (2018) 2477-2478. https://doi.org/10.1016/S0140-6736(18)31325-4.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1562</sb:first-page>
                              <sb:last-page>1576</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2019.02.054</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0560">Y. Yin, C. J. Chen, R. N. Yu, L. Shu, T. T. Zhang, D. Y. Zhang, Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold, Bioorg. Med. Chem. 27 (2019) 1562-1576. https://doi.org/10.1016/j.bmc.2019.02.054.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Wrobleski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mertzman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Spergel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gillooly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chaudhry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>DâArienzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Heimrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Muckelbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mulligan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aranibar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chiney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of <ce:italic>N</ce:italic>-methyl nicotinamide and <ce:italic>N</ce:italic>-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8953</sb:first-page>
                              <sb:last-page>8972</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.9b00443</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0565">R. Moslin, Y. Zhang, S. T. Wrobleski, S. Lin, M. Mertzman, S. Spergel, J. S. Tokarski, J. Strnad, K. Gillooly, K. W. McIntyre, A. Zupa-Fernandez, L. Cheng, H. Sun, C. Chaudhry, C. Huang, C. DâArienzo, E. Heimrich, X. Yang, J. K. Muckelbauer, C. Chang, J. Tredup, D. Mulligan, D. Xie, N. Aranibar, M. Chiney, J. R. Burke, L. Lombardo, P. H. Carter, D. S. Weinstein, Identification of N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2), J. Med. Chem, 62 (2019) 8953-8972. https://doi.org/10.1021/acs.jmedchem.9b00443.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fleischmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Pangan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mysler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bessette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peterfy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Durez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Ostor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Othman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Genovese</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, double-blind, randomized controlled trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arthritis Rheumatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1788</sb:first-page>
                              <sb:last-page>1800</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/art.41032</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0570">R. Fleischmann, A. L. Pangan, I. Song, E. Mysler, L. Bessette, C. Peterfy, P. Durez, A. J. Ostor, Y. Li, Y. Zhou, A. A. Othman, M. C. Genovese, Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, double-blind, randomized controlled trial, arthritis rheumatol. 71 (2019) 1788-1800. https://doi.org/10.1002/art.41032.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Hurley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bergeron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Barrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Balazs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Blair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bull</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chakravarty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Crackett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Deshmukh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>DeVoss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Dragovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Eigenbrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ellwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gaines</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ghilardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gibbons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gradl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gribling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hamman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Harstad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hewitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Kenny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.T.</ce:given-name>
                                 <ce:surname>Koehler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bir Kohli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Labadie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liimatta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mendonca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Narukulla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pulk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Reeve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Savage</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Steffek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ubhayakar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>van Abbema</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Aliagas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Avitabile-Woo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Kulagowski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4764</sb:first-page>
                              <sb:last-page>4785</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm4004895</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0575">M. Zak, C. A. Hurley, S. I. Ward, P. Bergeron, K. Barrett, M. Balazs, W. S. Blair, R. Bull, P. Chakravarty, C. Chang, P. Crackett, G. Deshmukh, J. DeVoss, P. S. Dragovich, C. Eigenbrot, C. Ellwood, S. Gaines, N. Ghilardi, P. Gibbons, S. Gradl, P. Gribling, C. Hamman, E. Harstad, P. Hewitt, A. Johnson, T. Johnson, J. R. Kenny, M. F. T. Koehler, P. Bir Kohli, S. Labadie, W. P. Lee, J. Liao, M. Liimatta, R. Mendonca, R. Narukulla, R. Pulk, A. Reeve, S. Savage, S. Shia, M. Steffek, S. Ubhayakar, A. van Abbema, I. Aliagas, B. Avitabile-Woo, Y. Xiao, J. Yang, J. J. Kulagowski, Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2, J. Med. Chem. 56 (2013) 4764-4785. https://doi.org/10.1021/jm4004895.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Parmentier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Voss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Graff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Argiriadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Camp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Padley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>George</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hyland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rosebraugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wishart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>InÂ vitro and inÂ vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Rheumatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1186/s41927-018-0031-x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0580">J. M. Parmentier, J. Voss, C. Graff, A. Schwartz, M. Argiriadi, M. Friedman, H. S. Camp, R. J. Padley, J. S. George, D. Hyland, M. Rosebraugh, N. Wishart, L. Olson, A. J. Long, InÂ vitro and inÂ vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 2:23. https://doi.org/10.1186/s41927-018-0031-x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Mohamed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>KlÃ¼nder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Camp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Othman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exposure-response analyses of upadacitinib efficacy in phase II trials in rheumatoid arthritis and basis for phase III dose selection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1319</sb:first-page>
                              <sb:last-page>1327</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/cpt.1543</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0585">M. F. Mohamed, B. Klunder, H. S. Camp, A. A. Othman, Exposure-response analyses of upadacitinib efficacy in phase II trials in rheumatoid arthritis and basis for phase III dose selection, Clin. Pharmacol. Ther. 106 (2019) 1319-1327. https://doi.org/10.1002/cpt.1543.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Van Rompaey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Galien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>van der Aar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Clement-Lacroix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nelles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Smets</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lepescheux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Christophe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Conrath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Vandeghinste</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vayssiere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>De Vos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Brys</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>van ât Klooster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Feyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Menet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3568</sb:first-page>
                              <sb:last-page>3577</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4049/jimmunol.1201348</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0590">L. Van Rompaey, R. Galien, E. M. van der Aar, P. Clement-Lacroix, L. Nelles, B. Smets, L. Lepescheux, T. Christophe, K. Conrath, N. Vandeghinste, B. Vayssiere, S. De Vos, S. Fletcher, R. Brys, G. van ât Klooster, J. H. Feyen, C. Menet, Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases, J. Immunol. 191 (2013) 3568-3577. https://doi.org/10.4049/jimmunol.1201348.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Vazquez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kaila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Strohbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>John D.</ce:given-name>
                                 <ce:surname>Trzupek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Mitton-Fry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>TenBrink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Arnold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Basak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Heasley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Langille</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Parikh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Casavant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Duclos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Fenwick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Caspers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ellen Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Symanowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of <ce:italic>N</ce:italic>-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1130</sb:first-page>
                              <sb:last-page>1152</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.7b01598</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0595">M. L. Vazquez, N. Kaila, J. W. Strohbach, John. D. Trzupek, M. F. Brown, M. E. Flanagan, M. J. Mitton-Fry, T. A. Johnson, R. E. TenBrink, E. P. Arnold, A. Basak, S. E. Heasley, S. Kwon, J. Langille, M. D. Parikh, S. H. Griffin, J. M. Casavant, B. A. Duclos, A. E. Fenwick, T. M. Harris, S. Han, N. Caspers, M. E. Dowty, X. Yang, M. Ellen Banker, M. Hegen, P. T. Symanowicz, L. Li, L. Wang, T. H. Lin, J. Jussif, J. D. Clark, J. Telliez, R. P. Robinson, R. Unwalla, Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases, J. Med. Chem. 61 (2018) 1130â1152. https://doi.org/10.1021/acs.jmedchem.7b01598.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.O.</ce:given-name>
                                 <ce:surname>Mascarenhas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Talpaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Foltz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Savona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Paquette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Turner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Coughlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Winton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Burn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>OâNeill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Assad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Haematologica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>327</sb:first-page>
                              <sb:last-page>335</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3324/haematol.2016.151126</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0600">J. O. Mascarenhas, M. Talpaz, V. Gupta, L. M. Foltz, M. R. Savona, R. Paquette, A. R. Turner, P. Coughlin, E. Winton, T. C. Burn, P. OâNeill, J. Clark, D. Hunter, A. Assad, R. Hoffman, S. Verstovsek, Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis, Haematologica. 102 (2017) 327-335. https://doi.org/10.3324/haematol.2016.151126.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Ludbrook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Hicks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Hanrott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Binks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Wyres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Watson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Simeoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Schifano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Reich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.M.</ce:given-name>
                                 <ce:surname>Griffiths</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>174</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>985</sb:first-page>
                              <sb:last-page>995</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/bjd.14399</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0605">V. J. Ludbrook, K. J. Hicks, K. E. Hanrott, J. S. Patel, M. H. Binks, M. R. Wyres, J. Watson, P. Wilson, M. Simeoni, L. A. Schifano, K. Reich, C. E. M. Griffiths, Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study, Br. J. Dermatol. 174 (2016) 985-995. https://doi.org/10.1111/bjd.14399.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Masarova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The rationale for immunotherapy in myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Hematol. Malig. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>310</sb:first-page>
                              <sb:last-page>327</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s11899-019-00527-7</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0610">L. Masarova, P. Bose, S. Verstovsek, The rationale for immunotherapy in myeloproliferative neoplasms, Curr. Hematol. Malig. Rep. 14 (2019) 310-327. https://doi.org/10.1007/s11899-019-00527-7.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McNally</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dekker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vangrevelinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Machauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Radimerski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and structural characterization of ATP-site ligands for the wild-type and V617F mutant JAK2 pseudokinase domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>587</sb:first-page>
                              <sb:last-page>593</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acschembio.8b00722</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0615">R. McNally, Q. Li, K. Li, C. Dekker, E. Vangrevelinghe, M. Jones, P. Chene, R. Machauer, T. Radimerski, M. J. Eck, Discovery and structural characterization of ATP-site ligands for the wild-type and V617F mutant JAK2 pseudokinase domain, ACS Chem. Biol. 14 (2019) 587-593. https://doi.org/10.1021/acschembio.8b00722.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nagaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.T.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jayaraman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Pasha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ethirajulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4638</sb:first-page>
                              <sb:last-page>4658</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm200326p</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0620">A. D. William, A. C.-H. Lee, S. Blanchard, A. Poulsen, E. L. Teo, H. Nagaraj, E. Tan, D. Chen, M. Williams, E. T. Sun, K. C. Goh, W. C. Ong, S. K. Goh, S. Hart, R. Jayaraman, M. K. Pasha, K. Ethirajulu, J. M. Wood, B. W. Dymock, Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma, J. Med. Chem. 54 (2011) 4638-4658. https://doi.org/10.1021/jm200326p.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.O.</ce:given-name>
                                 <ce:surname>Hexner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Serdikoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Swider</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Angeles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Emerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carroll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ruggeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dobrzanski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5663</sb:first-page>
                              <sb:last-page>5671</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2007-04-083402</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0625">E. O. Hexner, C. Serdikoff, M. Jan, C. R. Swider, C. Robinson, S. Yang, T. Angeles, S. G. Emerson, M. Carroll, B. Ruggeri, P. Dobrzanski, Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders, Blood. 111 (2008) 5663-5671. https://doi.org/10.1182/blood-2007-04-083402.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Tse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Garrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>885</sb:first-page>
                              <sb:last-page>887</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood.v98.3.885</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0630">M. Levis, K. F. Tse, B. D. Smith, E. Garrett, D. Small. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations, Blood. 98 (2001) 885-887. https://doi.org/10.1182/blood.v98.3.885.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Allebach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Tse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Baldwin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jones-Bolin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ruggeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dionne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells inÂ vitro and inÂ vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3885</sb:first-page>
                              <sb:last-page>3891</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood.v99.11.3885</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0635">M. Levis, J. Allebach, K. F. Tse, R. Zheng, B. R. Baldwin, B. D. Smith, S. Jones-Bolin, B. Ruggeri, C. Dionne, D. Small, A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells inÂ vitro and inÂ vivo, Blood. 99 (2002) 3885-3891. https://doi.org/10.1182/blood.v99.11.3885.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Beran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Giles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Dauses</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Allebach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3669</sb:first-page>
                              <sb:last-page>3676</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1182/blood-2003-11-3775</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0640">B. D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K. M. Murphy, T. Dauses, J. Allebach, D. Small, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia, Blood. 103 (2004) 3669-3676. https://doi.org/10.1182/blood-2003-11-3775.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib125">
                     <ce:label>[125]</ce:label>
                     <sb:reference id="sref125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Beck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zobel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Barber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lezina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Allchin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Blades</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Elliott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Lord</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ashworth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Porter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Wagner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthetic lethal screen demonstrates that a JAK2 inhibitor suppresses a BCL6-dependent IL10RA/JAK2/STAT3 pathway in high grade B-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>291</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16686</sb:first-page>
                              <sb:last-page>16698</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1074/jbc.M116.736868</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0645">D. Beck, J. Zobel, R. Barber, S. Evans, L. Lezina, R. L. Allchin, M. Blades, R. Elliott, C. J. Lord, A. Ashworth, A. C. Porter, S. D. Wagner, Synthetic lethal screen demonstrates that a JAK2 inhibitor suppresses a BCL6-dependent IL10RA/JAK2/STAT3 pathway in high grade B-cell lymphoma, J. Biol. Chem. 291 (2016) 16686-16698. https://doi.org/10.1074/jbc.M116.736868.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib126">
                     <ce:label>[126]</ce:label>
                     <sb:reference id="sref126">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mascarenhas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Baer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kessler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hexner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tremblay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sandy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Weinberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Pahl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Silverman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Goldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kosiorek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Dueck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase II trial of lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Lymphoma</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1343</sb:first-page>
                              <sb:last-page>1345</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/10428194.2018.1532509</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0650">J. Mascarenhas, M. R. Baer, C. Kessler, E. Hexner, D. Tremblay, L. Price, L. Sandy, R. Weinberg, H. Pahl, L. R. Silverman, J. D. Goldberg, H. Kosiorek, A. C. Dueck, R. Hoffman, Phase II trial of lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis, Leuk. Lymphoma. 60 (2019) 1343-1345. https://doi.org/10.1080/10428194.2018.1532509.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib127">
                     <ce:label>[127]</ce:label>
                     <sb:reference id="sref127">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Giacomini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chandrasekhar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Twelves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Whitney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lepist</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interaction of 2,4-diaminopyrimidineâcontaining drugs including fedratinib and trimethoprim with thiamine transporters</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Metab. Dispos.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>76</sb:first-page>
                              <sb:last-page>85</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1124/dmd.116.073338</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0655">M. M. Giacomini, J. Hao, X. Liang, J. Chandrasekhar, J. Twelves, J. A. Whitney, E. Lepist, A. S. Ray, Interaction of 2,4-diaminopyrimidine-containing drugs including fedratinib and trimethoprim with thiamine transporters, Drug Metab. Dispos. 45 (2017) 76-85. https://doi.org/10.1124/dmd.116.073338.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib128">
                     <ce:label>[128]</ce:label>
                     <sb:reference id="sref128">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wernig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Kharas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Okabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Leeman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Cullen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gozo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>McDowell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Levine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Doukas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Noronha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.D.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Soll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tefferi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Hood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>311</sb:first-page>
                              <sb:last-page>320</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccr.2008.02.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0660">G. Wernig, M. G. Kharas, R. Okabe, S. A. Moore, D. S. Leeman, D. E. Cullen, M. Gozo, E. P. McDowell, R. L. Levine, J. Doukas, C. C. Mak, G. Noronha, M. Martin, Y. D. Ko, B. H. Lee, R. M. Soll, A. Tefferi, J. D. Hood, D. G. Gilliland, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera, Cancer Cell. 13 (2008) 311-320. https://doi.org/10.1016/j.ccr.2008.02.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib129">
                     <ce:label>[129]</ce:label>
                     <sb:reference id="sref129">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pardanani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cervantes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Mesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Milligan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Masszi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mishchenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jourdan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Vannucchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Drummond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jurgutis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kuliczkowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gheorghita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Passamonti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Neumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tefferi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAMA. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>643</sb:first-page>
                              <sb:last-page>651</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1001/jamaoncol.2015.1590</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0665">A. Pardanani, C. Harrison, J. E. Cortes, F. Cervantes, R. A. Mesa, D. Milligan, T. Masszi, E. Mishchenko, E. Jourdan, A. M. Vannucchi, M. W. Drummond, M. Jurgutis, K. Kuliczkowski, E. Gheorghita, F. Passamonti, F. Neumann, A. Patki, G. Gao, A. Tefferi, Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis, JAMA. Oncol. 1 (2015) 643-651. https://doi.org/10.1001/jamaoncol.2015.1590.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib130">
                     <ce:label>[130]</ce:label>
                     <sb:reference id="sref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jamieson1</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hasserjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gotlib</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Talpaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Thiele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rodig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Pozdnyakova</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Transl. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>294</sb:first-page>
                              <sb:last-page>302</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1186/s12967-015-0644-4</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0670">C. Jamieson1, R. Hasserjian, J. Gotlib, J. Cortes, R. Stone, M. Talpaz, J. Thiele, S. Rodig, O. Pozdnyakova, Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis, J. Transl. Med. 13 (2015)294-302. https://doi.org/10.1186/s12967-015-0644-4.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib131">
                     <ce:label>[131]</ce:label>
                     <sb:reference id="sref131">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nagaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.T.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jayaraman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Pasha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ethirajulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa 1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>169</sb:first-page>
                              <sb:last-page>196</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm201112g</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0675">A. D. William, A. C.-H. Lee, K. C. Goh, S. Blanchard, A. Poulsen, Ì E. L. Teo, H. Nagaraj, C. P. Lee, H. Wang, M. Williams, E. T. Sun, C. Hu, R. Jayaraman, M. K. Pasha, K. Ethirajulu, J. M. Wood, B. W. Dymock, Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa 1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer, J. Med. Chem. 55 (2012) 169â196. https://doi.org/10.1021/jm201112g.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib132">
                     <ce:label>[132]</ce:label>
                     <sb:reference id="sref132">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Clayton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Walgren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Heinz-Taheny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Kreklau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bloem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pitou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Strelow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Halstead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Rempala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Parthasarathy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Gillig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Heinz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Stancato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Dowless</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Iversen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Burkholder</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Canc. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e109</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/bcj.2013.6</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0680">L. Ma, J. R. Clayton, R. A. Walgren, B. Zhao, R. J. Evans, M. C. Smith, K. M. Heinz-Taheny, E. L. Kreklau, L. Bloem, C. Pitou, W. Shen, J. M. Strelow, C. Halstead, M. E. Rempala, S. Parthasarathy, J. R. Gillig, L. J. Heinz, H. Pei, Y. Wang, L. F. Stancato, M. S. Dowless, P. W. Iversen, T. P. Burkholder, Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F, Blood Cancer J. 3 (2013) e109. https://doi.org/10.1038/bcj.2013.6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib133">
                     <ce:label>[133]</ce:label>
                     <sb:reference id="sref133">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Grebinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Inghrim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kempson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Pitts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Sack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lippy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Lorenzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>McDevitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Vuppugalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Trainor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Purandare</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of selective janus kinase 2 imidazo[4,5-d]pyrrolo[2,3-b]pyridine inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>845</sb:first-page>
                              <sb:last-page>849</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.5b00225</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0685">A. C. Hart, G. M. Schroeder, H. Wan, J. Grebinski, J. Inghrim, J. Kempson, J. Guo, W. J. Pitts, J. S. Tokarski, J. S. Sack, J. A. Khan, J. Lippy, M. V. Lorenzi, D. You, T. McDevitt, R. Vuppugalla, Y. Zhang, L. J. Lombardo, G. L. Trainor, A. V. Purandare, Structure-based design of selective janus kinase 2 imidazo[4,5-d]pyrrolo[2,3-b]pyridine inhibitors, ACS Med. Chem. Lett. 6 (2015) 845â849. https://doi.org/10.1021/acsmedchemlett.5b00225.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib134">
                     <ce:label>[134]</ce:label>
                     <sb:reference id="sref134">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Dugan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Gingrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Mesaros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Milkiewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Curry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Zulli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dobrzanski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Serdikoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Angeles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Albom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Aimone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Wells-Knecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Ator</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Ruggeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Dorsey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of janus kinase 2 for use in anticancer therapy: discovery of CEP-33779</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5243</sb:first-page>
                              <sb:last-page>5254</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm300248q</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0690">B. J. Dugan, D. E. Gingrich, E. F. Mesaros, K. L. Milkiewicz, M. A. Curry, A. L. Zulli, P. Dobrzanski, C. Serdikoff, M. Jan, T. S. Angeles, M. S. Albom, J. L. Mason, L. D. Aimone, S. L. Meyer, Z. Huang, K. J. Wells-Knecht, M. A. Ator, B. A. Ruggeri, B. D. Dorsey, A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of janus kinase 2 for use in anticancer therapy: discovery of CEP-33779, J. Med. Chem. 55 (2012) 5243â5254. https://doi.org/10.1021/jm300248q.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib135">
                     <ce:label>[135]</ce:label>
                     <sb:reference id="sref135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liongue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.Y.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1379</sb:first-page>
                              <sb:last-page>1386</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.exphem.2009.08.008</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0695">A. C. Ma, A. Fan, A. C. Ward, C. Liongue, R. S. Lewis, S. H. Cheng, P. K. Chan, S. F. Yip, R. Liang, A. Y. Leung, A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera, Exp. Hematol. 37 (2009) 1379-1386. https://doi.org/10.1016/j.exphem.2009.08.008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib136">
                     <ce:label>[136]</ce:label>
                     <sb:reference id="sref136">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kuroda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kodama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mizutani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nagoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Matsumoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Naito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Taniwaki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>619</sb:first-page>
                              <sb:last-page>624</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.leukres.2014.03.001</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0700">J. Kuroda, A. Kodama, Y. Chinen, Y. Shimura, S. Mizutani, H. Nagoshi, T. Kobayashi, Y. Matsumoto, Y. Nakaya, A. Tamura, Y. Kobayashi, H. Naito, M. Taniwaki, NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients, Leuk. Res. 38 (2014) 619-624. https://doi.org/10.1016/j.leukres.2014.03.001.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib137">
                     <ce:label>[137]</ce:label>
                     <sb:reference id="sref137">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shide</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Niwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Homan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sugahara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Horio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kuramoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kotera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shibayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Naito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shimoda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy of NS-018, a potent and selective JAK2/SRC inhibitor, in primary cells and mouse models of myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Canc. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e29</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/bcj.2011.29</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0705">Y. Nakaya, K. Shide, T. Niwa, J. Homan, S. Sugahara, T. Horio, K. Kuramoto, T. Kotera, H. Shibayama, K. Hori, H. Naito, K. Shimoda, Efficacy of NS-018, a potent and selective JAK2/SRC inhibitor, in primary cells and mouse models of myeloproliferative neoplasms, Blood Cancer J. 1 (2011) e29. https://doi.org/10.1038/bcj.2011.29.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib138">
                     <ce:label>[138]</ce:label>
                     <sb:reference id="sref138">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Baffert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>RÃ©gnier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>De Pover</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pissot-Soldermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Tavares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Blasco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Brueggen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>ChÃ¨ne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Drueckes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Erdmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gerspacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ledieu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nolan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ruetz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Trappe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vangrevelinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wartmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wyder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hofmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Radimerski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1945</sb:first-page>
                              <sb:last-page>1955</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1535-7163.MCT-10-0053</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0710">F. Baffert, C. H. Regnier, A. De Pover, C. Pissot-Soldermann, G. A. Tavares, F. Blasco, J. Brueggen, P. Chene, P. Drueckes, D. Erdmann, P. Furet, M. Gerspacher, M. Lang, D. Ledieu, L. Nolan, S. Ruetz, J. Trappe, E. Vangrevelinghe, M. Wartmann, L. Wyder, F. Hofmann, T. Radimerski, Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805, Mol. Cancer Ther. 9 (2010) 1945-1955. https://doi.org/10.1158/1535-7163.MCT-10-0053.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib139">
                     <ce:label>[139]</ce:label>
                     <sb:reference id="sref139">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Juba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Czerwinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casimiro-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Balbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Che</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hayward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Montgomery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Soucy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Coe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Langille</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chrencik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1971</sb:first-page>
                              <sb:last-page>1993</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.6b01694</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0715">A. Thorarensen, M. E. Dowty, M. E. Banker, B. Juba, J. Jussif, T. Lin, F. Vincent, R. M. Czerwinski, A. Casimiro-Garcia, R. Unwalla, J. I. Trujillo, S. Liang, P. Balbo, Y. Che, A. M. Gilbert, M. F. Brown, M. Hayward, J. Montgomery, L. Leung, X. Yang, S. Soucy, M. Hegen, J. Coe, J. Langille, F. Vajdos, J. Chrencik, J. Telliez, Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans, J. Med. Chem. 60 (2017) 1971â1993. https://doi.org/10.1021/acs.jmedchem.6b01694.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib140">
                     <ce:label>[140]</ce:label>
                     <sb:reference id="sref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Moy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Balbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Crouse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dickinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Symanowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hayward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Montgomery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bauman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casimiro-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Geoghegan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Quazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3442</sb:first-page>
                              <sb:last-page>3451</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acschembio.6b00677</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0720">J. B. Telliez, M. E. Dowty, L. Wang, J. Jussif, T. Lin, L. Li, E. Moy, P. Balbo, W. Li, Y. Zhao, K. Crouse, C. Dickinson, P. Symanowicz, M. Hegen, M. E. Banker, F. Vincent, R. Unwalla, S. Liang, A. M. Gilbert, M. F. Brown, M. Hayward, J. Montgomery, X. Yang, J. Bauman, J. I. Trujillo, A. Casimiro-Garcia, F. F. Vajdos, L. Leung, K. F. Geoghegan, A. Quazi, D. Xuan, L. Jones, E. Hett, K. Wright, J. D. Clark, A. Thorarensen, Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition, ACS Chem. Biol. 11 (2016) 3442â3451. https://doi.org/10.1021/acschembio.6b00677.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib141">
                     <ce:label>[141]</ce:label>
                     <sb:reference id="sref141">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mahajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Hogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shlyakhter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.G.</ce:given-name>
                                 <ce:surname>Salituro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Farmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Hoock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Pharmacol. Exp. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>353</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>405</sb:first-page>
                              <sb:last-page>414</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1124/jpet.114.221176</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0725">S. Mahajan, J. K. Hogan, D. Shlyakhter, L. Oh, F. G. Salituro, L. Farmer, T. C. Hoock. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease, J. Pharmacol. Exp. Ther. 353 (2015) 405-414. https://doi.org/10.1124/jpet.114.221176.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib142">
                     <ce:label>[142]</ce:label>
                     <sb:reference id="sref142">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Forster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chaikuad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Bauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Holstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Robers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Corona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gehringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pfaffenrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ghoreschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1335</sb:first-page>
                              <sb:last-page>1340</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.chembiol.2016.10.008</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0730">M. Forster, A.Chaikuad, S. M. Bauer, J. Holstein, M. B. Robers, C. R. Corona, M. Gehringer, E. Pfaffenrot, K. Ghoreschi, S. Knapp, S. A. Laufer, Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket, Cell Chem. Biol. 23 (2016) 1335-1340. https://doi.org/10.1016/j.chembiol.2016.10.008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib143">
                     <ce:label>[143]</ce:label>
                     <sb:reference id="sref143">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casimiro-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Juba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aulabaugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Balbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bauman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chrencik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Coe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Czerwinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Knafels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of cyanamide-based janus kinase 3 (JAK3) covalent inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10665</sb:first-page>
                              <sb:last-page>10699</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b01308</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0735">A. Casimiro-Garcia, J. I. Trujillo, F. Vajdos, B. Juba, M. E. Banker, A. Aulabaugh, P. Balbo, J. Bauman, J. Chrencik, J. W. Coe, R. Czerwinski, M. Dowty, J. D. Knafels, S. Kwon, L. Leung, S. Liang, R. P. Robinson, J. Telliez, R. Unwalla, X. Yang, A. Thorarensen, Identification of cyanamide-based janus kinase 3 (JAK3) covalent inhibitors, J. Med. Chem. 61 (2018) 10665â10699. https://doi.org/10.1021/acs.jmedchem.8b01308.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib144">
                     <ce:label>[144]</ce:label>
                     <sb:reference id="sref144">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Wrobleski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Spergel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kempson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shuster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gillooly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Heimrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chaudhry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ruzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mulligan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>DâArienzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aranibar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chiney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chimalakonda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Pitts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8973</sb:first-page>
                              <sb:last-page>8995</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.9b00444</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0740">S. T. Wrobleski, R. Moslin, S. Lin, Y. Zhang, S. Spergel, J. Kempson, J. S. Tokarski, J. Strnad, A. Zupa-Fernandez, L. Cheng, D. Shuster, K. Gillooly, X. Yang, E. Heimrich, K. W. McIntyre, C. Chaudhry, J. Khan, M. Ruzanov, J. Tredup, D. Mulligan, D. Xie, H. Sun, C. Huang, C. DâArienzo, N. Aranibar, M. Chiney, A. Chimalakonda, W. J. Pitts, L. Lombardo, P. H. Carter, J. R. Burke, D. S. Weinstein, Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165, J. Med. Chem. 62 (2019) 8973-8995. https://doi.org/10.1021/acs.jmedchem.9b00444.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib145">
                     <ce:label>[145]</ce:label>
                     <sb:reference id="sref145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Muckelbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chaudhry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Elzinga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dâarienzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gillooly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salter-Cid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aranibar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of imidazo[1,2-b]pyridazine derivatives as potent, selective, and orally active TYK2 JH2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>388</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.9b00035</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0745">C. Liu, J. Lin, R. Moslin, J. S. Tokarski, J. Muckelbauer, C. Chang, J. Tredup, D. Xie, H. Park, P. Li, D. Wu, J. Strnad, A. Zupa-Fernandez, L. Cheng, C. Chaudhry, J. Chen, C. Chen, H. Sun, P. Elzinga, C. Dâarienzo, K. Gillooly, T. L. Taylor, K. W. McIntyre, L. Salter-Cid, L. J. Lombardo, P. H. Carter, N. Aranibar, J. R. Burke, D. S. Weinstein, Identification of imidazo[1,2-b]pyridazine derivatives as potent, selective, and orally active TYK2 JH2 inhibitors, ACS Med. Chem. Lett. 10 (2019) 383â388. https://doi.org/10.1021/acsmedchemlett.9b00035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib146">
                     <ce:label>[146]</ce:label>
                     <sb:reference id="sref146">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mascarenhas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3008</sb:first-page>
                              <sb:last-page>3014</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-11-3145</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0750">J. Mascarenhas, R. Hoffman, Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis, Clin Cancer Res. 18 (2012) 3008-3014. https://doi.org/10.1158/1078-0432.CCR-11-3145.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib147">
                     <ce:label>[147]</ce:label>
                     <sb:reference id="sref147">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Q.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>261</sb:first-page>
                              <sb:last-page>270</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.exphem.2012.10.012</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0755">S. M. Gao, C. Q. Chen, L. Y.Wang, L. L. Hong, J. B. Wu, P. H. Dong, F. J. Yu, Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms, Exp. Hematol. 41 (2013) 261â270. https://doi.org/10.1016/j.exphem.2012.10.012.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib148">
                     <ce:label>[148]</ce:label>
                     <sb:reference id="sref148">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Quintas-Cardama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Estrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Borthakur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1124</sb:first-page>
                              <sb:last-page>1127</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.leukres.2012.03.003</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0760">A. Quintas-Cardama, H. Kantarjian, Z. Estrov, G. Borthakur, J. Cortes, S. Verstovsek, Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis, Leuk. Res. 36 (2012) 1124â1127. https://doi.org/10.1016/j.leukres.2012.03.003.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib149">
                     <ce:label>[149]</ce:label>
                     <sb:reference id="sref149">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.G.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Mustafa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Ramanujulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.Y.</ce:given-name>
                                 <ce:surname>Yen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8233</sb:first-page>
                              <sb:last-page>8262</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.6b00157</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0765">E. G. Yang, N. Mustafa, E. C. Tan, A. Poulsen, P. M. Ramanujulu, W. J. Chng, J. J. Y. Yen, B. W. Dymock, Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines, J. Med. Chem. 59 (2016) 8233â8262. https://doi.org/10.1021/acs.jmedchem.6b00157.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib150">
                     <ce:label>[150]</ce:label>
                     <sb:reference id="sref150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>143</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1847</sb:first-page>
                              <sb:last-page>1857</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.10.080</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0770">Y. Ge, C. Wang, S. Song, J. Huang, Z. Liu, Y. Li, Q. Meng, J. Zhang, J. Yao, K. Liu, X. Ma, X. Sun, Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma, Eur. J. Med. Chem. 143 (2018) 1847-1857. https://doi.org/10.1016/j.ejmech.2017.10.080.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>